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Abstract 
 
Successful reconstruction of bone defects is a major concern in orthopaedic surgery and 
remains an active area of basic and clinical research. In recent years, increasing efforts 
have been devoted to the development of injectable materials that can be applied through 
minimally invasive surgery, providing less discomfort to patients, a faster recovery and 
lower costs. Their effectiveness can be improved through association with therapeutic 
agents, which may be locally released to accelerate the process of bone regeneration. 
Particle-based materials have already been used as injectable bone fillers. The size and 
shape of the particles dictate their spatial rearrangement within the cavity, playing a 
critical role in new bone formation, and it has been suggested that spherical-shaped 
particles with a narrow size distribution may present some advantages compared to other 
types of microparticles. 
The main objective of this work was to develop microspheres with a uniform size, to be 
used as bone-defects fillers and as carriers for enzymes. As a specific application, the use 
of the system as an adjuvant therapeutic strategy to treat bone lesions associated with 
Gaucher disease (GD) was investigated, and microspheres were analysed as vehicles for 
the recombinant enzyme glucocerebrosidase (GCR), currently employed in its treatment. 
As a starting point, alginate was used as a model-matrix for the entrapment of recombinant 
GCR. GCR-loaded microspheres with a uniform size were prepared by droplet extrusion 
and ionotropic gelation with Ca2+. The enzyme retained full activity, and its stability at 
physiological pH was improved. GCR release profile was characterised by a high burst, 
followed by a stage of very slow release. The released enzyme was internalised by cultured 
GCR-deficient fibroblasts obtained from a GD patient, enhancing their residual enzymatic 
activity. 
As a strategy to modulate GCR release-kinetics and at the same time improve cell adhesion 
to alginate microspheres, hydroxyapatite (HAp) or calcium titanium phosphate (CTP) were 
added to the polymeric matrix. Calcium phosphate-alginate microspheres were prepared, 
using the same technique. GCR was incorporated in the microspheres before gel formation 
in two different ways: pre-adsorbed onto the ceramic particles or dispersed in the 
polymeric/ceramic paste. The two strategies resulted in distinct release profiles, being the 
former characterised by a lower initial burst and a more gradual release. 
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Adhesion of osteoblastic-like cells to calcium phosphate-alginate microspheres of different 
compositions was analysed. The ceramic-to-polymer ratio strongly influenced the ability of 
cells to adhere and spread on the microspheres surface. Cells were only able to adopt a 
flattened morphology on microspheres with a high percentage of ceramic. 
In view of these findings, microspheres composed only of calcium phosphate appeared to 
be suitable for the envisaged application. CTP and HAp microspheres were obtained by 
sintering calcium phosphate-alginate microspheres in order to burn-off the polymer and 
bond together the ceramic granules, while maintaining the spherical-shape of the particles. 
The microspheres were characterised using different techniques, and in vitro studies 
revealed that they can be used as supports for the culture of osteoblastic-like cells. 
The possibility of coupling the enzyme GCR to CTP and HAp microspheres using 
adsorption as an immobilisation method was considered. In order to investigate some 
fundamental aspects of the interaction of recombinant GCR with solid surfaces, some 
mechanistic studies using self-assembled monolayers (SAMs) of different functionalities 
were used to investigate the effect of surface chemistry and solution pH on GCR 
adsorption behaviour. Depending on the conditions used for adsorption, the integrity of the 
enzyme could be preserved and in some cases its catalytic efficiency could even be 
improved. 
Finally, some preliminary results indicate that calcium phosphate microspheres may be 
used to reversibly adsorb the enzyme while preserving its biological activity, and 
efficiently deliver it in vitro into GCR-deficient cells from GD type I patients. This 
suggests that physical adsorption of GCR to calcium phosphate microspheres may provide 
a simple and efficient method to couple the enzyme to the microspheres, and may enable 
its localised delivery to bone defects. 
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Resumo 
 
A Reconstrução de defeitos ósseos é considerada um problema maior em ortopedia, e a 
investigação nesta área mantêm-se activa, a nível clínico e fundamental. Recentemente, 
têm-se vindo a empregar esforços no sentido de se desenvolverem materiais injectáveis 
que possam ser implantados de uma forma minimamente invasiva. Deste modo, é possível 
diminuir o desconforto para o paciente bem como os custos associados ao procedimento, e 
promover uma recuperação mais rápida. A eficácia destes materiais poderá ser melhorada 
se lhes forem associados agentes terapêuticos adequados, que uma vez libertados 
localmente no defeito ósseo irão acelerar a  sua regeneração. 
Materiais sob a forma de pequenas partículas têm sido usados como injectáveis. O 
tamanho e formato das micropartículas ditam o modo como estas se organizam 
espacialmente no interior da cavidade, influenciando o processo de formação de novo osso. 
Vários estudos sugerem que partículas esféricas com uma distribuição de tamanhos 
apertada apresentam vantagens relativamente a outro tipo de partículas. 
O objectivo principal deste trabalho foi desenvolver micropartículas esféricas, de tamanho 
uniforme, para serem usadas como material de preenchimento de defeitos ósseos e como 
veículos de enzimas. Especificamente, estudou-se a sua aplicação como um método 
terapêutico adjuvante para o tratamento de lesões ósseas associadas  à doença de Gaucher. 
Por esse motivo, as microesferas foram utilizadas na imobilização da enzima recombinante 
glucocerebrosidase (GCR), actualmente utilizada  no tratamento desta doença. 
Como ponto de partida, utilizou-se alginato como uma matriz modelo para a  imobilização 
da enzima. Microesferas com um tamanho uniforme contendo a enzima foram preparadas 
utilizando a técnica de extrusão gota-a-gota seguida de gelificação na presença de Ca2+. A 
enzima reteve a totalidade da sua actividade biológica e a sua estabilidade a pH fisiológico 
foi melhorada. O perfil de libertação da GCR caracterizou-se por uma etapa inicial de 
libertação rápida, seguida de uma etapa de difusão muito lenta. Foram realizados estudos 
in vitro utilizando fibroblastos de Gaucher com uma actividade da GCR endógena 
inexistente ou residual. A enzima libertada foi internalizada  pelas células, resultando num 
aumento significativo da actividade enzimática intracelular. 
Por forma a modelar a cinética de libertação da GCR e, simultaneamente, melhorar a 
adesão celular às microesferas de alginato, foram adicionados fosfatos de cálcio 
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(hidroxiapatite, HAp; ou fosfato misto de cálcio e titânio, CTP) ao polímero. 
Microesferas de fosfato de cálcio/alginato foram preparadas usando a técnica 
anteriormente descrita. A enzima GCR foi incorporada nestas microesferas de dois modos: 
pré-adsorvida aos pós cerâmicos ou dispersa na pasta de polímero/cerâmico. As duas 
estratégias resultaram em perfis de libertação distintos, sendo o primeiro caracterizado por 
uma difusão mais gradual e uma diminuição da quantidade libertada na etapa inicial. 
A adesão de osteoblastos a microesferas de fosfato de cálcio/alginato de diferentes 
composições foi analisada. A proporção cerâmico-polímero influenciou significativamente  
a percentagem de adesão e a morfologia das células. Só se observaram células esticadas e 
fusiformes em  microesferas com elevadas percentagem de cerâmico. 
Estes resultados sugeriram que  microesferas compostas somente por fosfatos de cálcio 
poderiam ser adequadas para a aplicação pretendida. Microesferas de CTP e HAp foram 
obtidas por sinterização de microesferas de fosfatos de cálcio/alginato. Durante este 
processo o alginato é queimado e desaparece, ao mesmo tempo que os e grânulos de 
cerâmico se unem, mantendo-se a forma esférica das micropartículas. As microesferas 
foram caracterizadas por diferentes técnicas e estudos in vitro revelaram que as mesmas 
podem ser usadas como suporte de cultura de osteoblastos. 
A possibilidade de se associar, por adsorção, a enzima GCR às microesferas foi tida em 
consideração. Alguns aspectos fundamentais da interacção da GCR com superfícies sólidas 
foram primeiro estudados usando superfícies modelo. Para isso utilizaram-se 
monocamadas auto estruturadas (SAMs) com diferentes grupos funcionais. Os efeitos da 
química da superfície e do pH da solução no processo de adsorção foram investigados. 
Dependendo das condições usadas, foi possível preservar a integridade da enzima e até 
melhorar a sua eficiência catalítica. 
Ensaios preliminares mostraram que as microesferas de fosfatos de cálcio podem ser 
usadas para imobilizar a enzima GCR de um modo reversível, preservando a sua 
actividade biológica. A imobilização por adsorção constitui assim um método simples e 
eficiente de associar a enzima às microesferas e poderá permitir a sua libertação localizada 
em defeitos ósseos. 
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Résumé 
 
La reconstruction des défauts osseux est considérée un problème majeur en orthopédie et 
jusqu’à présent est un domaine de recherches fondamentales et cliniques. Des efforts sont 
focalisés sur le développement de matériaux destinés à des applications cliniques par 
chirurgie mini invasive qui permettent à la fois une réduction des complications 
invalidantes pour le patient, une récupération assez rapide ainsi qu’une diminution des 
coûts. L’efficacité de ces matériaux peut être améliorée par une intégration d’agents 
thérapeutiques permettant le relarguage in situ de principe actifs et l’accélération du 
processus de régénération osseuse. Des biomatériaux à base de particules ont été déjà 
utilisés  pour le comblement des défauts osseux. La taille et la forme de ces particules 
influencent leur distribution/disposition au sein du défaut osseux et par conséquent leur 
confère un rôle important dans le néoformation de l’os. Il a été suggéré que des particules 
en forme sphérique avec une distribution de taille réduite peut présenter des avantages en 
comparaison avec les autres types de microparticules.  
Le principale objectif de ce travail était de mettre au point des microspheres de taille 
uniforme afin d’être utilisées comme matériaux de comblement des défauts osseux et de 
support pour des molécules tellques les enzymes. L’utilisation de ce système comme 
stratégie thérapeutique adjuvante pour le traitement des lésions osseuses associées à la 
maladie de Gaucher a été étudiée. Les microspheres ont été analysées comme support de 
l’enzyme glucocerebrosidase recombinante (GCR), actuellement utilisées dans les 
traitements cliniques de cette maladie.  
Dans la première étape de ce travail, l’alginate a été utilisé comme modèle de matrice pour 
l’incorporation de GCR.  Des microspheres de taille uniforme, chargées de GCR, ont été 
préparé utilisant la technique d’extrusion goutte à goutte suivie de gélification en présence 
de calcium.  L’enzyme garde la totalité de son activité biologique et son stabilité au pH 
physiologique a été amélioré. Le profile de relarguage de GCR se caractérise par une étape 
initiale de libération rapide suivie par une étape de diffusion plus lente. Des études in vitro 
utilisant des fibroblastes de Gaucher avec une activité endogène de GCR inexistante ou 
résiduelle ont été réalisé. L’enzyme relarguée a été internalisée par les cellules, donnant 
lieu à une augmentation significative de l’activité enzymatique intracellulaire. 
De manière à modeler la cinétique de relarguage de GCR et, simultanément, améliorer 
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l’adhésion cellulaire aux microspheres d’alginate, des phosphates de calcium 
(hydroxyapatite, HAp; ou phosphate mixte de calcium et de titanium, CTP) ont été 
additionné au polymère. 
Les microspheres de phosphate de calcium/alginate ont été préparé utilisant des techniques 
antérieurement décrites. L’enzyme GCR a été incorporé à ces microsphères de deux 
manières: pre-adsorbée á la poudre de céramique ou dispersée dans la pâte de 
polymère/céramique. Les deux stratégies résultent en deux profiles de relarguage distincts; 
le premier caractérisé par une diffusion plus graduelle et une diminution de la quantité 
relarguée au cours de l’étape initiale. 
L’adhésion des ostéoblastes aux microsphères de phosphates de calcium/alginate de 
différentes compositions a été analysée. La proportion céramique/polymère influence 
significativement le pourcentage d’adhésion et la morphologie des cellules. Sont observées 
les cellules allongées et fusiformes uniquement sur des microsphères avec un pourcentage 
élevé de céramique. 
Ces résultas suggèrent que les microsphères composées uniquement de phosphate de 
calcium peuvent être adaptées à l’application clinique prétendue. Les microsphères de CTP 
et d’HAp ont été obtenues par sintérisation de microsphères de phosphate de 
calcium/alginate. Au cours de ce processus l’alginate est brûlée et ainsi disparaît. Au 
même temps les granules de céramiques s’unissent et les particules maintiennent une 
forme sphérique. Les microsphères ont été caractérisées par différentes techniques. Les 
études in vitro montrent qu’elles peuvent être utilisées comme support pour les cultures 
des ostéoblastes.  
La possibilité d’associer, par adsorption, l’enzyme GCR aux microsphères a été prise en 
considération. Certains aspects fondamentaux d’interactions de GCR avec des superficies 
solides ont été premièrement étudiés utilisant des modèles de superficie. Dans ce but, des 
monocouches auto structurées (SAM) possédant différents groupes fonctionnels  ont été 
utilisé. Les effets de la composition chimique de la superficie et du pH de la solution 
pendant le processus d’adsorption ont été étudiés. 
Selon les conditions utilisées, il a été possible de préserver l’intégrité de l’enzyme et même 
améliorer son efficacité catalytique. 
Des études préliminaires montrent que les microsphères de phosphates de calcium peuvent 
être utilisées pour immobiliser la GCR de façon réversible, préservant son activité 
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biologique. L’immobilisation par adsorption constitue une méthode simple et efficace 
permettant l’association de l’enzyme aux microsphères. Il est possible que cette méthode 
permettra le relarguage l’enzyme de manière localisée au niveau des défauts osseux. 
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Chapter I 
 
INTRODUCTION: MICROSPHERES FOR BONE REGENERATION 
AND LOCALISED DELIVERY OF ENZYMES 
 
 
 
1. Microspheres as injectable materials for bone regeneration 
 
1.1. General aspects 
 
Several congenital anomalies, diseases and trauma may result in bone loss. In many 
situations, the damaged tissue fails to regenerate or heal spontaneously, creating the need 
to fill defects in the skeleton. The use of autografts to restore original function, although 
considered by many surgeons to be the best option, is limited by the reduced availability 
and the risks associated with harvesting.1,2 On the other hand, allografts obtained from 
human donors, and xenografts obtained from other species exhibit limited regeneration 
potential, and can lead to immunorejection, and transmission of diseases.2 
The field of regenerative medicine has emerged as an alternative strategy that combines 
engineering and life sciences principles, to create biologically functional substitutes aiming 
at restoring, maintaining or improving tissue function.3,4 
Most strategies rely on the use of scaffold materials to provide a physical support for new 
tissue formation. The material can be seeded with cells prior to implantation, or implanted 
directly into the injured tissue and stimulate the host cells to promote local tissue repair.5 
Depending on the application, signalling molecules, such as growth factors, can be 
incorporated in the materials and improve their performance by stimulating the appropriate 
cells to migrate into the implant site, proliferate, and even differentiate along the desired 
lineage. In the ideal case, the material should degrade and resorbe, at a controlled rate, 
while being progressively replaced by histologically and functionally normal tissue. 
Although the majority of scaffolds described in the literature consist of block tri-
dimensional porous structures, in the past few years increasing efforts have been devoted 
to the development of injectable biomaterials as an alternative for bone augmentation or 
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replacement. The main advantage of using injectable materials is the possibility of filling 
bone-defects of different shapes and sizes using a minimally invasive surgery, which 
provides less discomfort to patients undergoing a variety of orthopaedic procedures, allows 
a faster recovery and has lower costs.6 
Some of the desirable features of a biomaterial for bone regeneration applications 
include:7-9 
 
• Be easily sterilisable to prevent infection, without losing key physicochemical 
properties; 
• Be easily available (“off-the-shelf”) and  easy to handle by the surgeon; 
• Be biocompatible, i.e., it must not elicit an unresolved inflammatory response nor be 
excessively immunogenic or cytotoxic; 
• Have adequate initial mechanical properties to provide proper support in the early 
stages of healing, without compromising the load-bearing capabilities of the newly 
formed tissue; 
• Promote the formation of a functionally normal tissue, identical to the original; 
• Promote, or at least permit, the growth and maturation of blood vessels on the implant 
site, to guarantee an adequate supply of nutrients and oxygen to the newly formed 
tissue; 
• Be biodegradable, i.e.,  it should degrade in vivo at a predictable and controlled rate, in 
concert to tissue growth, leading to biocompatible and ideally resorbable degradation 
products. 
 
Additionally, an injectable material must present adequate rheological properties. These 
must be balanced, so that the material can be easily manipulated during surgery, but at the 
same time be adaptable to the irregular wound site, were it must remain for an adequate 
period of time. Some of the requirements that an injectable material must ideally satisfy to 
be used as a bone defects filler are listed below:6,10 
 
• It must present an adequate fluidity to be extruded through the injection cannula 
without blocking it; 
• It must have an adequate viscosity to allow the correct filling of the cavity; 
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• It must enable the regulation of the amount injected using a monitoring system, for 
example by being sufficiently radiopaque, so that the injection may be stopped the 
moment the defect is filled, without overflow; 
• It must remain within the cavity, during an adequate period of time, withstanding 
blood flow and mechanical stress. 
 
A variety of injectable materials, both ceramic- and/or polymer-based, have been recently 
described in the literature. Most of them consist of self-setting cements,11,12 gels13 and 
liquid precursors that solidify in-situ under physiological conditions or in response to an 
external stimulus.14-16 
Micro- or nanoparticles suspended in autologous blood or other appropriate vehicle may 
also be used as injectable fillers for the regeneration of bone defects.17-22 Upon 
implantation, the microspheres-vehicle system is expected to easily conform to the 
irregular implant site, providing a permissible matrix for both tissue and vascular ingrowth, 
as required for effective healing. The particles may, in addition, be seeded with autologous 
cells prior to implantation, functioning as cell-carriers, and/or be loaded with bioactive 
agents to stimulate the process of tissue regeneration. These different approaches will be 
discussed in the following sections. 
 
 
1.2. Microspheres as bone defects fillers 
 
Successful closure of bone defects remains a major concern in reconstructive surgery. A 
wide variety of particle-based fillers have been described in the literature, including 
irregular multifaceted granules and smooth spherical particles of various sizes, with or 
without pores, and with broad or uniform size distributions.12,23-27 Depending on their 
characteristics, microparticles may find application in dental, periodontal, 
oral/maxillofacial and other orthopaedic surgical procedures.  
While block-based osseous fillers may form sparse bone at their periphery and even less 
bone in their interior, an assembly of particles may allow bone regeneration throughout its 
volume cross-section. However, the size and shape of the particles dictate their spatial 
rearrangement within the implant site, playing a critical role in new bone formation.28 
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Although some empty space is necessary to allow tissue and blood vessels ingrowth, 
excessive interstitial space, resulting from the use of very large particles, may favour the 
development of fibrous tissue and compromise adequate healing.29 In addition, large 
particles are more difficult to inject, leading to a more invasive implantation. 
On the other hand, very small particles, as well as particles with broad size distributions, 
result in dense packing at the defect, which may impair tissue ingrowth and 
vascularization.28 Depending on their size, very small particles may even be able to 
migrate from the implant site causing injury elsewhere. 
 
The shape of the microparticles is equally important. Irregularly shaped particles have 
sharp or angular edges that are more susceptible to wear and may damage the surrounding 
tissue once implanted and/or induce strong inflammatory responses.30 
The effect of particles size and shape on the degree of bone regeneration has already been 
studied by several authors.28-31 For example, Mankani et al.28 created a spectrum of 
roughly spherical particles of hydroxyapatite/tricalcium phosphate, with sizes in different 
ranges, from less than 44 µm to 1000-2000 µm. The particles were implanted along with 
human bone marrow cells in subcutaneous pockets in mice, and the type and extent of bone 
formation was estimated using different techniques. The best results were obtained when 
particles in the ranges of 100-250 µm and 250-500 µm were used. Particles were closely 
packed, with abundant bone and haematopoietic tissue occupying most of the interstitial 
space, and new bone fixing adjacent particles to each other. Largest particles in the ranges 
of 500-1000 µm and 1000-2000 µm were found to be widely separated by non-mineralized 
tissue. Bone tissue was sporadic and discrete and associated with individual particles. 
Transplants with the smaller particles, in the ranges of <100 µm, 44-62 µm and <44 µm, 
formed no bone. 
Additionally, the same authors created flat-sided hydroxyapatite particles measuring 100-
250 µm, which formed arrangements resembling closely packed stacks of plates and 
resulted in no bone formation and limited vascularisation. 
In another study,  Higashi et al.31 showed that transplantation of hydroxyapatite and beta-
tricalcium phosphate particles into hard tissue defects created in dogs resulted in superior 
bone formation around particles measuring 300 µm, while smaller particles with 40 µm 
were associated with less bone formation. 
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These examples highlight the relevance of particles size and shape on their ability to 
promote new bone formation, and suggest that spherical-shaped particles with a uniform 
and adequate size, which may be dependent on the application, present some advantages 
compared to other types of particulates described in the literature (Tab. 1). 
 
Table 1. Possible disadvantages of some types of particulate materials.28-30 
Type of microparticles Disadvantages 
Irregularly shaped particles • Sharp edges that are more susceptible to wear and may damage the 
surrounding tissue once implanted 
• Inhomogeneous packing at the defect creating irregular voids 
• May induce a strong inflammatory response and delay tissue ingrowth30 
Particles with a broad size 
distribution 
• Less predictable properties during injection 
• Inhomogeneous and dense packing at the defect that may impair tissue 
ingrowth and vascularization28 
• Cells at different stages during in vitro colonization 
Large particles 
 
• More difficult to inject, more invasive implantation 
• Lower bone formation in vivo due to excessive interstitial space that 
may favour the development of fibrous tissue28, 29 
Very small particles • Dense packing at the defect that may impair tissue ingrowth and 
vascularization28 
• Migration of the particles from the implant site causing injury elsewhere 
 
 
1.3. Microspheres as scaffolds for cell transplantation 
 
For tissue repair strategies involving cell transplantation, isolated cells or small cell 
aggregates from the patient or a donor may be directly injected into the damaged tissue or 
combined with a scaffold before implantation.4 When cells are injected as a suspension, 
their capacity to reform their respective tissue structure is limited since they lack a 
template to guide restructuring.5, 32 A scaffold material may than be used a carrier matrix to 
deliver cells to specific sites in the body, to define a potential space in which new tissue 
may develop, to guide the process of tissue development, and even to elicit specific cell 
functions.5, 33 
Although cells from different sources have already been employed for transplantation, 
therapies for bone repair generally involve the use of autologous bone marrow-derived 
stromal cells.34 In most situations, these cells have to be expanded in vitro to allow the 
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generation of a large transplantable cell population from a small biopsy. When a scaffold 
material is used, cells may be seeded on the scaffold and directly implanted, or the cell-
material construct may be further cultured to initiate tissue formation in vitro before 
implantation.5, 33 
Depending on the application and type of material, the association of cells with the 
scaffold may be promoted in different ways. When microspheres are used, cells can be 
either entrapped or encapsulated within the particles (matrix or reservoir systems) or be 
seeded at their surface (microcarrier systems) (Fig. 1). 
 
Figure 1. Schematic representation of microspheres loaded with cells: cells can be 
entrapped/encapsulated within the particles or be seeded at their surface. 
 
Encapsulation and entrapment techniques are used to physically isolate cells from the 
outside environment, while maintaining normal cellular physiology within a desired 
permeability barrier.35 For entrapment, cells are generally suspended in a gel or liquid 
precursor, which is subsequently crosslinked to form a spherical-shaped hydrogel network 
containing the dispersed cells. In microcapsules, cells become confined to a liquid core 
surrounded by a semi-permeable membrane.35,36 In both cases, the system must allow 
oxygen and nutrients to diffuse in, and metabolites to diffuse out, in order to guarantee the 
maintenance of cells viability.35 
Cells on the surface of 
microspheres 
Cells encapsulated in 
microspheres 
or
Microspheres with cells 
suspended in a vehicle 
+ Cells Microspheres 
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Most of the examples described in the literature are intended for long-term immobilisation, 
and in most situations these matrix or reservoir systems are aimed at providing 
immunoisolation. A classical application is the immobilisation of insulin-secreting cells in 
polymeric microspheres, for the treatment of diabetes.37  
Transplantation of cells within microspheres has also been used as a tool for tissue 
regeneration. In the field of orthopaedics, however, only a few examples have been 
described in the literature. For example, Spitzer et al. used microspheres composed of 
fibrin with or without α-tricalcium phosphate particles as a carrier for the entrapment and 
in vitro cultivation of periosteum-derived mesenchymal cells.38 Cells were able to 
proliferate and differentiate along the osteoblastic lineage in both matrices, but exhibited 
an increased expression of osteocalcin, a commonly used bone phenotypic marker, when 
the ceramic particles were present. 
Payne et al. described the entrapment of osteoblasts within fast-disintegrating gelatine 
microspheres, to be subsequently suspended in a poly(propylene fumarate) gel that 
solidifies in situ.39-41 These microspheres were used to protect cells during the crosslinking 
process, which otherwise would affect cells viability. In this case, the microparticles are 
expected to degrade soon after implantation, liberating the cells. 
Many cell types, however, perform poorly when suspended in a gel matrix losing their 
ability to proliferate or changing their phenotype. Consequently, some researchers have 
attempted to modify the scaffolds with bioactive moieties possessing inherent biological 
functionality in order to mimic, as close as possible, the natural extracellular matrix 
(ECM). One common example is the bulk functionalisation of hydrogel scaffolds with 
RGDs, which are short amino acid sequences that exist on integrin-binding proteins of the 
ECM and mediate the process of cell adhesion in vivo. In this sense, they are used to 
provide an improved environment for entrapped cells and also to promote the integration 
of the implanted cell-material construct after implantation. For example, Alsberg et al. 
showed that modification of alginate with RGD-containing peptides promotes osteoblast 
adhesion and spreading, whereas minimal cell adhesion is observed on unmodified 
hydrogels.42 Furthermore, the authors demonstrated that transplantation of primary rat 
calvarial osteoblasts within alginate beads revealed statistically significant increases of in 
vivo bone formation with RGD-modified alginate compared with unmodified alginate. 
Burdick JA et al. promoted the photoencapsulation of osteoblasts in injectable poly(ethylene 
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glycol) (PEG) hydrogels, and demonstrated that entrapped osteoblasts were able to form a 
mineralized matrix, which was enhanced in gels grafted with RGD adhesive peptides.43 
 
Anchorage-dependent cells may also be seeded on the surface of microspheres for 
subsequent transplantation. In this case, once implanted, cells may freely migrate and 
participate more actively in the process of tissue regeneration. The concept of culturing 
cells as monolayers on the surface of small spheres, commonly referred as microcarriers, 
was first conceived by Van Wezel44 and different types of microcarriers are currently 
available in the market. The large surface area-to-volume ratio provided by microcarriers 
allows easy propagation and high cell yields, while requiring much less culture medium 
and space than traditional monolayer culture techniques. In cell culture technology, 
microparticles have been used as an alternative culture-substrate for the in vitro growth of 
anchorage-dependent cells, for large-scale cell expansion and/or production of numerous 
cell products including vaccines, enzymes, antibodies, etc. More recently, attention has 
been drawn to the use of microparticles as injectable cell-carriers for tissue regeneration, 
including bone.17, 28, 45-49 
For example, Hsu et al. prepared microspheres comprised of particulate hydroxyapatite 
dispersed in a fibrous collagen matrix and used them as supports for the in vitro growth of 
osteoblasts isolated from rat calvaria.17 The cells proliferated along 7 days in culture and 
expressed alkaline phosphatase activity. Further studies demonstrated that osteoblasts 
cultured on these microspheres were also able to form a mineralized matrix.49 
 
 
1.4. Microspheres as vehicles for bioactive molecules 
 
Bone repair is a complex cascade of biological events regulated by specific cells, the 
extracellular matrix and distinct growth factors, which act as signalling molecules and 
modulate cell function. 
The biochemical stimulation of tissue regeneration via the local delivery of exogenous 
growth factors is currently one of the strategies used in bone repair therapies.50 By 
selecting the appropriate growth factors, the relevant type of cells may be induced to 
migrate into the implant site, proliferate and finally differentiate along the desired lineage. 
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Some of the most important growth factors with potential for bone regeneration include the 
various bone morphogenetic proteins (BMPs), the transforming growth factor beta (TGF-
β), the insulin-like growth factor (IGF), the fibroblast growth factor (FGF) and the vascular 
endothelial growth factor (VEGF).51 Their biological and clinical roles in skeletal growth 
and bone formation have been extensively investigated.52, 53 
However, the fragile nature of these proteinaceous agents, namely their short biological 
half-life and lack of long term stability, has limited their use for therapeutic purposes and 
has motivated the development of new delivery strategies based on the use of protective 
carriers.54, 55 The utilization of vehicles may also enable the simultaneous administration of 
a combination of growth factor with synergistic effects, and coordinate their actions by 
providing a controlled release kinetics in a temporal and tightly regulated sequence.54, 56 
Numerous examples of the use of microparticles as growth factors carriers for use in bone 
repair may be found in the literature.57-59 Depending on the specificity of the illness, other 
bioactive agents such as antibiotics and other pharmaceutical agents may also be 
incorporated in bone-defect fillers to improve their performance and enhance tissue 
regeneration. 
In the next section, an overview of the present technology used in the preparation of 
protein delivery systems, including a description of the most common protein-carrier 
coupling techniques, is provided. Protein stability in controlled release formulations and 
release mechanisms are also discussed. 
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2. Protein delivery systems 
 
2.1. General aspects 
 
During the past few years, remarkable advances in the area of biotechnology have allowed 
several genetically engineered protein drugs to be produced, which are now commonly 
used to treat numerous diseases.60 Despite their therapeutic potential, their clinical 
application is in many situations hampered by their unstable nature, high susceptibility to 
degradation and short in vivo half-life. For this reason, the effectiveness of these protein 
agents is in general highly dependent of a frequent-administration regimen, which 
compromises the patient’s quality of life, and often results in very expensive treatments. 
The development of new delivery routes, based on the use of protein vehicles, may 
suppress some of these shortcomings and improve the performance of protein 
pharmaceuticals, by providing an optimized therapy and better patient compliance. Some 
of the potential advantages that protein delivery systems may offer are listed below:61-64 
 
 
• Continuous or pulsatile protein release over extended periods of time; 
• Protection of protein drugs from rapid in vivo degradation and clearance, prolonging 
their half-lives and consequently their efficiency; 
• Avoidance of irregular plasma levels, with peaks and valleys, associated with 
conventional injections; 
• Localised delivery of proteins to targeted sites, body compartments or cell types, 
reducing their overall systemic exposure; 
• Self-regulation, providing periodic protein release when physiologically desirable or 
protein release triggered by an external stimulus. 
 
 
In the future, gene therapy may be able to replace protein therapeutics, but currently there 
are still considerable technical obstacles. For this reason, in the near future protein drugs 
are expected to retain or increase their importance, and with improvements in formulation 
and administration routes they may never become obsolete.63 
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2.2. Protein-carrier coupling techniques 
 
Most of the techniques used in the preparation of protein delivery systems rely on the 
association of proteins with soluble or solid carriers. There are several protein-carrier 
coupling strategies, which have been applied particularly within the field of enzyme 
immobilisation65 and, more recently, for controlled release of protein pharmaceuticals.61 
Some of the most commonly used protein coupling techniques are described below. The 
first two approaches are based on the establishment of physical or chemical bonds between 
protein molecules and a solid surface. The other approaches involve the physical 
entrapment of proteins within polymer lattices or microcapsules, and the formation of 
protein-polymer soluble conjugates. Finally, the last category consists on the association of 
proteins with biological structures such as liposomes and cells.66 
 
2.2.1. Physical and chemical attachment to a surface 
 
Non-specific physical adsorption of a protein from a solution on a solid surface is probably 
the simplest and longest known method of immobilisation. It requires little more than 
bringing the solid phase into contact with a protein solution for a short period of time. So, 
the ability to load the protein in a simple and cost-effective process, without using solvents 
or any polymerisation steps, is one of the greatest advantages of this method.65,67 
Proteins have different surface domains, with hydrophobic/hydrophilic and 
negatively/positively charged character, and as a consequence they are highly surface 
active. The most relevant phenomena involved in the process of protein adsorption are 
electrostatic and hydrophobic interactions, and also the intrinsic structural stability of the 
protein.68,69 The rate and extent of adsorption will be determined by the properties of the 
protein and its concentration in solution, by the characteristics of the adsorption matrix, 
and by the nature of the solvent and other properties of the medium, including pH, ionic 
strength and temperature.68 Proteins usually have higher affinity for moderately 
hydrophobic surfaces than for hydrophilic ones.68  
Upon adsorption, proteins generally undergo structural rearrangements dependent on the 
type and strength of the interactions established with the matrix.70-72 Conformational 
alterations may result on protein denaturation and/or loss of functional activity73, 74 or, in 
opposition, provide enhanced stability and/or biological functionality to the protein.71, 75-79 
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Physical adsorption methods have been widely used in the development of 
microparticulate carriers for the localised delivery of vaccines to the site of action,80-83 and 
for the delivery of proteinaceous agents in tissue regeneration applications.18, 84-86 
 
Although adsorption techniques are characterised by their practical simplicity, they lack 
the potential specificity of covalent techniques. Chemical immobilisation processes may be 
designed to induce protein molecules to be specifically bound in a favourable orientation, 
while allowing the retention of functional activity.87 Proteins possess different reactive 
groups available for chemical bonding, namely amines, carboxyl groups and thiols, as well 
as carbohydrate moieties in the case of glycoproteins.65 Different supports, with functional 
groups suitable for covalent coupling or susceptible to activation, have already been used.65 
A chemically immobilised protein may also be attached to the surface via a spacer group, 
which can provide greater steric freedom and thus greater biological functionality to the 
protein.67 
Although protein immobilisation through covalent attachment may result in loss of 
activity, chemical bonds are generally very stable and may confer higher thermal and 
storage stability to the immobilised protein by preventing structural rearrangement during 
use.65 
 
2.2.2. Entrapment and encapsulation within polymeric matrices 
 
Entrapment or encapsulation within polymeric matrices, are probably among the 
techniques most widely used in the designing of proteins delivery systems. Different 
vehicles, with a variety of geometries and configurations, have been fabricated from 
diverse types of natural and synthetic polymers.56,61,88-90 Micro- and nanoparticles are 
among the most popular forms since they can be applied through minimally invasive 
surgery. 
The term “entrapment” is commonly used for monolithic systems in which the protein 
becomes dispersed throughout the matrix, while the term “encapsulation” is used for 
reservoir systems in which the protein becomes confined to a cavity surrounded by a semi-
permeable membrane that regulates the release rate.  
The protein to be immobilised can be loaded into the hydrogel matrices after or before 
polymerisation.89 In the former case, loading is carried out by soaking a dried matrix in a 
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solution containing the protein. Usually, this procedure results in a rather heterogeneous 
distribution of the protein within the matrix, with a significant portion being localised at 
the surface. Moreover, loading of very high molecular weight proteins may be difficult, if 
their size prevent them to readily diffuse into the structure. Although this method may 
result in minor losses of protein integrity, the loading efficiencies that can be obtained are 
generally low.89 
In the other case, when proteins are present during the polymerisation step, their integrity 
may be compromised if the conditions used are too harsh. However, many polymers, 
namely those which are water-soluble, are able to form gels under very mild conditions, 
allowing proteins to be entrapped while retaining full activity.89 
 
2.2.3. Conjugation with soluble polymeric moieties 
 
The conjugation of proteins with other species, such as different proteins and water-soluble 
polymers provides a valuable means of altering the biological behaviour of the protein of 
interest, and has been envisioned for a variety of purposes.61, 91, 92 Among these are the 
ability to increase the hydrodynamic radius of the protein, which results in a decreased rate 
of renal clearance and a prolonged circulation half-life. Additionally, protein-polymer 
conjugates may exhibit increased solubility, lower immunogenicity and lower 
susceptibility to proteolysis than the isolated proteins.61,93 One of the polymers most 
widely used in the formation of protein-polymer conjugates is poly(ethylene glycol 
(PEG).94, 95 Conjugation with peptides and carbohydrate moieties has been used to assist in 
protein targeting to specific cell types.96, 97 
 
2.2.4. Association with biological structures 
 
Biological structures such as liposomes and cells also constitute potential carriers for the in 
vivo delivery of protein agents. 
Liposomes were characterised for the first time by Bangham et al.98 They were initially 
developed as models of biological membranes, and only after applied as drug delivery 
systems. Basically, liposomes are spherical lipid vesicles with one or more concentric 
lamellae, which are formed in aqueous solution on the dispersion of certain bilayer-
forming molecules.99 The hydrophobic part of the amphiphiles forms the hydrophobic 
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interior of the bilayers and the hydrophilic part, the polar head group, is in contact with the 
aqueous phase. The interior of the liposomes is an aqueous core with a chemical 
composition similar to the one of the solution used to prepare them. The chemical nature of 
the amphiphilic molecules and the method used to prepare the vesicles are selected taking 
into consideration the type of protein and the final application. Protein-containing lipid 
vesicles have been extensively applied in the biomedical field, particularly for enzyme-
replacement therapies and delivery of vaccines.99, 100 
Some cell types, in particular erythrocytes, have also been used as protein carriers.101,102 
Because of their biocompatible nature, these cells elicit little or none immune response. 
Additionally, they are readily available in large quantities and allow high entrapment 
efficiencies.101,102 Since the physiological turnover of erythrocytes involves their 
destruction primarily by macrophages of the spleen and liver, they are commonly used to 
selectively target these organs.101,102 
 
2.3. Protein stability in controlled release formulations 
 
Protein stability is probably one of the most important obstacles for the successful 
formulation of protein-delivery systems. 
Unlike other therapeutic agents, proteins are high molecular weight compounds with a 
defined structure, which is responsible for their unique biological functions. For this 
reason, proteins are very susceptible macromolecules that may easily become reversible or 
irreversible inactive by several mechanisms, such as unfolding, chemical alteration, self-
aggregation, etc.103-105 
During preparation, and throughout the lifetime of the delivery system, proteins may 
become exposed to potentially harmful conditions. Therefore, the degradation pathways 
and their impact on protein stability must be systematically analysed. Some common 
sources of protein inactivation are: interactions between the protein and the matrix, 
exposure of the protein to the conditions selected for the immobilisation process (type of 
solvents, temperature, pH, shear forces, etc.), and exposure of the protein to an altered 
environment associated with the degradation of the matrix (degradation products, pH, loss 
of excipients, etc).61, 103, 104 These interactions will ultimately influence the release rate and 
the overall condition of the released protein. 
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Two major stability problems, often encountered after implantation of the delivery system 
and during the release period, are the formation of insoluble protein-protein aggregates, 
usually in entrapment systems, and the irreversible adsorption of the protein to the 
carrier.106-108 While the formation of aggregates should be avoided as these are often 
therapeutically inactive and may be immunogenic, protein adsorption to the matrix should 
be reduced as much as possible, since a fraction of the valuable protein will be wasted. 
Fortunately, different strategies have been proposed to overcome these problems, namely 
through the control of  formulation parameters and the use of protective excipients.108-111 
 
2.4. Release mechanisms 
 
Depending on the application of the delivery system, the objective may be either to a have 
a transient or a long-term association of the protein to the carrier. Release of proteins from 
their vehicles will be, however, highly dependent on the coupling method initially used. 
For example, physical adsorption bonds are generally reversible, at least partially, 
following ionic and pH changes and especially in the presence of other proteins.112 Huber 
et al. have developed a sophisticated device with the ability to adsorb proteins from 
solution, hold them with negligible denaturation, and release them on command.113 In this 
case, surface properties are modulated by an active polymer which can be thermally 
switched between a more hydrophobic protein-adsorbing state to an antifouling hydrophilic 
state that promotes protein release. 
Covalent coupling of protein with soluble or non-soluble carriers, although generally 
irreversible in nature, may also be used for delivery purposes if biodegradable carriers or 
labile bonds are selected.67 
Protein release from matrix or reservoir systems can be governed by several mechanisms 
that can be generally classified as: (a) pure drug diffusion through a rate-controlling 
membrane or matrix (diffusion controlled), (b) degradation of the matrix (degradation 
controlled) or (c) counter-current diffusion of aqueous medium into the matrix (swelling 
controlled). This are however simplified models, and release profiles are often more 
complex resulting from a combination of mechanisms.61,89 
Some of the most commonly observed protein release profiles are illustrated in Fig. 2.61 
The zero-order profile is characterised by a constant release rate over time. The first-order 
Chapter I  
16 
profile, typical of a diffusion-controlled system, is characterised by a release rate that 
decreases with time. The biphasic release profile, which often occurs in degradable 
matrices, is characterised by two distinct release phases: the first one is characterised by 
protein diffusion from the surface and through the porous network, until a plateau is 
reached; and the second one is observed posteriorly, when the matrix begins to degrade 
liberating the remaining drug. Finally, there is the burst profile, which may also precede 
the other depicted release profiles and can generally be attributed to surface localised or 
non-incorporated proteins. 
 
 
Figure 2. Different time-dependent release profiles commonly observed in protein delivery 
systems.61 
 
Although major emphasis has been focused on the development of zero-order release 
systems, this profile is not always necessary and sometimes is not desirable. For example, 
a constant release over time may not match drug absorption by the body, which often 
decreases over-time.89 Also, for certain therapies that require fluctuating protein levels, as 
for example the delivery of insulin for patients with diabetes, the amount of drug released 
should be affected according to physiological needs. Some polymers, generally designated 
as “smart” or “stimulus responsive” can respond to environmental or external stimulus that 
trigger drug release.14,88,89,114 In self-regulated systems the release rate is controlled by 
feedback information, without any external intervention. Several approaches, such as pH-
sensitive polymers, enzyme-substrate reactions, pH-sensitive drug solubility, competitive 
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binding and metal concentration-dependent hydrolysis, may be used as rate-control 
mechanisms.114 In externally controlled systems, release may be modulated by external 
stimulus of different sources, such as: magnetic, ultrasonic, thermal, and electric.114 
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3. Gaucher disease 
 
3.1. General aspects 
 
Gaucher disease (GD) is an autosomal recessive disorder, characterised by the decreased 
catalytic activity and/or stability of the lysosomal enzyme glucocerebrosidase.115-118 This 
defect leads to an excessive intracellular accumulation of glucosylceramide, a constituent 
of biological membranes and its major natural substrate.115-118 Although 
glucocerebrosidase is present in almost all cell types, the accumulation of 
glucosylceramide is characteristically observed in macrophages, as a result of their role in 
the turnover of blood cells and consequently on the degradation of membrane glycolipids. 
The hallmark of GD is the occurrence of lipid engorged cells, designated Gaucher cells 
(Fig. 3a), in several organs (Fig. 3b), underling the most common clinical manifestations of 
the disease, namely organomegaly, haematological abnormalities and skeletal 
deterioration.115-118 
 
Figure 3. a) Gaucher cells in bone marrow aspirate118 b) targeted organs in GD.117 
 
Classically, three main variants of GD are considered on the basis of the presence and 
degree of neurological involvement. Type 1, the mildest and most common form, is 
characterised by the absence of neurological involvement and the onset of clinical 
manifestations may occur from childhood to adulthood. Type 2, is a rare variant causing 
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severe early-onset neurological manifestations usually fatal within 2 years of age, and type 
3 is a subacute juvenile-onset slowly progressing neurodegenerative form.  
The phenotypes and genotypes associated with GD are markedly heterogeneous, and there 
is a wide variability in the pattern and severity of disease involvement between and within 
each subtype. The most frequent mutation (N370S) is only present in type I GD patients.  
 
GD is the most prevalent and best studied lysosomal storage disease. The subtype I occurs 
with a frequency of 1 in 40000-60000 in the general population, and in 500-1000 among 
Ashkenazi Jews.119 
The birth prevalence of GD in Portugal is 1 in 73000.120,121  Among the 84 diagnosed GD 
patients, 21 are homozygots for the N370S mutation.120,121 However, according to the gene 
frequency determined in the general Portuguese population,120 about 200 homozygots for 
the N370S mutation can be predicted. These findings suggest that the great majority of 
homozygotes for this mutation present a mild and/or non classical clinical phenotype, 
remaining undiagnosed.120, 121 
 
3.2. Glucocerebrosidase 
 
Glucocerebrosidase (β-glucosidase, N-acyl-sphingosyl-l-β-D-glucoside glucohydrolidase, 
EC 3.2.1.45) is an acid hydrolase present in lysosomes of all nucleated cells of mammals. 
It is responsible for catalysing the conversion of glucosylceramide (N-acylsphingosyl-l-O-
β-D-glucoside), its major natural substrate, to ceramide and glucose, through hydrolysis of 
the O-β-D-glucosidic linkage (Fig. 4). 
 
Figure 4.  Structure of glucosylceramide (N-acylsphingosyl-l-O-β-D-glucoside). 
Glucose 
Ceramide
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In its natural physiological state, GCR is tightly associated to the inner membrane of 
lysosomes with substantial hydrophobic interaction, but no evidence of a transmembrane 
domain has been found.122 The mature unglycosylated human enzyme has 497 amino acids 
(Tab. 2) and has five predicted N-glycosylation sites, being the first four normally 
occupied.123 Studies with cultured human skin fibroblasts124 showed that in those cells 
glucocerebrosidase is synthesised as a 62.5 kDa precursor with high-mannose-type 
oligosaccharide chains and an apparent native isoelectric point of 6.0-7.0. Subsequent 
processing of the oligosaccharide moieties to sialylated complex-type structures results in 
formation of 65-68 kDa forms of the enzyme with apparent native isoelectric points of 4.3-
5.0. These forms are transported to lysosomes via unknown mechanisms and subsequently 
modified by the sequential action of lysosomal exoglycosidases, finally resulting in a 59 
kDa form with an isoelectric point near neutrality. The lysosomal enzyme may exist in 
different aggregation states, whether as a monomeric form or as an active larger complex 
containing negatively charged phospholipids and activator proteins (saposine C).125-127 
Presumably, these compounds facilitate the interaction of the enzyme with the substrate by 
inducing a structural change that conforms it into a more active state (Fig. 5).125,126 
 
Table 2. Amino acid sequence of human glucocerebrosidase.128  
 1 
| 
11 
| 
21 
| 
31 
| 
41 
| 
51 
| 
 
1 A R P C I P K S F G YSSVVCVCNA T Y C D S F D P P T FPALGTFSRY ESTRSGRRME LSMGPIQANH 60 
61 TGTGLLLTLQ PEQKFQKVKG FGGAMTDAAA L N I L A L S P P A QNLLLKSYFS E E G I G Y N I I R 120 
121 VPMASCDFSI RTYTYADTPD D F Q L H N F S L P EEDTKLK IPL IHRALQLAQR PVSLLASPWT 180 
181 SPTWLKTNGA VNGKGSLKGQ PGDIYHQTWA RYFVKFLDAY AEHKLQFWAV TAENEPSAGL 240 
241 LSGYPFQCLG F T P E H Q R D F I ARDLGPTLAN STHHNVRLLM LDDQRLLLPH WAKVVLTDPE 300 
301 AAKYVHGIAV HWYLDFLAPA KATLGETHRL FPNTMLFASE ACVGSKFWEQ SVRLGSWDRG 360 
361 MQYSHSIIT N LLYHVVGWTD WNLALNPEGG PNWVRNFVDS P I I V S I T K D T FYKQPMFYHL 420 
421 G H F S K F I P E G SQRVGLVASQ K N D L D V A L M HPDGSAVVVV LNRSSKDVPL TIKDPAVGFL 480 
481 E T I S P G Y S I H TYLWHRQ      
Abbreviations: A-Alanine, C-Cysteine, D-Aspartic acid, E-Glutamic acid, F-Phenylalaline, G-Glycine, H-
Histidine, I - Isoleucine, K-Lysine, L-Leucine, M-Methionine, N-Asparigine, P-Proline, Q-Glutamine. R-
Arginine, S-Serine, T-Threonine, V-Valine, W-Tryptophane, Y-Tyrosine. 
 
Purification of GCR requires detergents for complete extraction. The lipid-depleted 
purified enzyme is essentially inactive in vitro, and in order to reconstitute its catalytic 
activity, the presence of exogenous activators such as detergents, bile salts or negatively 
charged phospholipids becomes essential.126,129, 130 It exhibits an acidic pH optimum, 
around 5.5, under standard assay conditions, which is consistent to its lysosomal location.
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3.3. Therapeutic approaches for the management of GD 
 
Different mutations on the gene that encodes for GCR give rise to the expression of mutant 
proteins with defective catalytic properties and/or stability, which ultimately result in the 
manifestation of several debilitating symptoms.131 Besides palliative care, various 
treatments have been tried for the management of patients with GD. Some are still in use, 
and others have been discarded because of lack of effect or severe side-effects.  The two 
most relevant currently available therapies are discussed in the next sections. 
 
3.3.1. Currently available therapies: ERT and SRT 
 
Enzyme replacement therapy (ERT): After the enzymatic defect has been demonstrated 
in GD,132 consideration was given to the development of therapy for patients with this 
disorder, to prevent and/or correct the ongoing formation of lipid loaded Gaucher cells. 
The intravenous administration of exogenous GCR was proposed, and its rationale was 
based on the expected entry of the enzyme, through endocytosis, into the diseased cells and 
subsequent action in situ.132 However, unmodified glucocerebrosidase derived from natural 
sources was of limited therapeutic value, due to its apparent inability to reach and/or act in 
the target intracellular organelles, or its wastage in non-targeted areas, and clinical trials 
were disappointing.133,134 
Figure 5.  A proposed model for the 
degradation of membrane-bound 
glucosylceramide (GlcCer) by 
glucocerebrosidase and the activator 
protein saposin C (SAP-C).126 
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With the discovery that macrophages express a receptor specific for α-mannosyl 
terminated oligosaccharides,135, 136 attempts were made to modify the oligosaccharide 
chains of purified GCR in order to expose mannose residues, which could allow the 
targeting and intracellular trafficking of intravenously administered exogenous enzyme.137 
Improved delivery of human placental GCR to phagocytic cells was effectively achieved 
after treating the enzyme with neuraminidase, β-galatosidase and β-N-
acetylhexosaminidase.137 
These findings stimulated the commercial development and clinical use of an industrial 
formulation of mannose-terminated GCR derived from human placenta (Ceredase®), and 
the advent of enzyme replacement therapy in the early 1990s revolutionized the 
management of patients with GD.138 More recently, an analogue of the human enzyme was 
produced by recombinant DNA technology, using Chinese hamster ovary (CHO) cell 
cultures.128 Although both enzymes show a therapeutic similarity,139, 140 the recombinant 
product (Cerezyme®) presents the advantage of being more easily obtained, as it is 
theoretically unlimited in supply, and of being free of potential pathogenic agents. For this 
reason, it gradually replaced the placenta-derived enzyme in the treatment of GD.122  
After a decade of experience, the beneficial effects of ERT are clear, as it is clinically 
effective in halting the progression of GD and in reversing many of its debilitating 
manifestations. Several studies have been published and it has been well documented that 
ERT reduces organomegaly, improves haematological and biochemical indices, decreases 
bone related pain and induces compensatory growth in children.118,122,141 
 
Substrate reduction therapy (SRT): A novel oral treatment based on the inhibition of 
substrate biosynthesis has been recently suggested and is currently on clinical trials.142, 143 
It involves the use of the iminosugar N-butyldeoxynojirimycin (NB-DNJ, Zavesca®), 
which is an inhibitor of glucosyltransferase, the enzyme that initiates the glycosphingolipid 
biosynthetic pathway and catalyzes the formation of glucocerebroside.142, 143 NB-DNJ 
lowers the synthesis of glycosphingolipids, and consequently their accumulation, to rates at 
which the residual enzymatic activity, when existent, can catabolize stored and incoming 
substrate. Since this strategy is based on the use of a small molecule that is able to 
transverse the blood-brain barrier, it may be effective in the treatment of patients with 
neurological involvement. 
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3.3.2. Suggestions for improved or complementary therapies 
 
Despite the unquestionable benefits of ERT and the recent availability of SRT, several 
issues remain unresolved concerning both treatments, consequently limiting their 
effectiveness.144 Among these, are the dependence of ERT on a life-long frequent-
administration regimen, poor delivery of exogenous enzyme to bones and lungs, and its 
inability to cross the blood-brain barrier.144 In what concerns SRT, several adverse 
secondary effects have been described, probably related with the reduction on the level of 
several glycosphingolipids, and for that reason its use has been approved only for mild-to-
moderate types of GD in cases where ERT is not suitable.119,143 Moreover, both therapies 
are extremely expensive and therefore unavailable to patients in poor countries. 
Positive results on a radically different strategy designated by enzyme enhancement 
therapy (EEC), which may address some of the problems of ERT, have recently been 
reported.145,146 EEC is based on the use of small molecules as “pharmacological 
chaperones” to rescue misfolded and/or unstable mutant enzymes that have residual 
function. These compounds target the most common GD mutation (N370S). A therapy 
based on these chaperones has the potential to be much more convenient and less costly 
than ERT, because small molecules could be taken orally and would be cheaper to mass-
produce than whole enzymes. In addition, small molecules can be found that cross the 
blood-brain barrier, and perhaps address the neurological complications of GD, if they are 
caused by mutants that respond to chaperone therapy. 
 
ERT may also be improved by one of the following techniques, involving the production 
of less costly enzyme analogues and development of enzyme activators and/or stabilizers: 
 
Transgenic analogues of GCR: The high cost of the recombinant enzyme currently used 
in ERT, considered as one of the world’s most expensive drug,147 seriously restricts its 
availability, especially to patients in poor countries. A new source of GCR, involving its 
expression in plant-based systems, as already been proposed as an economically more 
viable alternative.147 Human GCR was engineered as a secreted protein in transgenic 
tobacco plant, and massive amounts of purified enzyme could be obtained.147  Apart from 
economic advantages, the production of protein pharmaceuticals using transgenic plants is 
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easier to control and products are unlikely to be contaminated by animal pathogens, 
microbial toxins or oncogenic sequences.148 However, transgenic GCR is not yet available 
in the market. 
 
Modifications of GCR: Efficacy of GCR therapeutics could presumably be achieved by 
improving at least one of the following properties: 1) prolonged functional circulation half-
life, 2) enhanced uptake by target cells, 3) improved intracellular trafficking to lysosomes 
and 4) prolonged intracellular functional half-life. This way, lower enzyme doses and/or 
less frequent administrations could lead to equal or better treatment efficacy in comparison 
to that obtained with conventional GCR therapeutics. Two strategies that have been 
proposed to achieve this are the modification of the enzyme through introduction of 
additional and/or specific glycosylation sites or its conjugation with non-antigenic 
polymeric moieties such as PEG.149,150 
 
Carriers for GCR: The development of adequate carriers for the in vivo delivery of GCR 
could also improve its therapeutic potential. Some attempts to develop vehicles for this 
enzyme were made in the past, prior to the discovery that macrophages express specific 
receptors for endocytosis of mannose-terminal glycoproteins. Entrapment of GCR into 
different vehicles was then envisaged, to exploit the inherent phagocytic ability of target 
cells that would account for the internalisation of exogenous enzyme.151-154 
Encapsulation of placental GCR in erytrocytes, coated with immunoglobulin to enhance 
specific uptake by macrophages, proved to be an effective strategy to target the enzyme to 
the relevant cells, but its clinical applicability was limited by the difficulties in purifying 
sufficient amounts of enzyme, and by the low entrapment efficiencies achieved.151,152  
Gregoriadis et al. performed clinical trials with liposome-entrapped placental GCR on a 
patient with type I GD, but no significant improvements in the clinical condition of the 
patient were observed after a long-term treatment.154 With the advent of ERT, and since 
clinical results obtained with liposome-entrapped placental GCR were disappointing, this 
approach was abandoned. 
More recently, Korablyov et al. prepared liposome-entrapped recombinant GCR with high 
entrapment efficiencies, and suggested that it would be worthwhile to re-examine the use 
of this type of carriers, by taking advantage of the availability of pure and efficacious 
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industrial enzyme formulations and of the greatly improved understanding of liposome 
technology and biofate.155 However, these studies were not further developed.  
 
3.4. Bone involvement in GD 
 
Skeletal lesions of GD are among its most debilitating consequences. Nearly all affected 
patients, approximately 80%, have some degree of bone involvement, and more than half 
may suffer from serious complications, including pathological fractures.156-158 The skeletal 
aspects of GD have a much greater impact on patient’s quality of life than the 
haematological and visceral abnormalities, by interfering with the activities of daily life 
and restricting mobility.158,159 
The degree and type of bone lesions are highly variable. Bone disease can be 
asymptomatic even when severe, or be accompanied by acute or chronic pain.157 A five-
stage classification of the skeletal alterations normally observed in GD has been proposed 
by Herman G et al., and is presented in Tab. 3.160 
 
Table 3. Staging of skeletal alterations in type 1 Gaucher disease.160 
Stage Skeletal alteration 
1 Diffuse osteoporosis 
2 Medullary expansion 
3 Localised destruction (osteolysis) 
4 Ischemic necrosis (long bones); sclerosis; osteitis 
5 Diffuse destruction; epiphyseal collapse; osteoarthrosis 
 
The development and progression of bone changes in GD potentially involves a variety of 
mechanisms (Tab. 4), which are poorly understood. 
Infiltration of bone and bone marrow tissues by Gaucher cells is believed to trigger a 
cascade of reactions.161 It results in apparently progressive displacement of the fat-rich 
marrow proper with a consequent shift in haematopoietic activity from proximal to more 
distal sites.161 Marrow expansion may cause vascular compression and/or occlusion and 
increased intraosseous pressure.161 Localised bone disease, including cortical thinning and 
long bone deformity, generally occurs in areas adjacent to bone marrow infiltration.161 
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Focal disease, consisting of osteonecrosis and osteosclerosis, is characterised by infarctions 
caused by Gaucher cells, thrombosis and possibly inflammatory processes.161 
Generalised osteopenia presumably results from abnormally high rates of bone resorption 
and reduced rates of bone formation, although osteoclasts and osteoblasts exhibit a normal 
morphology without lipid accumulation. There is no evidence that Gaucher cells directly 
erode bone, but they may stimulate bone resorption by secreting specific cytokines and 
lysosomal enzymes that will interfere with the normal functions of osteoclasts and 
osteoblasts.161 
 
Table 4. Etiologic mechanisms accounting for bone changes in Gaucher Disease.161 
1. Progressive accumulation of glucosylceramide 
2. Secretion or induction of cytokines that stimulate bone resorption 
3. Displacement of adipocytes and of hematopoietic elements 
4. Depletion of osteoblasts and osteoclasts precursors 
5. Increased intraosseous  pressure, with extravascular compression and occlusion 
 
 
Although ERT is clearly efficient in reverting most of the symptoms associated with GD, 
the skeleton response appears to be much slower and attenuated.122 The reasons behind this 
are not clearly understood yet. It may be related to an inefficiently delivery of exogenous 
enzyme to bone;162 or to its lower effectiveness in the target bone cells.122, 163 Quantitative 
analysis of exogenous mannose-terminated GCR uptake in the rat showed that the liver 
was the main site of uptake (ca. 65% of the dose), and that smaller amounts (less than 3%) 
were taken up by the spleen and bone marrow.164 However, the relatively slow skeletal 
response to enzyme therapy does not necessarily imply poor delivery of enzyme to the 
skeleton. In fact, tissue γ-scintigraphy distribution studies with tracer doses of radio-
iodinated mannose-terminated enzyme in patients with type I GD show avid uptake in the 
marrow in proportion to the putative cellular pool of macrophages in this organ.165 
Nevertheless, the authors also showed that the enzyme exhibits an apparent shorter half-
life in marrow tissue, which may have implications in the treatment, and suggest that 
frequent administration of subsaturating doses of enzyme may be needed to restore enzyme 
activity consistently in bone. 
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Several aspects concerning investigation on GD need further study, but it seems clear that 
the delayed and modest skeletal response to ERT remains the major issue in the overall 
effectiveness and management of patients affected by this disease.122 Apparently, and in 
particular in the case of adult patients with lesions in an advanced state of progression, 
skeletal disease is an example of end-organ damage for which adjuvant therapies are 
necessary to restore bone function more rapidly and/or to a greater extent than with the 
currently available therapies. It is conceivable to think that an earlier achievement of a 
complete response would allow an effective establishment of the individually lowest 
effective dose, and thus a less expensive treatment regimen. 
The challenges include the establishment of new strategies to prevent, reverse and control 
further bone abnormalities, to minimize patient discomfort, maximize function and 
enhance quality of life.  
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4. Aim and structure of the thesis 
 
In this thesis, different types of microspheres were developed to be used as injectable 
materials for bone regeneration and as enzyme delivery systems. 
Gaucher disease (GD), a genetic disturbance to which are associated disabling osteoporotic 
bone lesions, was selected as a model disease, where the use of an injectable material able 
to enhance bone regeneration and at the same time provide localised enzyme delivery to 
bone could be beneficial. For this reason, microspheres were analysed as vehicles for the 
recombinant enzyme glucocerebrosidase (GCR), currently used in the treatment of GD.  
 
The experimental work is presented along eight chapters (Chapters II to IX): 
 
Chapter II describes the use of alginate microspheres as a model-matrix for the 
entrapment of recombinant GCR. The enzyme was successfully entrapped in alginate 
microspheres, retaining full activity and exhibiting improved stability at physiological pH. 
Studies using GCR-deficient fibroblasts from a GD patient showed that released GCR was 
internalised by cells, significantly enhancing their residual enzymatic activity, with only 
half of the dose required using free-GCR. The in vitro GCR release profile was 
characterised by a high burst effect followed by a stage of very slow release. 
Whether or not this release kinetics is adequate for the therapeutic efficiency of GCR in the 
in vivo targeting of bone resident Gaucher cells needs to be evaluated. However, the 
possibility of obtaining different patterns of enzyme release increases the range of 
applications of the system. Moreover, it has been previously reported that attachment-
dependent cells are unable to specifically interact with alginate hydrogels, which promote 
minimal protein adsorption presumably due to their high hydrophilic nature.166 
So, as a strategy to modulate GCR release-kinetics and at the same time improve cell 
adhesion to alginate microspheres, calcium phosphate particles were added to the 
polymeric matrix and calcium phosphate-alginate microspheres were prepared. Two 
different types of calcium phosphates were used: hydroxyapatite (HAp), a ceramic widely 
used in orthopaedic applications, and calcium titanium phosphate (CTP), a ceramic that is 
currently under investigation in our laboratory and has been used as an immobilisation 
matrix for several enzymes.167 
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In Chapter III the preparation and characterisation of calcium phosphate-alginate 
microspheres is described. The ceramic powders were mixed with alginate and 
microspheres were prepared by droplet formation under a coaxial air flow, followed by 
ionotropic gelation of the polymeric matrix in the presence of Ca2+. This resulted in the 
formation of an alginate hydrogel network with entrapped ceramic particles. The individual 
components (ceramics and polymer) and the microspheres were characterised using 
different techniques. 
A preliminary evaluation of the microspheres as GCR delivery matrices was also 
undertaken. The enzyme was incorporated in the microspheres before gel formation in two 
different ways: pre-adsorbed onto the ceramic particles or directly dispersed in the 
polymeric/ceramic paste. The two strategies used for GCR entrapment resulted in distinct 
release profiles. When GCR was pre-adsorbed onto the ceramic powders prior to 
microspheres formation the initial burst was significantly reduced, compared to the one of 
alginate microspheres, and a more gradual release was obtained, showing that release-
kinetics modulation was achieved. 
In Chapter IV the adhesion of osteoblastic-like cells to calcium phosphate-alginate 
microspheres of different compositions was analysed. Results demonstrated that the 
ceramic-to-polymer ratio strongly influenced the ability of cells to adhere and spread on 
the microspheres surface. Cells were only able to adopt a flattened morphology on 
microspheres with a high percentage of ceramic. 
In view of these findings, microspheres composed only of calcium phosphate appeared to 
be suitable for the envisaged application. Calcium phosphate materials have long been 
recognized as adequate scaffolds for bone regeneration and some are already used in 
clinical practice. Moreover, they can be more easily sterilised, which is advantageous for 
both in vitro and in vivo applications. 
For that reason, calcium phosphate microspheres were subsequently prepared and 
characterised as described in Chapter V. The microspheres were obtained by sintering 
calcium phosphate-alginate microspheres in order to burn-off the polymer and bond 
together the ceramic granules, while maintaining the spherical-shape of the particles.  
In Chapters VI and VII the behaviour of bone cells cultured on calcium phosphate 
microspheres was investigated. In Chapter VI, the adhesion and proliferation of human 
osteoblastic-like cells (MG63 cell line) on HAp-microspheres was analysed, while in 
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Chapter VII a more detailed study on the proliferation, activity and osteogenic 
differentiation of bone marrow stromal cells cultured on CTP-microspheres is presented. 
Both materials seem adequate for the culture of bone cells. 
The possibility of coupling the enzyme GCR by adsorption to calcium phosphate- 
microspheres was then considered. Upon adsorption, however, proteins generally undergo 
structural rearrangements that may result in denaturation and/or loss of functional activity. 
Nevertheless, these structural rearrangements can sometimes be beneficial rather than 
detrimental, by leading to enhanced enzyme stability and/or activity. In order to investigate 
some fundamental aspects of the interaction of recombinant GCR with surfaces, and the 
suitability of using adsorption as a GCR immobilisation method, some mechanistic studies 
using highly ordered model surfaces were performed. 
In Chapter VIII self-assembled monolayers (SAMs) of different functionalities (X= CH3, 
OH and COOH) were used to investigate the effect of surface chemistry and solution pH 
on GCR adsorption to solid surfaces. These studies revealed that the amount and specific 
activity of adsorbed enzyme were strongly dependent on the conditions used. The results 
showed that GCR has higher affinity for hydrophobic than for hydrophilic surfaces, and 
that highest adsorption was obtained at the more acidic pH values, irrespective of the type 
of surface. However, adsorption on hydrophobic CH3-SAMs resulted in a decreased 
specific activity for all the pH tested. Adsorption on gold and on the more hydrophilic 
SAMs (OH- and COOH-), resulted in different degrees of inactivation at the more acidic 
pH, and in enzyme activation at higher pH values, near the isoelectric point of the enzyme. 
In view of these results, the possibility of using adsorption as a GCR immobilisation 
method seemed appropriate. In Chapter IX, some preliminary results on the ability of 
calcium phosphate microspheres to reversibly adsorb the enzyme while preserving its 
biological activity, and to efficiently deliver it into GCR-deficient cells from GD type I 
patients are presented. 
In the last part of this thesis (Chapter X), a short general discussion (concluding remarks) 
is presented, since a detailed discussion is already provided in each of the preceding 
chapters. Possible directions for future research (perspectives) are also given. 
Most part of the work described in this thesis (Chapters II to VIII) has been published or 
accepted for publication in international journals. 
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Papers resulting from this thesis: 
 
1. Barrias CC, Granja PL, Meriem L, Sá Miranda MC, Barbosa MA. Biological 
evaluation of calcium alginate microspheres as a vehicle for the localised delivery of a 
therapeutic enzyme. Accepted for publication in Journal of Biomedical Materials 
Research, 2005 (Chapter II). 
 
2. Ribeiro CC, Barrias CC, Barbosa MA. Calcium phosphate-alginate microspheres as 
enzyme delivery matrices. Biomaterials 2004;25:4363-4373 (Chapter III). 
 
3. Barrias CC, Ribeiro CC, Rodrigues D, Sá Miranda MC, Barbosa MA. Effect of 
calcium phosphate addition to alginate microspheres: modulation of enzyme release 
kinetics and improvement of osteoblastic cell adhesion. Key Engineering Materials 
2005;284-286:689-692 (Chapter IV). 
 
4. Ribeiro CC, Barrias CC, Barbosa MA. Preparation and characterisation of calcium-
phosphate microspheres for biomedical applications. Journal of Materials Science 
Materials in Medicine 2005, In Press (Chapter V). 
 
5. Barrias CC, Ribeiro CC, Barbosa MA. Adhesion and proliferation of human 
osteoblastic cells seeded on injectable hydroxyapatite microspheres. Key Engineering 
Materials 2004;254-256:877-880 (Chapter VI). 
 
6. Barrias CC, Ribeiro CC, Lamghari M, Sá Miranda MC, Barbosa MA Proliferation, 
activity and osteogenic differentiation of bone marrow stromal cells cultured on calcium 
titanium phosphate microspheres. Journal of Biomedical Materials Research A 
2005;72A:57-66 (Chapter VII). 
 
7. Barrias CC, Martins MCL, Sá Miranda MC, Barbosa MA. Adsorption of a therapeutic 
enzyme to self-assembled monolayers: effect of surface chemistry and solution pH on 
the amount and activity of adsorbed enzyme. Biomaterials 2005;26:2695-2704 
(Chapter VIII). 
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Contributions of the authors to the papers resulting from this thesis: 
 
Papers 1, 3, 5, 6 and 7: Barrias CC planned and conducted all the experimental work and 
wrote the manuscripts. However, the interdisciplinary nature of the investigation required 
the expertise and contribution of the co-authors in the following aspects: 
 
1. Granja PL: assistance in planning the experimental work; Lamghari M: 
assistance in planning the enzyme uptake studies by Gaucher disease fibroblasts. 
 
3. Ribeiro CC: synthesis of calcium titanium phosphate, assistance in the 
preparation and characterisation of the microspheres and in enzyme release studies; 
Rodrigues D: assistance in enzyme activity studies. 
 
5. Ribeiro CC: assistance in the preparation and characterisation of the 
microspheres. 
 
6. Lamghari M: isolation and culture of rat bone marrow stromal cells; Ribeiro CC: 
synthesis of calcium titanium phosphate. 
 
7. Martins MCL: assistance in the preparation and characterisation of self-
assembled monolayers and in enzyme adsorption studies. 
 
 
Papers 2 and 4: The work described in these two papers is the result of a strong 
collaboration between Barrias CC and Ribeiro CC. This partnership has arisen from the 
interest of the Ribeiro CC in finding a new application for calcium titanium phosphate, 
namely as an injectable bone-filler material, and the interest of Barrias CC in finding 
alternative ceramic materials for enzyme immobilisation. In paper 2 Barrias CC assisted 
Ribeiro CC in the preparation and morphological characterisation of the microspheres and 
in enzyme immobilisation and release studies.  In paper 4 Barrias CC assisted Ribeiro CC 
in the preparation and morphological characterisation of the microspheres. Barrias CC also 
participated in the writing of the two manuscripts. 
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ABSTRACT 
 
Gaucher disease (GD) is caused by the decreased activity and/or stability of the lysosomal 
enzyme glucocerebrosidase (GCR). The available treatment consists in the intravenous 
administration of exogenous GCR, and is effective in reverting most of the symptoms. 
However, in terms of bone pathology, which is among the most disabling manifestations, a 
slow and incomplete response is observed, indicating that adjuvant therapies are necessary 
to consistently restore GCR activity in bone and accelerate regeneration. In this study, 
calcium alginate microspheres were analysed as a vehicle for localised GCR delivery to 
bone. Results demonstrated that the entrapped enzyme retained full activity and exhibited a 
broader pH-dependent activity profile, compared to that of free-GCR, with improved 
stability at physiological pH. GCR release profile was established, and it was demonstrated 
that GCR could be released in a sustained manner. The biological behaviour of the system 
was evaluated by analyzing the uptake of released GCR by GCR-deficient cells from a GD 
patient, using different techniques: GCR activity measurements, radiolabelling and 
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cellulose acetate electrophoresis. Results demonstrated that GCR was internalised by cells 
significantly enhancing the residual enzymatic activity. To achieve an activity 
reconstitution level comparable with that obtained using free-GCR, only half of the dose 
was required with entrapped-GCR. 
Keywords: Localised delivery, therapeutic enzyme, calcium alginate, microspheres. 
 
 
INTRODUCTION 
 
Gaucher disease (GD), the most prevalent lysosomal storage disturbance, is a genetic 
disorder of lipid metabolism characterised by the markedly decreased catalytic activity 
and/or stability of the enzyme glucocerebrosidase (GCR), which results in intracellular 
accumulation of glucosylceramide.1,2 The occurrence of lipid-engorged cells, preferentially 
macrophages (Gaucher cells), in a variety of tissues where they replace their normal 
counterparts, underlies the most common signs of GD, namely: haematological 
abnormalities, organomegaly, and skeletal disease.1,2  Considering the non-neuronopathic 
form of GD (type 1), skeletal lesions are among the most debilitating consequences, having 
a much greater impact on patient’s quality of life than the haematological and visceral 
abnormalities. Nearly all affected patients show some degree of bone involvement, and 
skeletal complications are generally accompanied by an increased predisposition to 
fractures.1 
The currently available treatment consists in the intravenous administration of recombinant 
GCR. The modified enzyme exposes mannose residues that increase its affinity for 
mannose receptors on the target cells, allowing its internalisation and subsequent action in 
situ.3,4 Although the enzyme replacement therapy (ERT) seems to be efficient in reverting 
most of the symptoms, the delayed and modest skeletal response remains the major issue in 
the overall effectiveness and management of affected patients.1,5,6 This may be related to 
an inefficient delivery of exogenous enzyme to bone, or to its lower effectiveness in 
targeting bone Gaucher cells.1,2 It has been demonstrated that visceral organs avidly uptake 
most of the injected enzyme diverting it away from other sites affected by the disease.7 In 
addition, the apparently shorter half-life of GCR in marrow tissue suggests that frequent 
administration of subsaturating doses of enzyme may be needed to consistently restore 
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GCR activity in bone.7 This is indicative that adjuvant therapies are necessary in order to 
re-establish bone function more rapidly and/or to a greater extent than with ERT alone.1 
In the present work, a vehicle for recombinant GCR is proposed. In association with ERT, 
the present approach could contribute to solve orthopaedic disturbances associated with 
GD by providing local enzyme delivery to bone lesions associated with higher risks of 
fracture. 
Some attempts to develop GCR carriers for in vivo delivery were made in the past, prior to 
the recognition that macrophages expressed specific receptors for the endocytosis of 
mannosylated glycoproteins. Entrapment of GCR into different carriers, namely 
erythrocyte ghosts and liposomes, was then envisaged to exploit the phagocytic capacity of 
target cells that would account for the internalisation of the exogenous enzyme.8-11 
However, clinical trials were disappointing.8,10,11 The use of liposomes as GCR carriers 
was revisited some years ago.12 High encapsulation efficiencies were reported but, to the 
authors’ knowledge, these studies were not further developed. 
In this study, alginate was selected as a model-matrix for the entrapment of GCR, due to its 
versatility and well known applicability in the biomedical field. Sodium alginate forms 
relatively stable hydrogels through ionotropic gelation, in the presence of many multivalent 
ions, being Ca2+ the most widely used. The crosslinking process can be carried out under 
very mild conditions, at low temperature and in the absence of organic solvents, and 
hydrogels of different shapes can be prepared. Several proteins, including growth factors 
and enzymes, have already been successfully incorporated in alginate gels, retaining a high 
percentage of biological activity.13-18 Moreover, alginate hydrogels have been widely 
studied for cartilage and bone regeneration applications, as scaffolds and vehicles for 
biologically active molecules or cells.19-21 
The main objective of this study was to investigate if recombinant GCR could be entrapped 
in alginate microspheres crosslinked with Ca2+ (Ca-alginate microspheres), while 
preserving its biological activity, and be efficiently delivered to GCR-deficient cells  from 
type I GD patients.  
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MATERIALS AND METHODS 
 
Materials 
 
Pharmaceutical-grade sodium alginate with a high α-L-guluronic acid content (65-75%, as 
reported by the manufacturer) was kindly donated by Pronova Biopolymers and used 
without further purification. Sodium alginate aqueous solutions were prepared fresh as 
needed. GCR was purchased from Genzyme Corporation as a lyophilized powder. Na125I 
and Sephadex columns were purchased from Ammersham Pharmacia Biotech, 4-
methylumbelliferyl-β-D-glucopyranoside from Glycosynth and sodium taurocholate from 
Calbiochem. Cell culture reagents were purchased from Gibco, bicinchoninic acid (BCA) 
assay kit from Pierce, and cellulose acetate sheets (Cellogel) were obtained from 
Chemtron. Additional chemicals were purchased from Sigma. All solutions were prepared 
using distilled-deionised water. 
 
Preparation of Ca-alginate microspheres loaded with GCR 
 
Ca-alginate microspheres loaded with GCR were prepared at room temperature, under 
aseptic conditions, after filter-sterilising (0.22 µm) all the reagents, including the alginate 
solution. 125I-labelled GCR, prepared according to the Iodogen method,22  was used as a 
tracer. 125I-GCR was purified in a pre-packed PD-10 Sephadex G-25 M column previously 
blocked with 20% w/v bovine serum albumin (BSA) and equilibrated in phosphate-
buffered saline (PBS, pH 7.4). The final solution contained only trace amounts of free 125I 
(<2%), as estimated by trichloroacetic acid precipitation (TCA, 10% v/v). 
125I-GCR was combined with non-labelled GCR (107 cpm/mg) immediately prior to use, 
and dispersed in 3% w/v Na-alginate to a final concentration of 0.2 mg/mL. The solution 
was extruded drop-wise through a syringe fitted with a 25G needle into a 0.1 M CaCl2 bath 
(pH 5.6), where microspheres were allowed to harden for 30 min. The obtained GCR-
loaded microspheres were recovered and rinsed with saline (0.9% w/v NaCl). The 
gelling/washing solutions were counted for radioactivity in a γ-counter to estimate enzyme 
losses during the entrapment process. Microspheres were imaged using a digital camera 
and their diameter was estimated using a digital calliper (n=20). Different batches of 
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microspheres were prepared under the same conditions to test the reproducibility of the 
process. 
 
Characterisation of GCR-loaded Ca-alginate microspheres: loading and catalytic 
activity yields 
 
To determine the total amount of GCR initially present in freshly prepared microspheres, 
these were individually counted for radioactivity and the average value calculated (n=20). 
The catalytic activity of entrapped-GCR was also assayed at different pH values (in the 
range 4.0 to 7.0), using the assay described in detail below. GCR in solution (free-GCR) 
was used as a reference. Five replicates were used. The percentage of retained activity 
(activity yield) was calculated as the ratio of specific activity (activity per unit mass) of 
entrapped-GCR to that of free enzyme, at the respective pH optimums. 
 
GCR activity assay 
 
The catalytic activity of GCR was assayed as the hydrolysis of the fluorogenic substrate 4-
methylumbelliferyl-β-D-glucopyranoside (4-MU-Glc), as previously described.23 The final 
assay mixture contained 5 mM 4-MU-Glc and 6 mg/mL of sodium taurocholate in 50-100 
mM citrate-phosphate buffer (pH 5.5, unless otherwise stated). The reaction was allowed 
to proceed for 30 min in a humidified atmosphere at 37ºC and then stopped with 1 M 
glycine in 30% w/v NaOH (pH 10.3). The product 4-methylumbelliferone (4-MU) was 
quantified by fluorescence spectroscopy with excitation at 366 nm and emission at 445 nm, 
using commercial 4-MU as a standard. 
 
GCR release studies 
 
Release studies were performed using cell culture medium as the test solution. The 
medium was Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% v/v 
foetal bovine serum, 1.5% v/v Ultraser G, 2.5 µg/mL fungizone, 200 U-200 µg/mL 
peniciline-streptomicine and 50 µg/mL kanamicine (complete culture medium). Samples 
(n=3 batches of microspheres) were maintained under static conditions in a humidified 
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atmosphere of 5% v/v CO2 in air. Aliquots (n=5 per batch) from the supernatants were 
obtained at pre-defined time intervals and counted for radioactivity or assayed for 
enzymatic activity after dilution in 0.1% v/v Triton X-100 with 1% w/v BSA. Fresh 
medium was then added to maintain a constant volume. Microspheres were recovered at 
the end of the release study, rinsed with saline and counted for residual radioactivity. The 
rinsing solution was also counted to estimate enzyme losses during washing.  
 
Cell cultures 
 
Human fibroblasts from healthy subjects and from type I GD patients (GCR-deficient 
cells) were obtained from skin explants under consent of the local Ethics Committee, and 
cultured as described previously.23 Cells were routinely maintained in complete culture 
medium at 37ºC in a humidified atmosphere of 5% v/v CO2 in air. The medium was 
renewed every 3 days. For subculture, cells were rinsed twice with PBS and harvested with 
0.25% w/v trypsin-0.05% w/v ethylenediaminetetraacetic acid (EDTA). Finally, cells were 
centrifuged, resuspended in fresh complete culture and seeded in 6-well culture plates at a 
density of 2×104 cells/cm2. 
 
Uptake of GCR by GD fibroblasts 
 
To establish the amount of enzyme that must be added to the medium in order to obtain an 
acceptable level of GCR activity inside the cells, and to analyse if GCR internalisation 
increases in a dose-dependent manner, cells were treated with different concentrations of 
free-GCR (0-50 µg/mL). Intracellular GCR activity was determined after a period of 24 h. 
After that, the uptake of GCR by GD fibroblasts treated for 24 h with a defined amount of 
free- or entrapped-GCR (35 µg/mL, n=3) was evaluated. 
A similar study was performed using 125I-GCR as a tracer. In this case, the cell extracts and 
all the washing solutions were counted for radioactivity. The microspheres were recovered 
at the end of the assay, rinsed in saline and counted for residual radioactivity. 
In both assays, untreated cells from healthy subjects and from type I GD patients were used 
as references and cell extracts were prepared as described in detail below. 
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Preparation of cell extracts 
 
After treatment, cells were rinsed twice with warm PBS and harvested with 0.25% w/v 
trypsin-0.05% w/v EDTA. After centrifugation, supernatants were discarded and cells were 
washed three times with ice-cold PBS and extracted by brief sonication in 0.1% v/v Triton 
X-100. The homogenates were centrifuged (5 min, 10,000 rpm) to remove cell debris, and 
the supernatants (extracts) were used in total protein quantification, GCR activity 
measurements, and cellulose acetate electrophoresis. Enzymatic activities were determined 
as described above and normalised to total cell protein content, as measured by the BCA 
assay using BSA as a standard.24 
 
Cellulose acetate electrophoresis 
 
Extracts from control fibroblasts and from GD fibroblasts, before and after treatment with 
free- or entrapped-GCR, were subjected to cellulose-acetate gel electrophoresis as 
previously described.25 This technique is commonly used to separate enzymes in the native 
state primarily by charge, and bands are only visible if those enzymes are active. Briefly, 
samples were applied on cellulose-acetate sheets previously equilibrated in the 
electrophoretic buffer, which consisted of 30 mM sodium phosphate, containing 20% v/v 
ethylene glycol and 0.5% v/v Triton X-100. The sheets were placed in the electrophoretic 
tank at 4ºC, and a constant voltage (240 V) was applied for 2.5 h. GCR activity bands were 
stained by incubation at 37ºC for 1.5 h with 10 mM 4-MU-Glc, 0.2% w/v sodium 
taurocholate and 0.12% v/v Triton X-100 in 60 mM citrate-phosphate buffer (pH 4). The 
reaction was stopped with 1M glycine in 30% w/v NaOH (pH 10.3), and the fluorescent 
bands were visualised at 366 nm and photographed with a type 667 Polaroid film. 
 
RESULTS 
 
Preparation and characterisation of Ca-alginate microspheres loaded with GCR 
 
The entrapment of GCR in Ca-alginate microspheres was performed using 125I-GCR as a 
tracer. This study allowed the determination of the process efficiency, i.e., the percentage 
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of enzyme losses during the gelling/washing processes and the final GCR loading. During 
gelling and washing 35.6±9.9% and 3.1±0.8% of the enzyme was lost, respectively, 
resulting in a final loading of 73.2±9.4 µg per batch of microspheres (ca. 1.3 
µg/microsphere). As shown in Fig. 1, the obtained microspheres were spherically-shaped 
and presented a uniform size, with an average diameter of 2.4±0.1 mm.  
 
 
The catalytic activity of entrapped-GCR was also characterised. Fig. 2 shows the pH 
activity profiles of free- and entrapped-GCR. Results are expressed as relative activities, 
with 100% referring to the activity at the pH optimum for each case. The entrapped 
enzyme exhibited a broader pH-dependent activity profile, characterised by a greater 
retention of activity at higher pH values, namely near neutrality. Moreover, the pH 
optimum was shifted towards the alkaline region by approximately 0.5 pH units. 
The activity yield, calculated as the percentage of specific activity of entrapped GCR in 
relation to that of free enzyme, at the respective pH optimums, was 101±14%. 
2 mm 
 
Figure 1. Images of Ca-alginate 
microspheres loaded with GCR 
illustrating their spherical shape and 
uniform size. 
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Figure 2. Influence of pH on the 
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GCR release studies 
 
125I-GCR release from Ca-alginate microspheres at 37ºC in complete cell culture medium, 
the same conditions used in the uptake study, is presented in Fig. 3. The release profile was 
characterised by an initial burst, followed by a phase of very slow release. After 24 h, the 
concentration of GCR in the medium was 15.0±1.4 µg/mL, which corresponds to 
approximately 40% of the total amount of enzyme initially present in the microspheres. 
 
 
Uptake of GCR by GD fibroblasts 
 
Uptake of free-GCR at different concentrations by GD fibroblasts is presented in Fig. 4. By 
increasing the amount of available GCR in the medium up to 50 µg/mL, the level of GCR 
intracellular activity increases in a dose-dependent manner, without reaching saturation. 
GD fibroblasts were then treated with a defined amount (35 µg/mL) of free- or entrapped-
GCR. In Fig. 5, results are presented as the activity of GCR in cells, after an incubation 
period of 24 h. The endogenous activities of GCR in fibroblasts from healthy patients and 
from GD fibroblasts are also presented as references. In untreated GD fibroblasts, the 
activity of endogenous GCR is only residual, as expected. However, after treatment with 
free- or entrapped-GCR, the activity of GCR in GD fibroblasts was significantly raised, 
approximately 26-fold in both cases, demonstrating that the enzyme was internalised and 
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Figure 3. Release profile of GCR 
from Ca-alginate microspheres. 
Microspheres were incubated at 37ºC 
in complete cell culture medium and 
maintained under static conditions. 
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that, by comparison with the endogenous GCR activity in fibroblasts from healthy patients, 
an important activity reconstitution level was achieved. 
 
 
 
 
 
Figure 5. Activity of GCR in GD fibroblasts after treatment with free- or entrapped-GCR, 
normalised to the total cell protein content. GCR activity in untreated fibroblasts from healthy 
subjects and from type I GD patients were used as references. 
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Figure 4. Uptake of free-GCR by 
GD fibroblasts as a function of 
enzyme concentration in the 
medium. Cells were incubated at 
37ºC for 24 h with 0-50 µg/mL of 
free-GCR. 
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Uptake studies performed with 125I-GCR yielded similar results. Fig. 6a shows that after a 
period of 24 h, the amounts of enzyme internalised by GCR-deficient cells were 
approximately the same, whether cells were treated with free- or entrapped-GCR. 
However, as shown in Fig. 6b, although cells have been treated with the same initial 
quantity of free- or entrapped-GCR, the amounts of enzyme available in the medium in the 
two cases were distinct, since only 40% of the entrapped enzyme was released into the 
medium during the first 24 h, which is in accordance with the results already presented 
concerning the GCR released studies. Thus, both assays (GCR activity and radiolabelling) 
indicate that, in order to achieve an enzyme uptake comparable with that obtained using 
free-GCR, only half of the dose was required with entrapped-GCR. 
Figure 6. Uptake of free-GCR and entrapped-GCR by GD fibroblasts studied using 125I-GCR as a 
tracer: (a) Total 125I-GCR internalised by the cells normalised to the total cell protein content, and 
(b) Total 125I-GCR available in the medium. 
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Fig. 7 shows the electrophoretic patterns of GCR activity in extracts from control 
fibroblasts (lane a), from GD fibroblasts treated with free- or entrapped-GCR (lanes b and 
c, respectively) and from untreated GD fibroblasts (lane d). As expected, GCR activity was 
not present in the extract obtained from untreated GD fibroblasts. In all other samples, two 
distinct activity bands (designated band I and II), which represent different physiological 
forms of GCR, were distinguishable. Band I corresponds to the monomeric form of the 
enzyme, while band II corresponds to an aggregated form.25 These results qualitatively 
confirm the internalisation of both free- and entrapped-GCR by GD fibroblasts, evidencing 
its integrity in both cases. 
 
 
Figure 7. Electrophoretic patterns of GCR activity in extracts from: control fibroblasts (lane a), GD 
fibroblasts treated with free-GCR (lane b), GD fibroblasts treated with entrapped-GCR (lane c) and 
untreated GD fibroblasts (lane d). Bands I and II correspond to different physiological forms of the 
enzyme (monomeric and aggregated, respectively). The arrow points to the site were samples were 
loaded. 
 
 
DISCUSSION 
 
In the present study, the application of Ca-alginate microspheres as a vehicle for the 
localised delivery of recombinant glucocerebrosidase (GCR) was analysed. If successful, 
this strategy could be used for the therapeutic enhancement of skeletal repair in Gaucher 
disease. In addition, besides reducing the overall systemic exposure of exogenous GCR, a 
carrier such as the one proposed may be able to protect the enzyme from in vivo 
       a        b        c        d 
II 
I 
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degradation and prolong its biological half-life, thus increasing its therapeutic efficiency. 
GCR entrapment in Ca-alginate microspheres was performed using 125I-GCR as a tracer. 
Microspheres were prepared at pH 5.6, which is below the isoelectric point of the enzyme 
(in the range of 7 to 8), where it presents a net positive charge, thus theoretically favouring 
its interaction with the negatively charged carboxyl groups of the polyanionic alginate 
matrix (pKa of uronic acid residues ≈3.5).26 Enzyme losses during the entrapment process 
(ca. 36%) were in agreement with those reported by other authors,14 and are mainly related 
to the partially unhardened state of the microspheres during the initial gelling period, 
where they exhibit increased permeability. The obtained microspheres presented a 
spherical shape and a uniform size. Although for practical reasons large microspheres were 
used in this study, smaller ones (down to 400 µm) can be easily prepared in a similar way, 
by applying a coaxial air stream to pull out the alginate droplets into the crosslinking bath. 
Freshly prepared microspheres were characterised in terms of total GCR loading and 
catalytic activity at different pH values. Entrapped GCR retained full biological activity, 
suggesting that its native conformation was preserved during the entrapment process. 
Moreover, the entrapped enzyme exhibited a broader pH-dependent activity profile, 
compared to that of the free enzyme, with improved stability at more physiological pH 
values, and a pH optimum slightly shifted towards the alkaline region. This effect has 
already been reported by other authors16 and has been attributed to the presence of 
negatively charged carboxyl groups on the alginate matrix that may attract protons from 
the bulk solution, thus creating a more acidic local microenvironment.  
GCR release from Ca-alginate microspheres was monitored under similar conditions to 
those used in the cell culture studies, i.e., using complete cell culture medium as the test 
solution and performing the assay under static conditions for 24 h. The release kinetics 
appeared to be initially controlled by the diffusion of GCR from the surface of the 
microspheres (burst effect), followed by diffusion through the pores of the gel matrix. 
Whether or not this release profile is adequate for the therapeutic efficiency of GCR in the 
in vivo targeting of bone resident Gaucher cells needs to be evaluated. Although out of the 
scope of this study, modulation of drug release kinetics from hydrogel microspheres has 
been reported using different strategies, including the application of additional crosslinking 
or external coatings of polycations, as well as conjugation of the drug with a different 
carrier, in water-soluble or particulate form, prior to its entrapment.17,27,28 
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The biological behaviour of the system was characterised through short-term cell culture 
studies, using glucocerebrosidase-deficient fibroblasts from GD patients as a model. 
Although not being the relevant target cells, fibroblasts are also able to internalise 
recombinant GCR, through yet unknown mechanisms, and thus are a suitable model for 
evaluating the integrity of the released enzyme. To analyse the cellular uptake of GCR, 
preliminary studies were carried out, and dose response was investigated. Subsequently, 
GD fibroblasts were treated with the same amount of free or entrapped-GCR and enzyme 
uptake was analysed after 24 h of incubation. The intracellular activity of GCR in treated 
cells was then compared to that of the endogenous enzyme in fibroblasts from healthy 
subjects and GD patients. The two quantitative techniques used (GCR activity 
measurements and radiolabelling) showed that similar activity reconstitution levels were 
obtained with the two approaches (free- and entrapped-GCR), even if the amount of GCR 
released from Ca-alginate microspheres was lower (less than 50%) than the total amount of 
free-GCR present in the medium. This suggests not only that entrapped-GCR maintained 
its bioactivity, but also that it can be even more effective than the free enzyme. 
Internalisation of free- and entrapped-GCR was further confirmed qualitatively by 
cellulose acetate gel electrophoresis. Taken together, these results suggest that the alginate 
matrix provides a favourable microenvironment to the enzyme and potentiate its biological 
effect. 
 
 
CONCLUSIONS 
 
In the present study, a strategy for the therapeutic enhancement of skeletal repair in 
Gaucher disease via the localised delivery of exogenous glucocerebrosidase is proposed. 
The enzyme was successfully incorporated in Ca-alginate microspheres, retaining its 
biological activity. The biological behaviour of the system was evaluated by analysing the 
uptake of free- and entrapped enzyme by GCR-deficient fibroblasts from GD patients. 
Results demonstrated that both formulations were internalised by cells and, more 
importantly, that in order to achieve an activity reconstitution level comparable to that 
obtained using free-GCR, only half of the dose was required with entrapped-GCR, which 
suggests that entrapment in the alginate matrix potentiates its biological effect. 
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ABSTRACT 
 
The present study concerns the preparation and initial characterisation of novel calcium 
titanium phosphate-alginate (CTP-alginate) and hydroxyapatite-alginate (HAp-alginate) 
microspheres, which are intended to be used as enzyme delivery matrices and bone 
regeneration templates. Microspheres were prepared using different concentrations of 
polymer solution (1% and 3% w/v) and different ceramic-to-polymer solution ratios (0.1, 0.2 
and 0.4 w/w). Ceramic powders were characterised using X-ray diffraction, laser 
granulometry, Brunauer, Emmel and Teller (BET) method for the determination of surface 
area, zeta potential and Fourier transform infrared spectroscopy (FTIR). Alginate was 
characterised using high performance size exclusion chromatography. The methodology 
followed in this investigation enabled the preparation of homogeneous microspheres with a 
uniform size. Studies on the immobilisation and release of the therapeutic enzyme 
glucocerebrosidase, employed in the treatment of Gaucher disease, were also performed. The 
enzyme was incorporated into the ceramic-alginate matrix before gel formation in two 
different ways: pre-adsorbed onto the ceramic particles or dispersed in the polymeric matrix. 
The two strategies resulted in distinct release profiles. Slow release was obtained after 
adsorption of the enzyme to the ceramic powders, prior to preparation of the microspheres. 
An initial fast release was achieved when the enzyme and the ceramic particles were 
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dispersed in the alginate solution before producing the microspheres. The latter profile is 
very similar to that of alginate microspheres. The different patterns of enzyme release 
increase the range of possible applications of the system investigated in this work. 
Keywords: microspheres, enzyme-delivery, alginate, hydroxyapatite, calcium titanium phosphate. 
 
 
INTRODUCTION 
 
Osseous tumours, trauma and other debilitating diseases can create a need to fill defects in 
the skeleton. Most bone tissue engineering strategies rely on the use of temporary scaffolds 
that can be seeded with cells prior to implantation, or designed to induce the formation of 
bone from the surrounding tissue after implantation.1,2 The effectiveness of such materials 
can be highly improved if they can simultaneously act as drug delivery systems. Depending 
on the specificity of the illness, bioactive agents (e.g. growth factors or other protein-drugs) 
can be locally released and potentially accelerate the process of bone regeneration. 
In the past few years, increasing efforts have been devoted to the development of improved 
injectable materials aimed at providing an alternative for the filling of bone defects with less 
patient discomfort, as they can be applied through minimally invasive surgical procedures. 
Most injectable materials described in the literature consist of pastes, gels or liquid 
precursors that solidify in situ in response to some stimulus.3 Micro- or nano-particles have 
also been described, but they must be suspended in either autologous blood or other 
appropriate vehicle prior to injection. 
A variety of injectable materials, both ceramic- and polymer-based, have been developed for 
use in multiple orthopaedic applications.4-20 The combination of ceramic particles with 
polymeric matrices has also been extensively investigated, in an attempt to mimic bone 
tissue, which may itself be seen as a complex composite material made of organic and 
inorganic components. Different ceramic phases have been used, hydroxyapatite and 
tricalcium phosphate being the most common,4-9 as well as several polymeric matrices, both 
from synthetic10-14 or natural origin, the latter including collagen, chitosan, gelatine and 
alginate, among others.15-20 
This investigation describes the preparation and initial characterisation of novel calcium 
titanium phosphate-alginate (CTP-alginate) and hydroxyapatite-alginate (HAp-alginate) 
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microspheres intended to be used as injectable enzyme delivery matrices and bone filling 
materials. 
CTP is a bioactive ceramic currently under investigation in our laboratory.21 Its properties, 
namely the capacity of ion exchange and chemical adsorption,22 and the ability to act as an 
immobilisation matrix for several enzymes,23 suggest that it can successfully be used in the 
biomedical field. Furthermore, recent in vivo studies showed direct bone contact of 
implanted cylinders containing calcium titanium phosphate as the main phase.24 HAp, which 
has long been recognised for its bioactivity and osteoconductive properties and has been 
extensively tested as matrix in drug delivery applications,25,26 was also used in the present 
investigation. 
Alginate was chosen as the polymeric vehicle due to its useful properties and versatility. 
Ultra-pure grade alginates are considered biocompatible and biodegradable and have been 
widely used in many biomedical applications, not only as vehicles for biologically active 
molecules or cells, but also as scaffolds for tissue engineering, either as porous structures or 
modified with RGD-containing peptide sequences.27-29 Sodium alginate and most other 
alginates from monovalent metals are soluble in water, forming solutions of considerable 
viscosity. Due to their suitable rheological properties, alginates have long been used in the 
pharmaceutical industry as thickening or gelling agents, as colloidal stabilisers and as blood 
expanders.30 
CTP-alginate and HAp-alginate microspheres were prepared using the droplet extrusion 
method. The ceramic granules were mixed with alginate enabling the preparation of 
spherical particles through instantaneous crosslinking in the presence of calcium ions.30 
Compared to other methods of preparation of ceramic-polymer microspheres,31-33 this 
process presents the advantage of being simple and of being carried out at room temperature 
and in the absence of organic solvents, which makes it suitable for enzyme entrapment 
purposes. Moreover, the spherical particles can be easily recovered, without the need for 
fastidious washing processes, and present a regular size distribution even without subsequent 
fractionation by sieving. 
Analysis of the ability of these matrices to act as carriers for the enzyme 
glucocerebrosidase (GCR) was also undertaken. This enzyme is used in the treatment of 
Gaucher disease (type I), which is characterised by a number of severe disabling 
symptoms, including bone pathologies.34 GCR is highly unstable in solution under 
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µηπζ 4=
physiological conditions.35 Its immobilisation is currently under investigation in our group 
to overcome this problem. 
 
 
MATERIALS AND METHODS 
 
Materials 
 
Calcium titanium phosphate [CTP, CaTi4(PO4)6] was synthesised by solid state reaction as 
described elsewhere.21 Commercial hydroxyapatite (HAp) powder (CAM Implants) pre-
heated at 1000ºC was used as a reference. Pharmaceutical-grade sodium alginate (Protanal 
10/60 LS) with a high α-L-guluronic acid content (65-75%, as specified by the manufacturer) 
was kindly donated by Pronova Biopolymers and used without further purification. Na-
alginate solutions were prepared fresh as needed, using distilled-deionised water. Purified 
recombinant human glucocerebrosidase (GCR) was purchased from Genzyme Corporation 
as a lyophilised powder. Na125I and Sephadex columns were purchased from Amersham 
Pharmacia Biotech. Additional chemicals were purchased from Sigma. 
 
 
Characterisation of CTP and HAp powders: X-ray diffraction, specific surface area, 
granulometry and zeta potential determination 
 
The ceramic powders were analysed by X-ray diffraction (XRD, Philips PW 1710 
diffractometer) and their specific surface area was measured by gas adsorption according to 
the Brunauer, Emmel and Teller (BET) method. Granulometric analysis was performed 
using a laser scanner particle size analyser (Coulter Electronics Incorporation). Zeta potential 
(ZP) of CTP and HAp powders was measured with a Coulter Delsa 440 instrument. ZP was 
calculated automatically by the instrument based on the Smoluchowski formula: 
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where ζ is the ZP (mV), µ the electrophoretic mobility (µm.cm/V.s), η the viscosity of the 
fluid, and E the dielectric constant of the fluid. The principle of electrophoresis is that a 
particle will move in a liquid under the influence of an applied electric field provided its ZP 
is different from zero. The electrophoretic mobility is proportional to the ZP as shown in the 
equation above. 
The ZP of CTP and HAp powders were determined at several pH values. The powders were 
dispersed in 10 mM KCl and the pH was adjusted with 0.1 M HCl and 0.1 M KOH. 
 
 
Characterisation of alginate by HP-SEC  
 
High performance size exclusion chromatography (HP-SEC) was performed at room 
temperature using a modular system, composed of an isocratic pump (K-1001 Knaeur), a 
vacuum degasser (K-5002 Knaeur), a viscometer/right angle laser light scattering (RALLS) 
dual detector (T60 Viscotek), and a refractive index detector (K-5002 Knaeur) operating at 
the same wavelength as the RALLS detector (670 nm). Separations were performed with a 
set of PL aquagel-OH mixed columns. The mobile phase consisted of 0.1 M NaNO3 with 
0.02% w/v NaN3 and the flow-rate was maintained at 1.0 mL/min. Samples were dissolved 
in the mobile phase, filtered and injected through a manual injection valve equipped with a 
116 µL loop. 
 
 
Preparation of CTP-alginate and HAp-alginate microspheres 
 
CTP or HAp powders were dispersed in a pre-filtered (0.8 µm) Na-alginate solution under 
gentle stirring until a homogeneous paste was obtained. Different concentrations of the 
polymer solution (1% and 3% w/v), and different ceramic-to-polymer solution ratios (0.1, 
0.2 and 0.4 w/w) were tested. These will be designated as 10/1, 20/1, 40/1 (ceramic-to-
polymer solution ratios, using the 1% w/v Na-alginate solution) and 10/3, 20/3, 40/3 
(ceramic-to-polymer solution ratios, using the 3% w/v Na-alginate solution). The pastes were 
extruded drop-wise into a 0.1 M CaCl2 crosslinking solution, where spherical-shaped 
particles instantaneously formed and were allowed to harden for 30 min. The size was 
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controlled by regulating the extrusion flow rate using a syringe pump (Cole-Parmer), and by 
applying a coaxial air stream (Encapsulation Unit Var J1; Nisco). At completion of the 
gelling period the microspheres were recovered and rinsed in water in order to remove the 
excess CaCl2. Finally, they were dried overnight in a vacuum oven at 30ºC. The diameter of 
the microspheres was measured using an inverted plate microscope (Olympus) equipped 
with an ocular micrometer with an accuracy of 10 µm. 
 
 
Characterisation of CTP-alginate and HAp-alginate microspheres: SEM and FT-IR 
analysis 
 
Morphological characterisation of the microspheres (surface and transversal sections 
obtained by criofracture in liquid nitrogen) was carried out using scanning electron 
microscopy (SEM). Samples were sputter coated with gold using a JEOL JFC-100 fine coat 
ion sputter device, and observed using a JEOL JSM-6301F scanning microscope. 
Physicochemical characterisation of the microspheres and their components (CTP, HAp and 
Ca-alginate) were analysed by Fourier transform infrared spectroscopy (FTIR) using a 
Perkin Elmer system 2000 spectrometer. The FTIR spectrum of Na-alginate was also 
obtained and used as a reference. Microspheres were reduced to powder and were analysed 
as KBr pellets.  
 
 
Enzyme immobilisation in CTP-alginate and HAp-alginate microspheres  
 
The enzyme was incorporated into the ceramic-alginate microspheres (formulation 20/3) 
before gel formation in two different ways: pre-adsorbed onto the ceramic particles before 
mixing with the alginate solution, or dispersed in the polymeric-ceramic paste. Microspheres 
were subsequently prepared as previously described, without drying. In Fig. 1 a schematic 
representation of the matrices tested is presented. The matrices A and B were used as 
controls.  
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Figure 1.  Different enzyme immobilisation matrices tested: (A) enzyme adsorbed onto the ceramic 
powders, (B) enzyme dispersed in a pure alginate matrix, (C) enzyme and ceramic powders 
individually dispersed in the alginate matrix and (D) ceramic powders with pre-adsorbed enzyme 
dispersed in the alginate matrix. The matrices A and B were used as controls. 
 
Pre-adsorption of the enzyme onto CTP and HAp powders 
 
A solution containing glucocerebrosidase (GCR) was obtained by dissolving the enzyme in 
phosphate-buffered saline (PBS, pH 7.4) at a final concentration of 0.2 mg/mL and in the 
presence of 0.5 mg/mL of bovine serum albumin (BSA) as a stabiliser. The solution also 
contained radiolabelled (125I) enzyme (Iodogen method) as a tracer and 0.01 M NaI to 
competitively reduce binding by any free 125I species present. The specific radioactivity of 
the solution was 6.5×107 cpm/mg GCR. 
For adsorption tests, CTP and HAp powders (50 mg) were incubated with 500 µL of the 
enzyme solution. Samples were maintained at 4ºC in an orbital shaker at 250 rpm. At 
predefined time intervals, samples were centrifuged (5 min, 14,000 rpm) and the 
supernatants collected for analysis. The powders were washed twice with PBS and separated 
by centrifugation. The powders and all the supernatants were counted for radioactivity. The 
counts of each sample were averaged and surface concentration was calculated by the 
equation: 
Ceramic powder Glucocerebrosidase Alginate 
A +
C + +
B +
+D 
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where the Counts represent the radioactivity of the powders, the Asolution is the specific 
activity of the protein solution and SA is the surface area of the powders, which was 
calculated as described previously. 
 
Enzyme release studies  
 
Enzyme release studies were performed in PBS. Samples (n=3) were maintained at 37±0.2ºC 
in an orbital shaker at 120 rpm. At predefined time intervals, the supernatants were collected 
and counted for radioactivity and fresh PBS was added. In the case of the powder matrices 
(Fig. 1, matrix A) samples were centrifuged (5 min, 14,000 rpm) prior to collecting the 
supernatants. At the end, the matrices were recovered, washed twice with PBS and counted 
for residual radioactivity. 
 
 
RESULTS 
 
Characterisation of CTP and HAp powders 
 
X-ray diffraction and specific surface area   
 
X-ray diffraction analysis of the ceramics indicated the presence of mono phase crystalline 
compounds. The specific surface areas obtained using the BET method were 9.84 cm2/mg 
for the CTP powder and 76.00 cm2/mg for the HAp. 
 
Granulometric analysis 
 
The granulometric analysis of HAp and CTP powders is presented in Figs. 2a and 2b, 
respectively. The particle size distribution curves of both ceramics are narrow. In the case 
of the CTP powder, 90% (in volume) of the particles are smaller than 25.32 µm and have a 
)SA(cm(cpm/ng)A
)Counts(cpm)GCR(ng/cm 2
solution
2
×=
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volume average diameter of 11.00 µm. In the HAp powder 90% of the particles are smaller 
than 20.51 µm and the volume average diameter is 7.96 µm. 
 
Figure 2. Granulometric analysis of (a) CTP and (b) HAp powders. Cumulative (dashed line) and 
non-cumulative (solid line) volume percentage particle size distributions are plotted on the left and 
right axis, respectively. 
 
 
Zeta potential measurements 
 
ZP measurements of CTP and HAp powders as a function of pH are presented in Fig. 3. As 
can be observed, the isoelectric point of CTP occurs approximately at pH 3 whereas the 
isoelectric point of HAp occurs approximately at pH 6. To the best of our knowledge, the 
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isoelectric point of CTP has not been reported in the literature before. As far as the HAp is 
concerned, the results obtained are in agreement with those reported by other authors.36,37 
At physiological pH both ceramics are negatively charged, the CTP potential being more 
negative than that of HAp. 
 
 
Characterisation of alginate by HP-SEC  
 
The Na-alginate used in this study was characterised by an average molecular weight (Mw) 
of 1.3×105, a polidispersity index of 1.9 and an intrinsic viscosity of 6.4 dL/g, as 
determined by HP-SEC. 
 
 
Characterisation of CTP-alginate and HAp-alginate microspheres  
 
CTP-alginate and HAp-alginate microspheres were prepared using different concentrations 
of the polymer solution (1% and 3% w/v), and different ceramic-to-polymer solution ratios 
(0.1, 0.2 and 0.4 w/w). As soon as the ceramic-polymer droplets contacted with the 
crosslinking solution, spherical-shaped particles were instantaneously formed when using 
the 3% w/v alginate solution. An exception was observed for the HAp-alginate 40/3 paste, 
which was too viscous to be extruded in a reproducible manner. Particles obtained using 
the 1% w/v alginate solution presented a disc-shaped morphology and for that reason were 
not used in the subsequent experiments. 
-70
-60
-50
-40
-30
-20
-10
0
10
20
0 1 2 3 4 5 6 7 8 9 10 11 12
pH
Z
et
a 
Po
te
nc
ia
l  
 (m
V
)
CTP
HAp
Figure 3. Zeta Potential of 
CTP and HAp powders as a 
function of pH. 
Calcium phosphate-alginate microspheres 
75 
The diameters of the microspheres obtained (before and after drying) using the 3% w/v 
polymer solution and the different ceramic-to-polymer ratios are presented in Fig. 4. 
Figure 4. Diameters of alginate, CTP-alginate and HAp-alginate microspheres prepared using the 3% 
w/v alginate solution, before (wet state) and after drying (dry state). 
 
Before drying, microspheres of approximately 1000 µm were obtained when using pure 
alginate, CTP with alginate, and HAp with alginate. Upon drying, microspheres have 
undergone a volume contraction, which was more significant for the lower ceramic-to-
polymer solution ratio (0.1 w/w). Microspheres with diameters of 541±32, 606±21, and 
796±39 µm were obtained for the CTP 10/3, 20/3 and 40/3 formulations, respectively. When 
using HAp, microspheres with diameters of 512±44 µm and 749±22 µm were obtained for 
the 10/3 and 20/3 formulations. 
 
 
SEM analysis 
 
SEM images of the microspheres (20/3 formulations) are presented in Figs. 5 and 6. Upon 
drying, and contrary to alginate microspheres that shrank to a great extent and even collapsed 
(Fig. 5a), CTP-alginate (Fig. 5b) and HAp-alginate (Fig. 5c) microspheres maintained their 
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original shape, with no evidence of cracks. This suggests that both fillers provided additional 
control of shrinkage and avoided structural collapse. Different surface roughnesses were 
obtained, those of the HAp-alginate microspheres being smoother than those of CTP-
alginate. The ceramic powders are homogenously distributed in the alginate matrix (Fig. 6) 
with the granules densely packed and well embedded in the polymer. 
 
Figure 5. SEM image of microspheres: (a) Ca-alginate, (b) CTP-alginate and (c) HAp-alginate. 
 
 
Figure 6. Detail of a transversal section of: (a) CTP-alginate microspheres and (b) HAp-alginate, 
showing that the ceramic particles are well embedded in the polymer matrix. 
 
 
FTIR analysis 
 
FTIR spectra of calcium and sodium alginate are represented in Fig 7. Tab. 1 shows the 
possible assignments for the FTIR bands of the alginate salts.38 Both spectra are very similar 
and only slight differences can be observed in the width and height of the COO- bands. 
a b c
a b 
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Fig. 8 shows the FTIR spectra of CTP powder, Ca-alginate and CTP-alginate microspheres 
(formulations 10/3 and 40/3). The FTIR spectra of HAp powder, Ca-alginate and HAp-
alginate microspheres (formulations 10/3 and 40/3) are presented in Fig. 9. The characteristic 
bands of both ceramics are maintained in the microspheres indicating that the alginate did 
not induce subsequent modifications in the ceramics structure. Additional bands can be 
observed, corresponding to the presence of calcium alginate, namely at 3446 cm-1 (νOH), 
1619 and 1428 cm-1 (νCOO-), and 820 cm-1, identified in the literature as the combination of 
three possible vibrational modes (τCO+δCCO+δCCH).38 The intensity of these bands 
increases as the ceramic-to-polymer solution ratio decreases. Also, the ν3PO4 region (900-
1200 cm-1) becomes broader in the spectra of the microspheres, denoting the presence of the 
polymer. 
 
 
 
 
Figure 7. Transmittance (T%, arbitrary units) FTIR spectra of sodium and calcium alginate. 
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Table 1. Peak assignment of transmittance bands of Na-alginate and Ca-alginate FTIR spectra  
Na/Ca-alginate 
bands (cm-1) Peak Assignment
36 Na/Ca-alginate bands (cm-1) Peak Assignment
36 
3446 ν (OH) hydrogen bonded 1126 ν (CC), ν (CO) 
2929 ν (CH) 1088/1094 τ (CO), δ (CCO), δ (CC) 
2354 - 1029/1032 τ (CO), δ (CCO), δ (CC) 
2161/2169 - 947/945 ν (CO), δ (CCH) 
1619 ν (COO-) 903/905 ν (CO), δ (CCH) 
1420/1428 ν (COO-) 809/820 τ (CO), δ (CCO), δ (CCH) 
1318/1320 ν (COO-)   
 
 
 
 
 
Figure 8. Transmittance (T%, arbitrary units) FTIR spectra of Ca-alginate, CTP-alginate 10/3 and 
40/3 microspheres, and CTP powder. 
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Figure 9. Transmittance (T%, arbitrary units) FTIR spectra of Ca-alginate, HAp-alginate 10/3 and 
40/3 microspheres, and HAp powder. 
 
Enzyme immobilisation in CTP-alginate and HAp-alginate microspheres 
 
Pre-adsorption of the enzyme onto CTP and HAp powders 
 
Fig. 10 shows typical adsorption time profiles of GCR onto CTP and HAp powders. The 
adsorption process was carried out at 4°C for different periods of time (10, 120 and 1440 
min). For both ceramics there is an initial period of rapid adsorption followed by a slower 
approach to a limiting value. After 1440 min, CTP adsorbed 41.28 ng GCR/cm2, a much 
higher amount of enzyme per unit surface are than HAp (1.94 ng GCR/cm2). 
Fig. 11 represents the percentage of enzyme, with respect to the total amount used, which 
becomes adsorbed to the ceramic powders (21% in the case of CTP and 10% in the case of 
HAp), as well as the percentage of enzyme that remains in solution after incubation. The 
percentage of enzyme removed from the solids during washing (1st and 2nd washes) is also 
represented. The percentages of 21% and 10% were measured after washing, indicating 
that the enzyme remained well adsorbed onto the powders. 
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Figure 10. Time profiles of glucocerebrosidase adsorption onto CTP and HAp powders. The 
adsorption process was carried out at 4°C for different periods of time (10, 120 and 1440 min). Data 
labels represent the amount of adsorbed protein per unit surface area (ng/cm2) of the powders. 
 
Figure 11. Adsorption of glucocerebrosidase onto CTP and HAp powders: percentage of 
radioactivity that becomes associated to the powders after an incubation period of 10 min (4°C). The 
percentages of radioactivity that remain in the supernatant and are washed out from the powders are 
also depicted. 
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Enzyme release studies 
 
Fig. 12 shows the release profiles obtained for the different matrices previously described 
using CTP as the ceramic phase. The release profiles using HAp were similar (results not 
shown). When the enzyme was dispersed in the ceramic-alginate mixture before gel 
formation (matrix C), the release profile seems to be initially controlled by the diffusion of 
GCR from the surface of the beads, with a burst of 33.6±3.3% of total loading, followed by 
diffusion through the pores of the gel matrix until reaching a plateau at 55.4±4.6%. The 
overall release profile was not significantly different from what was obtained using a pure 
alginate matrix (matrix B). When the enzyme was pre-adsorbed onto the ceramic powders 
prior to the preparation of the microspheres (matrix D), the initial burst was significantly 
reduced (9.4±1.4%) and a slower release profile was obtained. The results obtained when 
using matrix A were similar to those reported for matrix D.  
 
 
 
Figure 12. Enzyme release profiles from the matrices tested using CTP: (A) enzyme adsorbed onto 
the ceramic powders; (B) enzyme dispersed in a pure alginate matrix; (C) enzyme and ceramic 
powders individually dispersed in the alginate matrix; and (D) ceramic powders with pre-adsorbed 
enzyme dispersed in the alginate matrix. The matrices A and B were used as controls. 
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DISCUSSION 
 
CTP-alginate and HAp-alginate microspheres were prepared using the droplet extrusion 
method combined with ionotropic gel formation in the presence of Ca2+.27 Polymer-ceramic 
mixtures of different compositions were prepared and drop-wise extruded into a crosslinking 
solution containing Ca2+. As soon as the droplets contacted with the solution, spherical 
particles were instantaneously formed, due to the rapid establishment of calcium-mediated 
associations between poly-guluronic acid sequences on the polymer backbone.27 This 
resulted in the formation of an alginate hydrogel network with entrapped ceramic particles. 
The process was carried out at room temperature and in the absence of organic solvents, 
which is ideal for the envisaged applications of these materials as enzyme carriers. 
The described methodology enabled the preparation of homogeneous microspheres 
presenting a regular size distribution, even without being fractioned by sieving. During the 
drying process and depending on their composition, microspheres underwent volume 
contractions at different extents. Shrinkage is related to water loss from the polymeric 
hydrogel phase, explaining why formulations with high ceramic-to-polymer contents 
underwent less contraction. 
SEM observation of the microspheres showed that the ceramic particles were well embedded 
and homogeneously distributed in the alginate matrix, suggesting a good wettability of the 
ceramics by the polymer solution. The surface morphology of the microspheres was 
dependent on the type of ceramic used, the HAp-alginate microspheres being smoother than 
the CTP-alginate ones. Differences were essentially attributed to the different mean particle 
sizes of the two ceramic powders. Although the granulometric analysis revealed that the 
particles of both powders were similar in size (90% of CTP particles are smaller than 25.32 
µm and have an average diameter of 11.00 µm, while 90% of the HAp particles are smaller 
than 20.51 µm and the average diameter is 7.96), the surface area measurements indicated 
that HAp particles have a much higher surface area (76 cm2/mg) than CTP (9.8 cm2/mg).  
Physicochemical characterisation of CTP-alginate and HAp-alginate was carried out by 
FTIR spectroscopy. The spectra showed that the characteristic bands of both ceramics are 
maintained in the microspheres, indicating that the alginate did not induce subsequent 
modifications in the structure of the ceramics. 
A preliminary analysis of the ability of CTP-alginate and HAp-alginate microspheres to act 
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as carriers for the enzyme glucocerebrosidase (GCR), a therapeutic enzyme used in the 
treatment of Gaucher disease, was carried out. 
The possibility of exploiting the capacity of both components to act as enzyme delivery 
systems was investigated, since both may immobilise proteins.23-27 For this reason, the 
enzyme was incorporated into the ceramic-alginate matrix before gel formation in two 
different ways, as described before. Concerning GCR loading capabilities of the ceramics 
used in this study, results showed that CTP adsorbs 41.28 ng/cm2, a much higher amount of 
enzyme per unit surface than HAp (1.94 ng/cm2). This may be attributed to the presence of 
BSA, used to stabilise the enzyme, as explained below. At physiological pH, both ceramics 
are negatively charged, the zeta potential of CTP being more negative than that of HAp. At 
pH 7.4, the enzyme is in the vicinity of its isoelectric point exhibiting a neutral net charge. 
Under the conditions used, BSA presents a net negative charge39 and will probably bind to a 
lesser extent to CTP than to HAp, due to increased repulsive charge, thus leaving the surface 
more available for GCR adsorption. Decreased adsorption of HSA (human serum albumin) 
onto CTP than onto HAp powders was observed by the authors (unpublished data), 
supporting this hypothesis. Despite being a very complex process, protein adsorption 
generally reflects hydrophobic/hydrophilic or electrostatic interactions between the protein 
and the surface. It seems that under the conditions used, the electrostatic characteristics of 
CTP favours the immobilisation of GCR. 
Other authors, in studies concerning applications in the biotechnology industry,22 
demonstrated the capacity of CTP to immobilise several enzymes. To the best of our 
knowledge this is the first time that this ceramic is used for the immobilisation of 
glucocerebrosidase. 
Release studies were performed with different matrices. When the enzyme was dispersed in 
the ceramic-alginate mixture before gel formation (matrix C), the release profile seemed to 
be initially controlled by the diffusion of GCR from the surface of the beads, with a 
significant burst, followed by diffusion through the pores of the gel matrix until reaching a 
plateau. The overall release profile was not significantly different from what was obtained 
using a pure alginate matrix (matrix B), suggesting that the enzyme does not interact, to a 
great extent, with the embedded ceramic particles. When the enzyme was pre-adsorbed onto 
the ceramic powders prior to the preparation of the microspheres (matrix D) the initial burst 
was significantly reduced and a slower release rate was achieved. For matrix A (powders) 
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the results were similar, suggesting that the alginate does not offer an additional resistance to 
enzyme diffusion. 
With the different matrices proposed, distinct release kinetics can be obtained and suitable 
strategies can be selected depending on the final application. Some aspects remain, however, 
to be investigated, namely the activity of the enzyme when released from the matrices used 
in this work (ongoing studies). Although protein immobilisation, either by entrapment or 
adsorption, often results in conformational alterations that may render the protein inactive, 
several authors have reported improved enzyme activity and/or stability in immobilised 
preparations when compared to their free forms.40 
 
 
CONCLUSIONS 
 
This study describes the preparation and initial characterisation of CTP-alginate and HAp-
alginate microspheres, which are intended to be used as enzyme delivery matrices and bone 
regeneration templates. The proposed methodology enabled the preparation of homogeneous 
microspheres with a uniform size, where the bulk properties of the ceramics were 
maintained, indicating that the alginate did not induce any modifications in the structure of 
the ceramics. Preliminary studies on the immobilisation and release of the therapeutic protein 
glucocerebrosidase were also performed. The enzyme was incorporated into the ceramic-
alginate matrix before gel formation in two different ways: pre-adsorbed onto the ceramic 
particles or dispersed in the matrix. The two strategies resulted in distinct release profiles, 
suggesting that, depending on the application, the more suitable one can be selected. 
 
 
Acknowledgements 
 
The authors would like to acknowledge Dr. Clara Sá Miranda for the GCR samples, Eng. 
Alexandra Lemos for the zeta potential determinations, and programme Praxis XXI from the 
Portuguese Foundation of Science and Technology (FCT) for awarding Cristina Barrias a 
scholarship. This work was carried out under contract POCTI/FCB/41523/2001. 
Calcium phosphate-alginate microspheres 
85 
REFERENCES 
 
1. Griffith LG, Naughton G. Tissue engineering: Current challenges and expanding 
opportunities. Science 2002;295:1009-1014. 
2. Hench LL, Polak JM. Third-generation biomedical materials. Science 2002;295:1014-
1017. 
3. Temenoff JS, Mikos AG. Injectable biodegradable materials for orthopedic tissue 
engineering. Biomaterials 2000;21:2405-2412. 
4. Laurencin CT, Lu HH. Polymer-ceramic composites for bone tissue engineering. In: 
Davies JE, editor. Bone engineering. Toronto: Em squared; 2000. p. 463-472. 
5. Gauthier O, Bouler J-M, Weiss P, Bosco J, Daculsi G, Aguado E. Kinetic study of bone 
ingrowth and ceramic resorption associated with the implantation of different injectable 
calcium-phosphate bone substitutes. J Biomed Mater Res 1999;47:28-35. 
6. Dupraz A, Delecrin J, Moreau A, Pilet P, Passut N. Long term bone response to 
particulate injectable ceramic. J Biomed Mater Res 1998;42:368-75. 
7. Grimandi G, Weiss P, Millot F, Daculsi G. In vitro evaluation of a new injectable 
calcium phosphate material. J Biomed Mater Res 1998;39:660-666. 
8. Gauthier O, Boix D, Grimandi G, Aguado E, Bouler JM, Weiss P, Daculsi G. A new 
injectable phosphate biomaterial for immediate bone filling of extraction sockets: a 
preliminary study in dogs. J Periodontol 1999;70:375-383. 
9. Peter SJ, Nolley JA, Widmer MS, Mervin JE, Yaszemski MJ, Yasko AW, Engel PS, 
Mikos AG. In vitro degradation of a poly (propylene fumarate)/β-tricalcium phosphate 
composite orthopedic scaffold. Tissue Eng 1997;3:207-215. 
10. Sims CD, Butler PEM, Casanova R, Lee BT, Randolph MA, Lee WPA, Vacant CA, 
Yamremchuk MJ. Injectable cartilage using polyethylene oxide polymer substrates. Plast 
Reconstr Surg 1996;98:843-850. 
11. Suggs LJ, Shive MS, Garcia CA, Anderson JM, Mikos AG. In vitro cytotoxicity and in 
vivo biocompalibility of poly (propylene fumarate-co-ethylene glycol) hydrogels. J 
Biomed Mater Res 1999;46:22-32. 
12. Suggs LJ, Krishnan RS, Garcia CA, Peter SJ, Anderson JM, Mikos AG. In vitro and in 
vivo degradation of poly(propylene fumarate-co-ethylene glycol) hydrogels. J Biomed 
Mater Res 1998;42:312-320. 
Chapter III  
86 
13. Frazier DD, Lathi VK, Gerhart TN, Hayes WC. Ex vivo degradation of a poly (propylene 
glycol-fumarate) biodegradable particulate bone cement. J Biomed Mater Res 
1997;35:383-389. 
14. Kharas GB, Kamanetsky M, Simantirakis J, Beinlich KC, Rizzo A-MT, Caywood GA, 
Watson K. Synthesis and characterization of fumarate-based polyesters for use in 
bioresorbable bone cement composites. J Appl Polym Sci 1997;66:1123-1137. 
15. Paige KT, Cima LG, Yaremchuck MJ, Vacant JP, Vacant CA. Injectable cartilage. Plast 
Reconstr Surg 1995;96:1390-1400. 
16. Paige KT, Cima LG, Yaremchuck MJ, Vacant JP, Vacant CA. De novo cartilage 
generation using calcium-alginate-chondrocyte constructs. Plast Reconstr Surg 
1996;97:168-180. 
17. Kulseng B, Skjak-Braek G, Ryan L, Andersson A, King A, Faxvaag A, Espevik T. 
Transplantation of alginate microcapsules. Transplantation 1999;67:978-984. 
18. Martinetti R, Dolcini L, Ravaglioli A, Krajewski A, Mangano C. Experimental study on 
hydroxyapatite/N-carboxymethyl chitosan fillers. Sedel L, Rey C, editors. Bioceramics 
10. Paris: Pergamon/Elsevier Science; 1997. p. 503-506.  
19. Maruyama M, Ito M. In vitro properties of a chitosan-bonded self hardening paste with 
hydroxyapatite granules. J Biom Mat Res 1996;32:527-532. 
20. Dupraz A, Nguyen TP, Richard M, Daculsi G, Passuti N. Influence of a cellulosic ether 
carrier on the structure of biphasic calcium phosphate ceramic particles in an injectable 
composite material. Biomaterials 1999;20:663-673. 
21. Ribeiro CC, Barrias CC, Barbosa MA. Calcium titanium phosphate: properties of an 
alternative biomaterial (Submitted to Acta Materialia 2004). 
22. Alamo J, Chemistry and properties of solids with NZP skeleton. Solid State Ionics 
1993;63:547-561. 
23. Takahiro S, Motohiro T, Hosono H. Application of a microporous glass-ceramic with a 
skeleton of CaTi4(PO4)6 to carriers for immobilization of enzymes. J Ferment Bioeng 
1991;72:384-391. 
24. Gross U, Muller-Mai C, Voigt C, Mesgarian M, Berger G, Ploska U. Tissue response in 
femur of rabbits after implantation of a new calcium titanium phosphate composition. 
Key Eng Mat 2001;192-195:383-386. 
25. Otsuka M, Matsuda Y, Fox JL, Higuchi WI, Yu D, Wong J. A novel skeletal drug 
Calcium phosphate-alginate microspheres 
87 
delivery system for anti bacterial drugs using self-setting hydroxyapatite cement. Chem 
Pharm Bull (Tokyo) 1990;38:3500-3502. 
26. Guicheux J, Grimandi G, Trecant M, Faivre A, Takahashi S. Apatite as a carrier for 
growth hormone: in vitro characterization of loading and release. J Biomed Mater Res 
1997;34:165-170. 
27. Gombotz WR, Wee SF. Protein release from alginate matrices. Adv Drug Deliv Rev 
1998;31;267-285. 
28. Eiselt P, Yeh J, Latvala RK, Shea LD, Mooney DJ. Porous carriers for biomedical 
applications based on alginate hydrogels. Biomaterials 2000;21:1921-27. 
29. Alsberg V, Anderson K, Albeiruti A, Franceshi RT, Mooney DJ. Cell interactive alginate 
hydrogels for bone tissue engineering. J Dent Res 2001;80:2025-2029. 
30. Smidsrod O, Draget KI. Chemistry and physical properties of alginates. Carbohyd 
Europe 1996;14:6-13. 
31. Sivakumar M, Manjubala I, Panduranga Rao K. Preparation, characterization and in vitro 
release of gentamicin from coralline hydroxyapatite-chitosan composite microspheres. 
Carbohyd Pol 2002;49:281-288. 
32. Qiu QQ, Ducheyne P, Ayyaswamy PS. New bioactive, degradable composite 
microspheres as tissue engineering substrates. J Biomed Mater Res 2000;52:66-76. 
33. Hsu FY, Chueh S-C, Wang YJ. Microspheres of hydroxyapatite/reconstituted collagen as 
supports for osteoblast cell growth. Biomaterials 1999;20:1931-1936. 
34. Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 
years. Blood Rev 1998;12:115-133. 
35. Xu YH, Ponce E, Sun Y, Leonova T, Bove K, Witte D, Grabowski GA. Turnover and 
distribution of intravenously administered mannose-terminated human acid beta 
glucosidase in murine and human tissues. Pediatr Res 1996;39:313-322. 
36. Ferraz MP, Monteiro FJ, Serro AP, Saramago B, Gibson IR, Santos JD. Effect of 
chemical composition on hydrophobicity and zeta-potential of plasma spayed HA/CaO-
P2O5 glass coatings. Biomaterials 2001;22:3105-3112. 
37. Lopes MA, Monteiro FL, Santos JD, Serro AP, Saramago B. Hydrophobicity, surface 
tension, and zeta potential measurements of glass reinforced hydroxyapatite composites. 
J Biomed Mater Res 1999;45:370-375. 
38. Dupuy B, Arien A, Minnot AP. FT-IR membranes made with alginate/polylysine 
Chapter III  
88 
complexes. Variations with mannuronic or guluronic content of the polysaccharides. Art 
Cells, Blood Subs Immob Biotech 1994;20:71-82. 
39. Peters T. All about albumin: biochemistry, genetics and medical applications. San Diego 
CA : Academic Press Inc; 1996. 
40. Nakanishi K, Sakiyama T, Imamura K. On the adsorption of proteins on solid surfaces, a 
common but very complicated phenomenon. J Biosci Bioeng 2001;91:233-244. 
 
* Key Engineering Materials 2005;284-286:689-692                                                                      89 
Chapter IV 
 
 
Effect of calcium phosphate addition to alginate microspheres: 
modulation of enzyme release kinetics and improvement of cell adhesion* 
 
Barrias CC,1,2 Ribeiro CC,1,2,3 Rodrigues D,4 Sá Miranda MC,4 MA Barbosa1,2 
 
1 INEB – Instituto de Engenharia Biomédica, Laboratório de Biomateriais, R. Campo Alegre 823, 
4150-180 Porto, Portugal 
2 Universidade do Porto, Faculdade de Engenharia, Dep. de Engª Metalúrgica e de Materiais, R. Dr. 
Roberto Frias, 4200-465 Porto, Portugal 
3 ISEP – Instituto Superior de Engenharia do Porto, Dep. de Física, Porto, Portugal  
4 IBMC – Instituto de Biologia Molecular e Celular, Unidade de Biologia do Lisossoma e 
Peroxissoma (UNILIPE), Rua do Campo Alegre, 823, 4150-180 Porto, Portugal 
 
 
ABSTRACT 
 
In this study, the addition of calcium phosphate powders to an alginate matrix was 
evaluated as a strategy to modulate enzyme release-kinetics from alginate microspheres 
and, simultaneously, to improve cell adhesion to the polymer. Pre-adsorption of the 
enzyme to the ceramic powders resulted in a more adequate release pattern. The ratio of 
ceramic-to-polymer had a pronounced effect on osteoblast adhesion to microspheres. Cells 
were only able to spread on microspheres with the highest percentage of ceramic (0.4 w/w 
using a 1.5% w/v alginate solution). 
Keywords: hydroxyapatite, calcium titanium phosphate, alginate, microspheres, enzyme release, 
cell adhesion  
 
INTRODUCTION 
 
The activity of the enzyme glucocerebrosidase (GCR) is deficient in type I Gaucher 
disease (GD), a genetic disturbance that characteristically results in severe haematological 
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abnormalities, organomegaly and skeletal deterioration.1 The currently available treatment 
is based on the intravenous administration of exogenous enzyme, and it seems to be 
efficient in reverting most of the symptoms.1 However, in terms of bone pathology, which 
is among the most disabling manifestations of GD (type 1), a slow and incomplete 
response to the treatment is observed, even when high doses are used, indicating that 
adjuvant therapies are necessary in order to consistently restore enzyme activity in bone.1 
An injectable vehicle for local GCR-delivery to bone is currently under investigation. GCR 
was previously entrapped in alginate microspheres, retaining full activity and exhibiting 
improved stability at physiological pH. Studies using GCR-deficient fibroblasts from a GD 
patient showed that released GCR was internalised by cells, significantly enhancing their 
residual enzymatic activity, with only one half of the dose required using free-GCR. 
Release profiles were characterised by a high burst effect followed by a stage of very slow 
release. As a strategy to modulate GCR release-kinetics and at the same time improve 
osteoblastic cell adhesion to alginate microspheres, calcium phosphate powders of 
hydroxyapatite (HAp) or calcium titanium phosphate (CTP) were added to the polymeric 
matrix and ceramic-alginate microspheres were prepared by droplet extrusion followed by 
ionotropic gelation with Ca2+. In this study, GCR release kinetics and osteoblast adhesion 
to ceramic-alginate microspheres of different compositions were analysed. 
 
 
MATERIALS AND METHODS 
 
Preparation and characterisation of HAp-alginate and CTP-alginate microspheres 
 
HAp or CTP powders were mixed with Na-alginate solution (1.5 and 3% w/v) at different 
ratios (0.1, 0.2 and 0.4 w/w). The different formulations are designated in the text as 40/1.5 
(0.4 w/w ceramic using 1.5% w/v Na-alginate) and 10/3, 20/3 and 40/3 (0.1 to 0.4 w/w 
ceramic, using 3% w/v Na-alginate). The paste was extruded drop-wise into a CaCl2 bath, 
where microspheres were instantaneously formed. Size was controlled by applying a 
coaxial air stream. After 30 min, microspheres were recovered and rinsed in water. 
Characterisation was carried out by FTIR and SEM. Diameters were measured using an 
optical microscope with an ocular micrometer. 
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GCR entrapment in HAp-alginate and CTP-alginate microspheres and release 
studies 
 
Radiolabelled enzyme (125I-GCR, Iodogen method) was incorporated in the 
polymeric/ceramic paste prior to extrusion in two different ways: directly dispersed in the 
paste or pre-adsorbed onto the ceramic particles. Ceramic-alginate microspheres with 
entrapped GCR were then prepared as already described. Alginate microspheres with 
entrapped GCR were used as controls. For enzyme adsorption, the ceramic powders were 
immersed in 0.1 mg/mL GCR solution in phosphate-buffered saline (PBS, pH 7.4) and 
incubated at room temperature for 30 min under agitation. A control GCR solution at 0.1 
mg/mL was incubated under the same conditions (without powders) to account for 
eventual enzyme losses due to adsorption to the tubes walls. At the end, powders were 
washed in PBS and separated by centrifugation. To determine the amount of adsorbed 
GCR, the concentration of enzyme in the supernatants before and after adsorption was 
quantified by the bicinchoninic acid method. GCR activity in the supernatants and in the 
powders was assayed as the hydrolysis of the substrate 4-methylumbelliferyl-β-D-
glucopyranoside (5 mM) in 50-100 mM citrate-phosphate buffer (pH 5.5) and in the 
absence of activators. GCR release studies from the different matrices were performed in 
PBS at 37ºC and 120 rpm. At predefined time intervals, aliquots from the supernatants 
were collected and counted for radioactivity and fresh PBS was added to maintain a 
constant volume. 
 
 
Cell adhesion studies 
 
Microspheres were pre-incubated in 70% v/v ethanol, equilibrated overnight in α-minimal 
essential medium supplemented with 10% v/v foetal bovine serum, and finally seeded with 
osteoblast-like MG63 cells. Alginate and HAp microspheres were used as controls. After 
24 h, microsphere-cell constructs were visualised by SEM and by confocal laser scanning 
microscopy (CLSM). For CLSM, f-actin filaments were stained with Alexafluor 488-
conjugated phalloidin (Molecular Probes) and nuclei were counterstained with propidium 
iodide (Sigma). 
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RESULTS AND DISCUSSION 
 
Preparation and characterisation of HAp-alginate and CTP-alginate microspheres 
 
Spherical-shaped microparticles presenting a uniform size (Fig.1a) were prepared. The 
diameters of CTP-alginate microspheres ranged from 450±14 µm to 796±39 µm, while the 
diameters of HAp-alginate microspheres ranged from 412±23 µm to 749±22 µm, both 
depending on the formulation. SEM images of both types of microspheres revealed that the 
ceramic particles are well embedded and homogenously distributed in the alginate matrix 
as illustrated in Fig.1b (20/3 HAp-alginate microspheres). FTIR analysis (data not shown) 
indicates that the characteristic spectral bands of both ceramics are maintained in the 
microspheres, in comparison with the starting powders, suggesting that the alginate did not 
induce subsequent modifications in the ceramics structure. 
 
 
GCR entrapment in HAp-alginate and CTP-alginate microspheres and release 
studies 
 
The enzyme was incorporated in the ceramic-alginate paste prior to the preparation of the 
microspheres in two different ways: directly dispersed in the paste or pre-adsorbed onto the 
ceramic particles. The ceramic powders used were characterised by a specific surface area 
of 9.8 cm2/mg (CTP) and 76.0 cm2/mg (HAp). Adsorption was performed at pH 7.4, which 
is near the enzyme isoelectric point (in the range 7 to 8) where the enzyme exhibits higher 
structure stability and therefore a smaller tendency to denaturate upon adsorption. The 
amount of adsorbed GCR was calculated by quantifying GCR depletion from the 
Fig 1. a) Photograph of CTP-
alginate microspheres (40/3) 
illustrating their uniform size; 
b) SEM of a HAp-alginate 
microsphere (20/3) showing 
the ceramic particles 
embedded in the polymer. 
Alginate 
HAp 
b a 1 cm 
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supernatant. Preliminary assays showed that the incubation time selected (30 min) was 
sufficiently long to attain steady-state adsorption values. GCR has higher affinity for CTP 
powder, which adsorbed 41.8±1.1 ng GCR/cm2, than for HAp, which adsorbed 4.3±0.4 ng 
GCR/cm2.  The variation in plateau values for the two ceramics is probably related to 
differences in protein-surface electrostatic interactions. Fig. 2a depicts GCR activity in the 
initial solution (free enzyme only) and in the presence of the two ceramic powders after 
adsorption (free + adsorbed enzyme) as a function of the GCR amount in the assay. In all 
cases, GCR activity increases linearly with the amount of enzyme present, but while in the 
presence of HAp there is some degree of inactivation, in the presence of CTP a higher 
catalytic efficiency was observed. Differences probably result from GCR conformational 
alterations in the adsorbed state. The specific activity (activity per unit mass) of GCR 
adsorbed on CTP and HAp powders after washing and re-suspending in fresh PBS 
(adsorbed enzyme only) were c.a. 91.5±4.9% and 10.3±0.1% of the control (free enzyme), 
respectively. These values may however be underestimated due to enzyme losses by 
desorption during washing. 
 
 
Release studies 
 
The two strategies used for GCR entrapment in the alginate matrix resulted in distinct 
release kinetics, but similar results were obtained for both ceramics tested. Fig. 2 shows 
typical release profiles obtained with HAp-alginate and alginate microspheres. When GCR 
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was pre-adsorbed onto the ceramic powders prior to microspheres formation the initial 
burst was significantly reduced, from ca. 50% to 11% (t=150 min) compared to the one of 
alginate microspheres, and a slower and more linear release profile was obtained, showing 
that release-kinetics modulation was achieved. The release profile of GCR directly 
dispersed in the ceramic/polymer matrix was not significantly different from the control 
(data not shown), suggesting that the GCR does not interact, at least to a great extent, with 
the embedded ceramic particles. 
 
Cell adhesion studies 
 
The ability of cells to adhere and spread on the surface of HAp-alginate and CTP-alginate 
microspheres of different compositions was assessed by CLSM (Fig. 3) and SEM (Fig. 4). 
Figures are referred to HAp-alginate microspheres but similar results were obtained for 
both ceramics tested. No adherent cells could be found on the surface of control alginate 
microspheres (data not shown). This was not unexpected since it has been previously 
reported that attachment-dependent cells are unable to specifically interact with alginate 
hydrogels, which promote minimal protein adsorption presumably due to their high 
hydrophilic nature.2 Upon addition of HAp or CTP particles to the alginate matrix a 
distinct cell behaviour was observed, depending on the ceramic-to-polymer ratio used. For 
the lower ceramic-to-polymer ratios (formulations 10/3, 20/3 and 40/3) only dispersed 
round cells and/or multicellular aggregates could be observed on the microspheres surface 
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(Fig. 3a, 3b and 4a). However, on microspheres prepared with the higher ceramic-to-
polymer ratio (formulation 40/1.5) cells were able to attach, spread and adopt a spindle-
shaped morphology (Fig. 3c and 4b). Filopodial extensions could be observed both by 
CLSM and SEM. Cells on control HAp microspheres were well flattened exhibiting a 
typical osteoblastic-like morphology (Fig. 3d and 4c). Enhanced cell adhesion in polymer-
ceramic composites in comparison with their polymeric counterparts has been previously 
demonstrated by other authors.3 
 
Fig 3. CLSM images of MG63 cells cultured for 24 h on: a) 10/3, b) 20/3, c) 40/1.5 HAp-alginate 
microspheres and d) HAp microspheres. 
Fig 4. SEM images of MG63 cells cultured for 24 h on: a) 20/3, b) 40/1.5 HAp-alginate 
microspheres and c) HAp microspheres. 
 
 
CONCLUSIONS 
 
The addition of calcium-phosphate particles to alginate allowed the modulation of GCR 
release kinetics. The ratio of ceramic-to-polymer had a pronounced effect on osteoblasts 
adhesion to microspheres. Cells were only able to spread on microspheres with the higher 
percentage of ceramic. 
a                                   b                                  c                                 d 
a b c 
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ABSTRACT 
In the present work, a novel route for the preparation of porous ceramic microspheres is 
described. Two ceramic powders, calcium titanium phosphate (CTP) and hydroxyapatite 
(HAp), were mixed with a sodium alginate solution that enabled the preparation of spherical 
particles, using the droplet extrusion method combined with ionotropic gelation in the 
presence of Ca2+. The spherical particles were subsequently sintered, to burn-off the polymer 
and obtain calcium phosphate microspheres with a uniform size and an interconnected 
porous network. CTP microspheres with diameters ranging from 513±24 µm to 792±35 µm 
and with pores of approximately 40 µm were obtained. HAp microspheres presented 
diameters of 429±46 µm and 632±40 µm and pores of ca. 2 µm. Depending on the 
formulations tested; the structure of both calcium phosphates may become altered during the 
sintering process, suggesting that the ratio between the ceramic phase and the polymer 
solution is a critical parameter. Porous microspheres prepared using the described 
methodology are promising candidates as bone defect fillers and scaffolds for bone tissue 
regeneration.  
Keywords: porous microspheres, calcium titanium phosphate, hydroxyapatite, alginate, bone 
regeneration. 
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INTRODUCTION 
 
Due to the large number of orthopaedic surgical interventions performed each year, bone 
repair has become a subject of intensive investigation. The use of calcium phosphate 
ceramics in bone regeneration, either alone or in combination with a polymeric phase, has 
become a common practice, since these materials generally provide good biological 
responses and adequate mechanical properties. Although calcium phosphate ceramics have 
traditionally been used as dense or porous three-dimensional scaffolds, increasing efforts 
have been devoted to the development of injectable formulations for bone-defects filling 
applications, since they can be applied through minimally invasive techniques.1 Most 
injectable ceramic materials described in the literature consist of micro or nanoparticles 
suspended in appropriate vehicles.2-7 In such systems, the shape of the microparticles 
determines their packaging characteristics, spherical particles being more suitable for 
implantation than non-homogeneous granules, since they conform better to irregular 
implant sites. Moreover, uniform particles present more predictable flowing properties 
during injection.8-11 
In certain applications, the effectiveness of these microparticulate materials can be highly 
improved if they can act simultaneously as carriers for biologically active molecules. In 
this sense, porous materials are advantageous, since they present additional surface area, an 
important parameter that strongly influences the loading capacity and release rates that can 
be obtained. 
In the present work, novel ceramic porous microspheres are proposed, which could find 
applicability in the field of bone regeneration, both as injectable bone-filling materials and 
drug delivery matrices. Two ceramic powders, calcium titanium phosphate (CTP) and 
hydroxyapatite (HAp), were tested. CTP, a bioactive ceramic currently under investigation 
in our laboratory,12 is a potential material to be used in the biomedical field as it presents 
interesting properties, namely the ability to act as an immobilisation matrix for several 
enzymes.13-16 HAp, which possesses a chemical structure similar to bone mineral, has long 
been recognized in the biomedical field for its osteoconductivity and capacity to act as 
matrix for drug delivery17-18 and was used as a reference material. Alginate was chosen due 
to its suitable rheology and ability to form relatively stable hydrogels under mild 
conditions.19 
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CTP-alginate and HAp-alginate microspheres were first prepared using the droplet extrusion 
method as described in a previous work.16  The ceramic powders were mixed with alginate, 
which enables the preparation of spherical particles through instantaneous crosslinking in the 
presence of Ca2+.16 The obtained microspheres were then dried and subsequently sintered to 
burn-off the polymer and aggregate the ceramic granules, allowing the preparation of 
ceramic microspheres with a uniform size and interconnected porous network. 
Compared to other methods of preparing ceramic microspheres described in the literature,8-11 
this novel process presents the advantage of simplicity and of being carried out in the 
absence of organic solvents or oils, thus enabling the recovery of the spherical particles 
without the need of fastidious washing processes. Moreover, the obtained microspheres 
present a regular size distribution, even without a subsequent fractionation by sieving. 
In this study, the preparation and physicochemical characterisation of CTP and HAp 
microspheres prepared according to the described methodology are presented. 
 
 
MATERIALS AND METHODS 
 
Characterisation of the ceramic powders 
 
CTP was synthesised by solid-state reaction as described elsewhere.12 HAp was kindly 
donated by CAM Implants. Both ceramics were analysed by X-ray diffraction (XRD, Philips 
PW 1710 diffractometer), and their granulometry characterised using a laser scanner particle 
size analyser (Coulter Electronics Incorporation). The specific surface area of each powder 
was measured by gas adsorption according to the BET (Brunauer, Emmel and Teller) 
method. Both powders were observed by scanning electron microscopy (SEM). Samples 
were sputter coated with gold using a JEOL JFC-100 fine coat ion sputter device, and 
observed using a JEOL JSM-6301F scanning microscope. 
 
Preparation of CTP and HAp microspheres 
 
Ceramic powders were dispersed in a pre-filtered (0.8 µm) 3% w/v sodium alginate solution 
(Pronova Biopolymers) under gentle stirring until a homogeneous paste was obtained. 
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Different ceramic-to-polymer solution ratios (0.1, 0.2 and 0.4) were tested. These will be 
designated as 10/3, 20/3 and 40/3 (different ceramic-to-polymer solution ratios, using a 3% 
w/v sodium alginate solution). Preliminary assays were conducted to determine the 
maximum ceramic-to-polymer solution ratio and it was observed that for ratios higher than 
0.4 the pastes obtained became too viscous to be handled and extruded. The pastes were 
extruded drop-wise into a 0.1 M CaCl2 crosslinking solution, where spherical-shaped 
particles instantaneously formed and were allowed to harden for 30 min. The size of the 
microspheres was controlled by regulating the extrusion flow rate using a syringe pump 
(Cole Parmer) and by applying a coaxial air stream (Encapsulation Unit Var J1; Nisco). At 
completion of the gelling period, microspheres were recovered and rinsed in water in order 
to remove the excess CaCl2. Finally, they were dried overnight in a vacuum-oven at 30ºC, 
and then sintered at 1100ºC with a uniform heating rate of 5ºC/min, and a 1 h stage at the 
maximum temperature.  
 
 
Characterisation of the microspheres 
 
The diameter of the microspheres (n=20) was measured using an inverted plate microscope 
(Olympus) equipped with an ocular micrometer with an accuracy of 10 µm. 
Morphological and physicochemical characterisation was carried out using SEM and Fourier 
transform infrared spectroscopy (FTIR). For FTIR analysis, microspheres were reduced to 
powder and analysed as KBr pellets using a Perkin Elmer System 2000 spectrometer. 
In order to identify the composition of the residue that results from burning the polymer 
during sintering, calcium alginate microspheres, produced as described, were submitted to 
the same heating cycle used for preparing CTP and HAp microspheres. The obtained residue 
was analysed by XRD and FTIR. 
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RESULTS 
 
Characterisation of the ceramic powders 
 
XRD of the ceramics indicated the presence of monophase crystalline compounds. 
Granulometric analysis of the powders revealed that 90% of the CTP particles are smaller 
than 25.32 µm, with a volume average diameter of 11.0 µm, and that 90% of the HAp 
particles are smaller than 20.51 µm, with a volume average diameter of 7.96 µm.  However, 
surface area measurements indicated that HAp particles have a much higher surface area (76 
cm2/mg) than CTP (9.8 cm2/mg) suggesting that the results obtained in the HAp 
granulometric analysis are overestimated, probably due to particle aggregation. Both 
powders were observed by SEM, which confirmed that CTP particles are in fact much larger 
than the HAp particles (data not shown).  
 
Characterisation of CTP and HAp microspheres 
 
To produce CTP and HAp microspheres, CTP-alginate and HAp-alginate mixtures of 
different compositions were prepared and drop-wise extruded into a 0.1M CaCl2 solution. As 
soon as the ceramic-polymer droplets contacted with the crosslinking bath, spherical 
particles of approximately 1000 µm were instantaneously formed, due to the rapid 
establishment of calcium-mediated junctions between poly-guluronate chains on the polymer 
backbone.18 An exception was observed for the 40/3 HAp formulation, with which it was not 
possible to obtain spherical particles due to the high viscosity of the ceramic-polymer 
mixture. 
During drying, the volume contractions varied with the formulation as shown in Fig.1 which 
presents the diameters of dried CTP and HAp microspheres, that were obtained before 
(ceramic-polymer microspheres) and after sintering (ceramic microspheres). 
It can be concluded that the higher the ceramic-to-polymer solution ratio used, the lower the 
particles contraction during drying. Upon sintering, microspheres maintained their original 
spherical shape. In the case of the HAp microspheres their diameter further decreased 
approximately 20%, while CTP microspheres practically maintained their original 
dimensions. 
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Figure 1. Diameters of CTP microspheres; and HAp microspheres, before and after sintering. 
 
 
Such differences are probably related to the different particle size distributions and, in 
particular, to the higher percentage of fine particles in HAp that results in a more effective 
packaging during sintering. With the described methodology, microspheres with a regular 
size distribution were obtained without being necessary a subsequent fractioning by sieving. 
Microspheres with average final diameters of 513±24 µm, 602±28 µm, and 792±35 µm were 
obtained for the CTP 10/3, 20/3 and 40/3 formulations, respectively; while with HAp 
microspheres diameters of 429±46 µm and 632±40 µm were obtained for the 10/3 and 20/3 
formulations, respectively. 
 
0
100
200
300
400
500
600
700
800
900
CTP 10/3 CTP 20/3 CTP 40/3
M
ic
ro
sp
he
re
s d
ia
m
et
er
, 
µm
Before sintering
After sintering
 
0
100
200
300
400
500
600
700
800
900
HAp 10/3 HAp 20/3
M
ic
ro
sp
he
re
s d
ia
m
et
er
, µm
Before sintering
After sintering
Preparation and characterisation of calcium phosphate microspheres 
103 
SEM analysis 
 
SEM pictures of CTP and HAp microspheres, before and after sintering, are presented in Fig. 
2. Only the results obtained with the 20/3 formulation are given, as similar results were 
obtained for the other formulations tested. The analysis revealed that in both cases 
microspheres were homogeneous, in terms of size and shape. No evidence of cracks was 
found. CTP microspheres (Fig. 2 a, b, c) present a rather rough surface, while HAp 
microspheres (Fig. 2 d, e, f) are smoother. Such differences are mainly attributable to the 
differences in granulometry of the two ceramics, since the CTP particles are much larger 
than those of HAp. The volume contraction that occurred upon sintering in the case of HAp 
microspheres is evident (Fig. 2 a, b). 
 
 
 
Figure 2. SEM images of CTP and HAp microspheres before and after sintering: (a) non-sintered 
CTP microsphere; (b, c) sintered CTP microspheres; (d) non-sintered HAp microsphere; (e, f) 
sintered HAp microspheres. 
 
a b c
d  fe
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Non-sintered microspheres revealed, at higher magnifications, a homogeneous distribution of 
the ceramic phase in the alginate matrix (Fig. 3 a, d). It should be noted, however, that since 
the particles of HAp powder are much smaller than those of CTP, the former appear to be 
more densely packed. Upon sintering the polymer phase is substituted by a porous network 
(Fig. 3 a, b, e, f). The interconnectivity of the pores and their homogeneous distribution are 
clearly observed in Fig. 3b, 3c and 3f, respectively. Pores of approximately 40 µm were 
obtained when using CTP as the ceramic phase, while HAp resulted in pores of 
approximately 2 µm. Results were similar for all the formulations tested. Differences in 
porosity may be attributed to the different granulometries of the two compounds, which 
result in different packaging of the ceramic particles during drying and sintering, as already 
suggested.  
 
 
 
Figure 3. SEM images of the surface of CTP and HAp microspheres before and after sintering: (a) 
non-sintered CTP microsphere, (b, c) sintered CTP microspheres; (d) non-sintered HAp microsphere, 
(e, f) sintered HAp microspheres. 
a b c 
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FTIR and XRD analysis 
 
The FTIR spectrum of the residue powder obtained after subjecting Ca-alginate 
microspheres to a sintering cycle (Fig. 4) showed the presence of bands characteristic of 
carbonates, namely the ones in the intervals 1409-1483 cm-1, 1020-1100 cm-1 and 800-890 
cm-1.20, 21 The band at 3642 cm-1 is assigned to O-H vibrations, suggesting the presence of a 
hydroxide compound.20, 22 XRD analysis of the residue (Fig. 5) identified it as a mixture of 
Ca(OH)2 (portlandite) and CaCO3 (calcite), confirming the results obtained by FTIR. 
Wavenumber (cm-1) 
Figure 4. FTIR spectrum of the residue powder obtained after sintering Ca-alginate microspheres. 
2  θ 
♦ 
♦ 
♦ 
♦ 
♦ ♦ ♦ 
• 
• 
• • • • • 
♦ 
♦ • 
♦ • • • • • • • 
0
200
400
600
800
1000
1200
1400
1600
1800
2000
0 10 20 30 40 50 60 70
In
te
ns
ity
0               10                20               30              40              50                60             70 
2 θ       
2000 
1800 
1600 
1400 
1200 
1000 
800 
600 
400 
200 
0 
 
4000 3000 2000 1500 1000 400
5 
10 
15 
20 
25 
30 
40 
45 
50 
55 
60 
65 
70 
3847
3642 
3451 
2975
1639
1409
1088
1050
1020
916 
875 
847 
1483 
T% 
35 
 
Figure 5. XRD spectrum of the Ca-alginate residue:♦–Portlandite Ca(OH)2; •–Calcite CaCO3. 
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FTIR spectra of CTP powder and CTP microspheres are presented in Fig. 6. The changes 
that are observed in the spectra of CTP microspheres when compared to those of the CTP 
powder, suggest that a reaction between CTP and Ca-alginate must have occurred during 
sintering, leading to structural modifications that resulted in the appearance of new bands in 
the ν3PO4 and ν2PO4 phosphate zone, as well as a band at 726 cm-1. These bands are more 
evident in the spectrum of the sample with the lowest ceramic-to-polymer solution ratio 
(10/3), and becomes less defined as the ceramic-to-polymer solution ratio increases, being 
the FTIR spectrum of the 40/3 formulation very similar to the one of CTP powder. 
 
Figure 6. FTIR spectra of CTP powder and of different formulations of CTP microspheres. 
 
Fig. 7 shows the FTIR spectrum of (a) 10/3 CTP microspheres, (b) commercial calcium 
pyrophosphate (Ca2P2O7; Sigma Aldrich) and (c) titanium pyrophosphate synthesised in our 
laboratory. Several bands characteristic of pyrophosphate groups, namely the ones in the 
ranges: 900-1200 cm-1, 700-770 cm-1 and 500-600 cm-1, are common to spectra (a) and (b), 
suggesting the formation of a calcium pyrophosphate phase in the CTP microspheres as a 
consequence of the sintering process. However, the existence of that phase could not be 
detected by XRD analysis (Fig. 8) leading to the assumption that the phase is either 
amorphous or present in residual concentrations. In addition, XRD analysis showed the 
presence of small quantities of titanium oxide (rutile) in the sintered CTP microspheres, its 
4000 3000 2000 1500 1000 400
CTP powder 
 
CTP-Alg 20/3 
 
T% 
CTP-Alg 10/3 
Wavenumber (cm-1)
Preparation and characterisation of calcium phosphate microspheres 
107 
concentration being higher in the formulation 10/3. This was not unexpected considering the 
hypothesis described above. If a calcium pyrophosphate is formed, probably some titanium 
will become available to form an oxide. 
 
Figure 7. FTIR spectra of CTP-Alg 10/3 microspheres, calcium pyrophosphate (Ca2P2O7), and 
titanium pyrophosphate (TiP2O7). 
 
Figure 8. XRD of CTP powder and of different formulations of CTP microspheres. 
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In what concerns HAp microspheres, XRD analysis of the HAp powder and HAp 
microspheres revealed that after sintering no decomposition of the ceramic occurred, since 
no extraneous phases could be identified. Fig. 9 shows the FTIR spectra of HAp powder and 
10/3 HAp microspheres. It is worth noting the appearance of carbonate bands at 1440 cm-1 
and 876 cm-1 in the samples with the 10/3 ceramic-to-polymer solution ratio, suggesting the 
presence of a carbonated hydroxyapatite. This may have practical implications, since it is 
well established that the presence of carbonates in calcium phosphate materials is an 
important factor contributing to the in vivo integration of the implant. For the 20/3 and 40/3 
formulations, the FTIR spectra of the microspheres are practically identical to the one of 
HAp, but the presence of carbonate bands is less evident. No signs of calcium hydroxide 
were observed in the sintered CTP-alginate and HAp-alginate microspheres. 
 
 
Figure 9. FTIR spectra of HAp powder and HAp-Alginate 10/3 microspheres. 
 
In order to clarify if a carbonated apatite has been obtained, or if the carbonate bands were 
due to formation of a calcium carbonate residue, resultant from the burning of alginate, 10/3 
HAp microspheres were subjected to a second sintering cycle at 1100ºC for 1 h. When 
heated to this high temperature, any free calcium carbonate would disappear since calcium 
carbonate (calcite) decomposes at approximately 825ºC into CaO and CO2.23 The FTIR 
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spectra of the re-heated HAp microspheres still presented the carbonate bands, confirming 
the presence of a carbonated apatite.  
 
 
DISCUSSION 
 
There are several reports described in the literature concerning the development of HAp or 
HAp-polymer granulates with spherical geometry.8-11, 24-28 Most of the methods used to 
produce microspheres have the disadvantage of using organic solvents or oils thus needing 
several washing stages to eliminate them. For instance, Sunny et al10 produced HAp/chitosan 
microspheres by the dispersion of HAp/chitosan slurry in liquid parafin, with the addition of 
gluteraldehyde to harden the spheres. Sivakumar et al11, 28 developed a method to produce 
coralline HAp/chitosan and coralline HAp/gelatin composite microspheres using a PMMA 
dispersion solution containing toluene as a crosslinking agent. The experimental method 
proposed in this study has the advantage of not using such reactants,  thus allowing the 
recovery of the microspheres without the need of fastidious washing processes. 
Another advantage of the present methodology is the possibility of producing spherically 
shaped particles with uniform sizes. Irregularly or densely packed granules have been 
described in the literature as being the cause of inflammatory reactions and slower bone 
formation.29 Uniformly packed spherical particles would lead to a regular inter-particle 
porosity, thus contributing to easier migration of bone cells. Moreover, since our aim is to 
use the microspheres in an injectable form, their flowing properties during injection will be 
more predictable if their shape and size are more regular. 
Since these microspheres may also be used to deliver growth factors and other proteins, their 
porosity is a critical parameter since it may strongly influence their loading capacity. The 
raise in porosity that occurs upon sintering will significantly increase the surface area and 
allow higher loading yields. 
This investigation has shown that the ratio between the ceramic phase and the polymer 
solution is of critical importance in the composition of the sintered microspheres. In the case 
of the CTP-alginate microspheres, a calcium pyrophosphate was formed after sintering, and 
its concentration increases as the ceramic to polymer ratio decreases. When subjected to the 
same heating cycle used for sintering the microspheres, CTP powder does not suffer any 
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change in composition. These observations suggest that the formation of the pyrophosphate 
phase is related to the presence of alginate. Sodium alginate forms a relatively stable 
hydrogel of calcium alginate through ionotropic gelation in the presence of Ca2+. A possible 
mechanism to explain the formation of the pyrophosphate phase after sintering is the 
interaction between calcium ions from the alginate and phosphate groups from the ceramic, 
possibly forming an acid salt. When a solid orthophosphate, which contains hydrogen bonds 
(e.g. CaHPO4) is heated to an appropriate temperature, there is a loss of water accompanied 
by pyrophosphate formation.30, 31 The amount of pyrophosphate formed is related to the 
number of hydrogen bonds present in the system. Pyrophosphate ion is a well-known 
inhibitor of apatite formation.31-33 Legeros et al.33 have demonstrated that the presence of 
pyrophosphate ions are efficient in promoting the formation of amorphous calcium 
phosphates. The microspheres prepared in this investigation are aimed at promoting 
mineralization. Therefore, a formulation with a high ceramic to polymer ratio will be more 
adequate. 
With HAp-alginate microspheres it was observed that the sintering process leads to the 
formation of carbonated hydroxyapatite. The carbonate ions were probably incorporated in 
the HAp structure according to the following reaction: 34 
 
2OH- (apatite) + CO2 → CO32- (apatite) + H2O 
 
 
which was probably favoured by an increase of the local concentration of CO2 resulting from 
the burning of alginate. This is in agreement with the fact that carbonate bands are more 
intense in the low ceramic to polymer ratio formulations. The substitution of carbonate in 
well and poorly crystallized hydroxyapatite is well documented in the literature. It has been 
suggested that planar CO3 ion substitutes for tetrahedral PO4 groups in hydroxyapatite 
prepared at room (or body) temperature while in high temperature preparations (about 
1000ºC), CO3 substitutes for OH.31  
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CONCLUSIONS 
 
Porous ceramic microspheres with a uniform size were prepared using a novel methodology 
consisting of sintering spherical particles, obtained by droplet extruding a mixture of ceramic 
powders and sodium alginate followed by ionotropic gelation of the polymeric matrix in the 
presence of Ca2+. Possibly, microspheres with different porosities may be produced by this 
method, by varying the granulometry of the ceramic powders. The ratio between the ceramic 
phases and the polymer solution is a critical parameter in the composition of the sintered 
microspheres and must be carefully selected. These materials could find applicability in the 
field of bone regeneration, both as injectable bone-filling materials and drug delivery 
matrices. 
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ABSTRACT 
 
In the present work, the interaction of human osteoblast-like MG63 cells with novel 
hydroxyapatite (HAp) microspheres was investigated. Cells were seeded on the 
microspheres and incubated for up to 7 days. The cell-material constructs were visualised 
by scanning electron microscopy and confocal laser scanning microscopy, and the rate of 
cell proliferation was estimated using the Neutral Red assay. The results showed that 
osteoblastic cells were able to adhere and proliferate on the HAp microspheres, which are 
intended to be used as injectable support-materials for bone regeneration. 
Keywords: Injectable microspheres, hydroxyapatite, bone regeneration, osteoblast-like MG63 cells 
 
 
INTRODUCTION 
 
The use of injectable biomaterials for bone regeneration purposes has received much 
attention recently.1 The main advantage of such strategy relies on the possibility of filling 
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defects of different shapes and sizes, while requiring only minimally invasive techniques 
for implantation, which provide less patient discomfort. Microparticles, suspended on 
appropriate vehicles, are among the most common forms of injectable materials. Once 
implanted, they are expected to conform to the irregular implant site, with more or less 
close packing, and to encourage host cell migration, attachment, proliferation and 
differentiation. The interstices between the particles, if presenting an appropriate size, may 
also provide a space for both tissue and vascular ingrowth.  
In a previous work, a novel route for the preparation of calcium-phosphate microspheres 
was described.2,3 The ceramic granules are first mixed with alginate, which enables the 
preparation of homogeneous spherical particles through ionotropic gelation in the presence 
of Ca2+. The spherical particles are subsequently sintered to burn-off the polymer and fuse 
the ceramic granules, producing pure hydroxyapatite (HAp) microspheres.2,3 In the present 
study, the ability of HAp microspheres to support the adhesion and growth of human 
osteoblastic cells was investigated using the MG63 cell line. 
 
 
MATERIALS AND METHODS 
 
HAp microspheres were prepared as previously described.2,3 Briefly, HAp powder (CAM 
Implants) pre-heated at 1000ºC was mixed with sodium alginate solution (3% w/v) at a 
ratio of 0.2 w/w and well homogenised. The paste was extruded drop-wise into a 0.1M 
CaCl2 crosslinking solution, where spherical-shaped particles instantaneously formed and 
were allowed to harden for 30 min. The size of the microspheres was controlled by 
regulating the extrusion flow rate using a syringe pump and by applying a coaxial air 
stream (Encapsulation Unit Var J1; Nisco). At completion of the gelling period, 
microspheres were recovered and rinsed in water in order to remove the excess CaCl2. 
Finally, they were dried overnight in a vacuum-oven at 30ºC, and then sintered at 1100ºC 
for 1 h, with a uniform heating rate of 5ºC/min from room temperature. 
The size of the microspheres was determined using a laser scanner particle size analyser 
(Coulter Electronics), and their morphology was analysed by optical microscopy. 
Cell culture studies were performed using MG63 osteoblast-like cells, which express a 
number of features characteristic of relatively immature osteoblasts. Cells were routinely 
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maintained in α-minimal essential medium (α-MEM) supplemented with 10% v/v foetal 
calf serum, 2.5 µg/mL fungizone and 50 µg/mL gentamicine. Microspheres were steam 
sterilised (120ºC, 20 min) and pre-incubated in culture medium overnight in non-tissue 
culture plates, to avoid cell adhesion on the bottom of the wells. MG63 cells were seeded 
on the microspheres at 500 cells/mg and incubated at 37ºC in a humidified atmosphere of 
5% v/v CO2 in air for 4 h, or 1, 3, 5 and 7 days with the medium being replaced every 2 
days. Cell proliferation was estimated using the neutral red (NR) assay. Cells seeded on 
tissue culture grade polystyrene (TCPS) plates were used as a control. Cell morphology 
was visualised at different time points by scanning electron microscopy (SEM) and 
confocal laser scanning microscopy (CLSM). 
 
RESULTS AND DISCUSSION 
 
The granulometric analysis of the microspheres (Fig. 1a) revealed that the size distribution 
of the main population of particles is narrow and follows a normal distribution, with 90% 
(in volume) of the particles being smaller than 600 µm and having an average diameter 
around 550 µm. A second population of microspheres with an average diameter around 
1000 µm and corresponding to approximately 4% of the particles was also identified. 
Sieving could easily eliminate these larger microspheres, which result from occasional 
particle-particle aggregation during the extrusion process. An optical micrograph of the 
microspheres is presented in Fig. 1b and illustrates their uniformity. 
 
Figure 1. (a) Particle size distribution; and (b) optical microscopy image of the HAp microspheres.  
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SEM analysis of the cell-microspheres constructs revealed that after an initial period of 4 h 
(Fig 2a), some adherent cells could already be observed on the surface of the microspheres. 
Because the ability of cells to attach, adhere and spread will influence their capacity to 
proliferate and differentiate in contact with the material, this initial phase is of critical 
importance.4 After 1 day (Fig. 2b and 2c) several cells exhibiting a spindle-like 
morphology were dispersed on the surface of the microspheres. Some round cells (possibly 
mitotic cells) were also present.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. SEM images (several magnifications) showing MG63 human osteoblastic cells on the 
surface of hydroxyapatite microspheres after an incubation period of: (a) 4 h; (b and c) 1 day 
(image 3b was obtained with the backscattered electrons mode); (d-f) 5 days; and (g-i) 7 days. 
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At day 5 (Fig. 2d to 2f), cells were well flattened exhibiting numerous filopodial-like 
extensions and cell-cell contact points. Finally, at day 7 (Fig 2g to 2i) the microspheres 
were almost completely covered by cells that formed continuous layers in some regions. 
 
The distribution of cells on HAp microspheres (day 5) was also visualised using CLSM. 
(Fig. 3a). Pictures constructed by superimposing images obtained using both the 
fluorescence and reflection channels showed numerous cells on the surface, a result similar 
to the one obtained by SEM. 
 
The number of viable cells on the surface of the microspheres was evaluated by performing 
the NR assay at different time points. This assay is based on the incorporation of a vital 
colorant by viable cells, and its subsequent fixation at anionic sites on the surface of 
lysosomal membranes. As any alteration of the membranes will result in a diminished 
fixation of the colorant, only viable cells will be stained, and so the intensity of the 
developed coloration allows the indirect quantification of the number of viable cells in the 
sample. Fig. 3b shows that the number of viable cells, both on the surface of the 
microspheres and on control TCPS plates, gradually increased along the 7 days in culture, 
indicating that cells were actively proliferating. 
 
Figure 2. (a) CLSM image showing osteoblastic cells (red areas) on the surface of HAp 
microspheres (day 5); and (b) proliferation of cells on HAp microspheres estimated by the NR 
assay. 
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CONCLUSIONS 
 
In this study it was demonstrated that HAp microspheres are able to support human 
osteoblastic cells adhesion and proliferation. Further studies to evaluate the influence of 
these materials on the expression of the osteoblastic phenotype are in progress. 
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ABSTRACT 
 
In this study, the behaviour of bone marrow stromal cells cultured on calcium titanium 
phosphate (CTP) microspheres was analysed. Cell adhesion and proliferation were estimated 
by the neutral red assay and by total DNA quantification. Morphology and deposition of 
extracellular matrix were assessed by confocal laser scanning microscopy and/or scanning 
electron microscopy. The expression of the osteoblastic phenotype was evaluated by 
monitoring alkaline phosphatase activity and osteocalcin secretion. Results revealed that cells 
were able to attach and spread on the surface of CTP microspheres, and gradually grow into 
nearly confluent monolayers. Moreover, cells were able to bridge adjacent microspheres 
forming microsphere-cell clusters. Cells produced an abundant amount of fibrillar 
extracellular matrix that covered the substrate surface. Alkaline phosphatase activity peaked 
around days 7-14 and then decreased until day 21. Cells secreted osteocalcin, with higher 
levels being detected at day 14 than at day 21. 
Taken together these results suggest that CTP microspheres are appropriate scaffolds for the 
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growth and differentiation of cells along the osteoblastic lineage. 
Keywords: Calcium titanium phosphate, microspheres, bone marrow stromal cells, osteogenic 
differentiation 
 
 
INTRODUCTION 
 
Microparticulate systems offer exciting possibilities across many fields of regenerative 
medicine and have been extensively studied for several applications. The most important ones 
include delivery vehicles for drugs, proteins or genes and matrices for imunoisolation of 
transplanted cells. Recently, attention has been drawn to the use of microparticles as 
injectable scaffolds for tissue regeneration.1-5 Microparticles can be seeded with autologous 
cells prior to implantation, functioning as cell-carriers, or designed to encourage host cell 
migration, attachment, proliferation and differentiation once implanted. The main advantage 
of this approach, compared to the traditional block scaffolds, is that small particles can be 
combined with a vehicle and be administered by injection, thus giving the possibility of filling 
defects of different shapes and sizes though minimally invasive surgery. Upon implantation, 
the microspheres-vehicle system is expected to easily conform to the irregular implant site, 
whereas the interstices between the particles may provide a space for both tissue and vascular 
ingrowth, as required for effective healing. 
In cell culture technology, microparticles have been used as an alternative culture-substrate to 
in vitro growth of anchorage-dependent cells, for large-scale cell expansion and/or production 
of numerous cell products including vaccines, enzymes, antibodies, etc. The concept of 
culturing cells as monolayers on the surface of small spheres, commonly referred as 
microcarriers, was first conceived by Van Wezel6 and different types of microcarriers are 
currently available in the market. The large surface area-to-volume ratio provided by 
microcarriers allows easy propagation and high cell yields, while requiring much less culture 
medium and space than traditional monolayer culture techniques. 
For the culture of some specific types of cells, a microcarrier culture may also present other 
advantages. For example, the phenotype of chondrocytes7,8 is better retained in microcarriers 
than in flat surfaces. Although the exact reasons for this remain uncertain, it has been 
suggested that the thee-dimensional structure provided by microcarriers may probably better 
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mimic the environment found in vivo.7 
In a previous work, a methodology for the preparation of calcium phosphate microspheres has 
been described.9,10 Ceramic granules of hydroxyapatite (HAp) or calcium titanium phosphate 
(CTP) were mixed with sodium alginate, and microspheres were prepared by drop formation 
under coaxial air flow, followed by ionotropic gelation in the presence of Ca2+. The particles 
were subsequently sintered to burn-off the polymer and aggregate the ceramic granules. 
Besides its simplicity, one of the most important advantages of this method is that it allows 
the preparation of spherical-shaped particles with an adequate and uniform size. 
Calcium phosphate materials have long been recognised as adequate scaffolds for bone 
regeneration and some are already used in clinical practice. Moreover, they are amenable to 
sterilization, which is advantageous for both in vitro and in vivo applications. We have 
already reported that HAp microspheres promote the attachment and proliferation of human 
osteoblastic MG63 cells.5 In the present work, the behaviour of bone marrow stromal cells, 
recognized as osteogenic cells, cultured on CTP microspheres was investigated though 
analysis of cell attachment and morphology, cell proliferation, deposition of extracellular 
matrix and expression of osteogenic differentiation markers. 
 
 
MATERIALS AND METHODS 
 
Preparation and characterisation of microspheres 
 
Calcium titanium phosphate [CTP, CaTi4(PO4)6] microspheres were prepared as reported 
previously.9,10  Briefly, CTP was synthesised by solid-state reaction as described elsewhere10 
and mixed at a ratio of 0.4 with 2% w/v sodium alginate (Pronova Biopolymers) aqueous 
solution. After homogenisation the paste was extruded drop-wise into a 0.1 M CaCl2 
crosslinking solution, where spherical-shaped particles instantaneously formed and were 
allowed to harden for 30 min. The size of the microspheres was controlled by regulating the 
extrusion flow rate using a syringe pump and by applying a coaxial air stream (Encapsulation 
Unit Var J1, Nisco). At completion of the gelling period, microspheres were recovered and 
rinsed in water in order to remove the excess CaCl2. Finally, they were dried overnight in a 
vacuum-oven at 30ºC, and then sintered at 1100ºC for 1 h, with a uniform heating rate of 
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5ºC/min from room temperature. 
Physicochemical characterisation was carried out by Fourier transform infrared spectroscopy 
(FTIR). For analysis, microspheres were reduced to powder and analysed as KBr pellets using 
a Perkin Elmer System 2000 spectrometer. The size of the microspheres was estimated using 
an inverted platen microscope (Olympus PME3-ADL) equipped with an ocular micrometer 
with an accuracy of 10 µm, and their morphology was analysed by digital imaging and 
scanning electron microscopy (SEM). Tissue culture treated polystyrene (TCPS) 
microcarriers (Biosilon, Nunc™) were used as a control and were also characterised in terms 
of size and by SEM.  
 
 
Cell isolation and culture 
 
Rat bone marrow stromal cells were used under consent of the local ethic committee, and 
were isolated and cultured according to the method of Maniatopoulos et al.11 Briefly, the 
femurs and tibias of Wistar rats (male, 4 weeks old) were aseptically excised from the hind 
limbs, the epiphyses were cut off and the medullary space was flushed with α-minimal 
essential medium (Gibco) supplemented with 10% v/v foetal bovine serum, 50 µg/mL 
gentamicin and 0.3 µg/mL fungizone (standard medium). Cells were plated in 75-cm2 flasks 
and incubated at 37ºC in a humidified atmosphere of 5% v/v CO2. Non-adherent cells were 
removed after 24 h. Adherent cells were subsequently cultured for 1 week, with the medium 
renewed every 3 days. Cells from the first passage were used. 
 
 
Cell seeding on microspheres 
 
Microspheres were steam sterilised (120ºC, 20 min), placed in non-treated 96-well plates (14 
mg/well, ca. 1-cm2 surface area) to avoid cell adhesion to the bottom of the wells, and pre-
incubated in standard medium overnight. TCPS microcarriers (4.5 mg/well, ca. 1-cm2 surface 
area) were used as a control. Cells were seeded at 1.2×104 cells/cm2 in half of the total volume 
to be used, and cell-microspheres constructs (n=5) were incubated (37ºC, 5% v/v CO2 in air) 
in standard medium supplemented with 10-8 M dexamethasone, 50 µg/mL ascorbic acid and 
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10 mM β-glycerophosphate. The remaining medium was added after 24 h. Medium was 
renewed every 3 days. Materials without cells processed and cultured under the same 
conditions were used as references. 
 
 
Cell adhesion and morphology 
 
The number of adherent cells on the microspheres was assessed by the neutral red (NR). Cell 
distribution and morphology was analysed by SEM and by confocal laser scanning 
microscopy (CLSM). All assays are described in detail below. 
  
NR assay 
 
The culture medium was discarded and replaced by fresh medium containing 50 
µg/mL NR (Sigma). Plates were incubated at 37ºC for 3 h. At the end, the supernatant 
was discarded and microsphere-cell constructs washed twice with phosphate-buffered 
saline (PBS). The NR absorbed by the cells was extracted with 1% v/v acetic acid 
in 50% v/v aqueous ethanol. After being well homogenised on a shaker platform, the 
supernatants were transferred to another 96-well plate, and the optical density was 
read at 540 nm with reference to 620 nm (OD540/620) in a microplate 
spectrophotometer. Cell number was determined using the linear region of a standard curve 
where absorbance was plotted against known numbers of cells counted using a Neubauer 
chamber. 
 
SEM 
 
Microsphere-cell constructs were washed twice with PBS and fixed in 1.5% v/v 
glutaraldehyde in 0.14 M sodium cacodylate (pH 7.4) for 30 min at room temperature. 
Dehydration was carried out by sequential immersion in serial diluted ethanol solutions of 50, 
60, 70, 80, 90 and 100% v/v. Samples were then transferred to hexamethyldisilazane (HMDS) 
and air-dried at room temperature overnight. Finally, the microsphere-cell constructs were 
sputter-coated with gold using a JEOL JFC-100 Fine Coat Ion Sputter device, and observed 
using a JEOL JSM-6301F scanning microscope. 
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CLSM 
 
Microsphere-cell constructs were washed twice with PBS, fixed in 4% v/v formaldehyde 
(methanol-free; Polyscience) for 15 min, permeabilized with 0.1% v/v Triton X-100 for 5 min 
and incubated in 10 mg/mL bovine serum albumin and 100 µg/mL RNAse for 45 min at room 
temperature. F-actin filaments were stained with Alexafluor-conjugated phalloidin (Molecular 
Probes) for 20 min and nuclei were counterstained with 10 µg/mL propidium iodide (Sigma) 
for 10 min. Finally, samples were washed with PBS and mounted in Vectashield®. CLSM 
images were acquired on a BioRad MRC 600 microscope. 
 
 
Cell proliferation and differentiation 
 
Cell proliferation was assessed by the NR assay (described above) and by total DNA 
quantification. Levels of alkaline phosphatase (ALP) activity and osteocalcin (OC) secretion, 
markers of osteoblastic differentiation, were determined. 
Microsphere-cell constructs were rinsed twice with PBS and cell lysates were obtained by 
brief sonication in 1% v/v Triton X-100. The homogenates were centrifuged to remove 
ceramic particles and used in ALP and total DNA assays. The supernatant culture media were 
reserved for OC analysis. All assays are described in detail below. 
 
Total DNA quantification 
 
DNA content was determined by the method of Labarca and Paigen12 using calf thymus DNA 
as a standard. Briefly, cell lysates were mixed with 0.1 µg/mL bisbenzimide (Hoechst 33258; 
Sigma) in 10 mM Tris-HCl, 1 mM ethylenediaminetetraacetic acid (EDTA) and 0.2 M NaCl 
(pH 7.4) and fluorescence was read with excitation at 356 nm and emission at 458 nm.  
 
ALP colorimetric analysis and histochemical staining 
 
ALP was assayed as the hydrolysis of the artificial substrate p-nitrophenol phosphate. Cell 
lysates were incubated in 2 mM p-nitrophenol phosphate, 0.2 M bicarbonate buffer (pH 10), 
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0.05% v/v Triton X-100, and 4 mM MgCl2 for 60 min at 37°C. The reaction was stopped by 
adding 1 M NaOH, and the product was quantified at 405 nm, using a set of p-nitrophenol 
standards. 
For histochemical staining, microsphere-cell constructs were washed twice with PBS, fixed in 
4% v/v formaldehyde for 15 min, washed in water and incubated for 30 min in Naphtol AS-
MX phosphate/ Fast Violet B salt (Sigma) at room temperature and in the dark. Finally, cells 
were washed in water, air dried, and observed under a stereo microscope (Olympus SZX9). 
 
OC quantification 
 
For analysis of OC, supernatant media were centrifuged (2 min at 10,000 rpm) to remove cell 
debris, stored at –20ºC and then thawed before analysis. OC was assayed using the Rat-MID 
Osteocalcin ELISA kit (Osteometer BioTech A/S, Denmark) according to the manufacturer’s 
instructions. 
 
 
Statistical Analysis 
 
Data are presented as mean ± standard deviation (n=5) and were analysed using the Mann-
Whitney U test. Differences between groups were considered statistically different when 
p<0.05. 
 
 
RESULTS 
 
Preparation and characterisation of CTP microspheres 
 
The CTP-alginate suspension dropped into CaCl2 solution formed gel beads instantaneously. 
During sintering, the polymer was burned off and the CTP granules became associated, while 
the original spherical-shape of the particles was maintained. The average diameter of CTP 
microspheres was 607±30 µm (n=20), as assessed by optical microscopy. TCPS microcarriers 
have an average diameter of 205±120 µm. Fig.1 illustrates the spherical-shape of CTP 
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particles (Fig. 1a) as well as their uniform size (Fig. 1b). CTP microspheres present a rougher 
surface than TCPS microcarriers (Fig. 1c). 
 
 
 
Figure 1. (a) SEM micrograph and (b) photograph (digital camera) of CTP microspheres illustrating 
their spherical shape and uniform size; (c) SEM micrograph of TCPS microcarriers. 
 
 
Physicochemical characterisation was performed by FTIR. The FTIR spectra of CTP powder 
and CTP microspheres were identical, showing that the ceramic kept its integrity, and for that 
reason were not included here. In a previous work10 it was demonstrated that depending on 
the ceramic-to-polymer ratio used in the preparation of the microspheres, the structure of CTP 
may become altered during the subsequent sintering process. In the present study a high 
ceramic-to-polymer ratio was selected to guarantee the absence of extraneous phases, namely 
of calcium pyrophosphates, in the sintered microspheres. Further details on the 
characterisation of CTP microspheres are provided elsewhere.9,10 
 
 
Culture of bone marrow stromal cells on CTP microspheres 
 
Cell attachment, adhesion and spreading 
 
Cells were seeded at approximately the same density per surface area on both materials 
(1.2×104 cells/cm2). The number of adherent cells after 24 h of incubation was estimated 
ca b 
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using the NR assay (Fig. 2a). Approximately 16% of the seeded cells attached to CTP 
microspheres, whereas 46% attached to TCPS microcarriers. After 24 h of culture, both 
spindle-shaped and well-flattened cells were observed by SEM (Fig. 2b) on the surface of 
CTP microspheres. 
 
 
 
 
Figure 2. (a) Number of cells per cm2 attached to CTP and TCPS microspheres following 24 h of 
incubation. Data labels represent the percentage of attached cells in relation to the amount of cells 
initially employed (1.2×104 cells/cm2); (b) SEM image of a flattened cell on the surface of a CTP-
microsphere at 24 h. 
 
 
 
CLSM images of bone marrow stromal cells after 5 days of culture on CTP microspheres are 
presented in Fig. 3. Cells were found to be reasonably well distributed between microspheres 
(Fig. 3a). Cells were able to spread throughout the substrate surface and adopt a typical 
osteoblast-like morphology (Fig. 3b). Numerous cell-cell contact points were detected and, in 
some regions, cells started to form continuous cell layers. At higher magnification (Fig. 3c), 
filamentous actin organised in thick stress fibbers could be visualised. 
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Figure 3. CLSM images of bone marrow stromal cells cultured for 5 days on the surface of CTP 
microspheres, showing: (a) a uniform distribution of cells between microspheres (original 
magnification, 50×); (b) cells with a typical osteoblast-like morphology throughout the surface 
(original magnification, 100×); and (c) filamentous actin organised in thick stress fibbers (original 
magnification, 800×). Cells were stained with phalloidin (F-actin) and counterstained with propidium 
iodide (DNA). 
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Cell proliferation and production of extracellular matrix (ECM) 
 
Cell proliferation, estimated by the NR assay and by total DNA quantification, is depicted in 
Fig. 4a and 4b. Cells proliferated during the first 2 weeks of culture as demonstrated by both 
assays. The number of cells increased approximately 12-fold in relation to day 1, both on CTP 
microspheres and on TCPS microcarriers. The gradual increase in DNA content during the 
same period followed a similar pattern (Fig. 4b). 
 
Figure 4. Cell proliferation on CTP microspheres as assessed by: (a) NR  assay; (b) total DNA 
quantification. TCPS microcarriers were used as controls. 
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SEM images of bone marrow stromal cells cultured for 21 days on the surface of CTP and 
TCPS microspheres are presented in Fig. 5. The surface of CTP microspheres is almost 
completely covered by dense layers of cuboidal cells (Fig. 5a, 5b) that deposited an abundant 
amount of ECM, forming a three-dimensional fibril network (Fig. 5 b, 5c). The presence of 
ECM could already be detected at day 14 (data not shown). Cells grown on TCPS 
microcarriers (Fig. 5d) exhibit a flat, well-spread appearance and formed confluent 
monolayers.  
 
 
 
 
 
Figure 5. SEM images of bone marrow stromal cells cultured for 21 days on the surface of CTP 
microspheres, showing: (a, b) the substrate surface almost completely covered by dense layers of bone 
marrow cells; (b, c) a fibrillar ECM underlying cells. (d) SEM image of bone marrow stromal cells 
cultured for 21 days on the surface of a TCPS microsphere. 
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Cells were able to establish bridges between adjacent CTP microspheres, forming 
microsphere-cell clusters (Fig. 6). 
 
 
 
Figure 6. SEM images of bone marrow stromal cells cultured for 21 days on the surface of CTP 
microspheres, showing the establishment of cell bridges between adjacent microspheres. 
 
 
Osteogenic differentiation 
 
The expression of the osteoblastic phenotype was evaluated by monitoring ALP activity and 
OC secretion. Bone marrow stromal cells cultured on microspheres expressed ALP activity as 
assessed by histochemical staining and colorimetric analysis (Fig. 7). Temporal expression of 
ALP activity is depicted in Fig. 7a. As shown, ALP activity of cells cultured on CTP 
microspheres gradually increased along the first 2 weeks of culture, peaked around days 7-14, 
and then started to decrease. ALP levels were always significantly higher (p<0.05) than those 
of cells cultured on TCPS microcarriers. Histochemical ALP staining of microsphere-cell 
constructs after 7 days of culture (Fig. 7b) showed localised areas with intense staining for 
ALP (pink regions). OC secretion of cells cultured on CTP microspheres (Fig. 8) was higher 
at day 14 than at day 21 (p=0.03), and levels were significantly enhanced compared with cells 
grown on TCPS microcarriers (p=0.03). 
 
a b 
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Figure 7. Expression of ALP activity by bone marrow stromal cells cultured on the surface of CTP 
microspheres as assessed by: (a) colorimetric analysis; (b) histochemical staining (pink areas). TCPS 
microcarriers were used as controls. Differences between days 7 and 14 are not statistically significant, 
but differences between the two materials are always statistically significant (p<0.05).  
 
 
Figure 8. OC secretion by bone marrow stromal cells cultured on the surface of CTP microspheres at 
days 14 and 21. TCPS microcarriers were used as controls. Differences between the two materials, and 
between days 14 and 21 for each material, are statistically significant (p=0.03). 
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DISCUSSION 
 
In this study, CTP microspheres were investigated for their ability to support adhesion, 
growth, and osteogenic differentiation of bone marrow stromal cells in vitro. 
The methodology used to prepare CTP microspheres has been previously reported.9,10 One of 
the most important advantages of this method is that it allows the preparation of spherical-
shaped particles with an adequate and uniform size. It has been previously suggested13 that 
the size and shape of microparticles for bone regeneration have a critical role in new bone 
formation by dictating the relative arrangement of particles within the implant site. Although 
some empty space is necessary to allow tissue and capillary ingrowth, excessive interstitial 
space, associated with the use of very large particles, may favour the development of fibrous 
tissue and compromise adequate healing. In addition, large particles are more difficult to 
inject, leading to a more invasive implantation. On the other hand, very small particles, as 
well as particles with broad size distributions, result in dense packing at the defect, which 
may impair tissue ingrowth and vascularization,13 and some may be able to migrate from the 
implant site and cause injury elsewhere. Some authors found superior bone formation around 
particles measuring 0.3–0.6 mm, and demonstrated that larger and smaller particles were 
associated with less bone formation.13,14 The shape of the microparticles is equally important. 
Irregularly shaped particles have sharp edges that are more susceptible to wear and may 
damage the surrounding tissue once implanted and/or induce strong inflammatory 
responses.15 For all the above reason, it seams that spherical-shaped particles with a uniform 
and adequate size may present some advantages compared with other type of microparticles 
described in the literature. 
Cell-material interaction studies were performed using rat bone marrow stromal cells. Bone 
marrow has long been recognised as a source of progenitor stromal cells that can be induced 
to differentiate along the osteoblastic lineage if cultured under appropriate conditions.11,16-18 
The development of osteoblastic cells from bone marrow stromal precursors is characterised 
by a sequence of events, involving cell adhesion, proliferation and expression of osteogenic 
differentiation markers, which are related to the synthesis, deposition and subsequent 
mineralization of a collagenous ECM.   
The initial phase of the culture is probably the most critical stage, because the ability of cells 
to attach, adhere and spread will influence their capacity to proliferate and differentiate in 
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contact with the material.19 In a microparticulate culture, the percentage of attached cells, in 
relation to the amount initially employed, is generally lower than the one obtained using flat 
surfaces, and the number of cells per microsphere is likely to be distributed over a range. To 
increase the possibility of cell-microsphere effective collisions, microspheres were inoculated 
with cells suspended in the smallest possible volume, because often proliferation will only 
occur if there is a sufficient density of attached cells per microsphere. The percentage of 
adherent cells after 24 h of culture was lower on CTP microspheres (16%) that on TCPS 
microcarriers (46%). Despite the lower percent of adhesion, CLSM images of the 
microsphere-cell constructs after 5 days of culture revealed that CTP microspheres were 
uniformly colonised by cells, which underwent cytoskeleton reorganisation, spread on the 
surface, and adopt a typical osteoblast-like morphology. Moreover, differences in cell 
adhesion apparently did not have an effect on growth and activity, as cells proliferated on 
both substrates at a similar rate, increasing approximately 12-fold in relation to day 1 in 2 
weeks, and produced an abundant amount of fibrillar ECM. The results presented in this study 
further demonstrated that cells cultured on CTP microspheres are able to differentiate, and 
that ALP activity and osteocalcin secretion levels are significantly enhanced when compared 
with cells cultured on TCPS microcarriers.  
The two substrates differ in terms of size, chemical composition and surface roughness, all of 
which are likely to influence protein adsorption and ultimately cell behaviour in contact with 
the materials.20,21 In particular, CTP microspheres present a surface rougher than the one of 
TCPS microcarriers, which may partially explain our results, because it has long been known 
that cell attachment, proliferation and differentiation are sensitive to surface 
microtopography.22,23 Several authors have reported altered attachment and enhanced 
differentiation of osteoblast-like cells on rough surfaces in comparison with smother ones, 
and suggested that structural features of the surface modulate the expression of phenotypic 
markers and influence the way cells respond to regulatory factors.21,22,24 On smooth surfaces, 
osteoblasts-like cells are able to attach and proliferate but generally assume a more flattened 
fibroblastic appearance, and express relatively low levels of osteogenic markers.22 
Regarding the chemical composition of the cell culture substrate, several reports on the 
positive effects of different types of calcium phosphates on osteogenic differentiation may be 
found in the literature, and it has already been reported that osteoblastic cells grown on these 
materials express increased ALP activity and/or OC levels compared with plastic surfaces.25-27 
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For the particular case of CTP, Knabe et al.28 examined the effect of this calcium phosphate 
on the expression of bone-related genes and proteins by human bone-derived cells, and 
compared it with that of titanium and HAp-coated titanium. They showed that CTP had a 
more pronounced effect on osteoblastic differentiation, because it induced a greater 
expression of an array of osteogenic markers than that recorded for cells cultured on the other 
materials.  
 
 
CONCLUSIONS 
 
Bone marrow stromal cells were cultured for up to 21 days on CTP microspheres. Cells were 
able to attach, adopt a typical osteoblast-like morphology, and gradually proliferate along 2-3 
weeks of culture. SEM images showed that the substrate surface becomes almost completely 
covered by dense layers of bone cells and a fibrillar ECM. Cells expressed ALP activity and 
secreted OC, which confirmed that differentiation along the osteoblastic lineage occurred. 
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ABSTRACT 
 
The adsorption of a therapeutic enzyme to self-assembled monolayers (SAMs) of different 
functionalities (X= CH3-, OH- and COOH-) was evaluated as a function of solution pH. 
Radiolabelling studies showed that the enzyme has higher affinity for hydrophobic than for 
hydrophilic surfaces, and that highest adsorption was obtained at the more acidic pH values 
(4.5 and 5.5), irrespective of the type of surface. IRAS and XPS measurements confirmed 
this tendency. Dye-binding studies and fluorescence quenching were used to investigate if 
a pH variation induces any conformational changes on the enzyme. Both methods suggest 
that lowering the pH from physiological to acidic values triggers an increased exposure of 
non-polar sites in the enzyme, which may modulate its adsorption behaviour to the more 
hydrophobic surfaces. At pH 4.5 the enzyme carries a substantial positive net charge and 
therefore relatively low native-state stability. As a consequence, surface-binding may be 
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favoured, irrespective of the type of surface, by providing increased conformational 
entropy to the enzyme. The specific activity of the adsorbed enzyme was strongly 
dependent on the conditions used. A decrease in specific activity (ca. 30 % of control) was 
observed after adsorption on CH3-SAMs for all the pH tested. Adsorption on gold and on 
the more hydrophilic SAMs (OH- and COOH-), resulted in different degrees of 
inactivation at the more acidic pH (4.5), and in enzyme activation (up to ca. 230% of 
control) at higher pH (7-8), near the isoelectric point of the enzyme. 
Keywords: Adsorption, enzyme, self-assembled monolayers (SAMs), enzyme activation 
 
 
INTRODUCTION 
 
Adsorption of proteins and their interaction with surfaces has been the subject of 
considerable research in the biomedical field. Numerous proteins, including several 
enzymes, have been immobilised through adsorption on different supports to be used in a 
wide range of therapeutic and diagnostic applications. In drug delivery, controlled protein 
adsorption has been used as a means to temporarily couple the protein to the vehicle.1 
Reversibility of binding and the retention of an active conformation of the protein upon 
immobilisation and subsequent release are essential requirements. On the other hand, the 
proper transport and delivery of entrapped proteins from polymeric microcarriers, for 
example, is also intimately linked with protein adsorption. In this case, however, the extent 
of unspecific and irreversible adsorption of the protein to the matrix should be reduced as 
much as possible, since a fraction of the total entrapped amount will consequently become 
unavailable, leading to an incomplete release profile and wastage of valuable protein.2 The 
selection of the most adequate delivery matrix for a certain application could clearly 
benefit from previous knowledge on the adsorption behaviour of the protein of interest. 
The process of protein adsorption is complex and is affected by various factors. The rate 
and extent of adsorption will be determined by the properties of the protein and its 
concentration in solution, by the characteristics of the adsorption matrix, the nature of the 
solvent and other properties of the medium, namely pH, ionic strength and temperature.3 
The most relevant phenomena involved in the process of protein adsorption are 
electrostatic and hydrophobic interactions and protein’s intrinsic structural stability.3 Upon 
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adsorption, proteins generally undergo structural rearrangements dependent on the type 
and strength of the interactions established with the matrix.4,5 Although conformational 
alterations may result on protein denaturation and/or loss of functional activity,6,7 in some 
situations they can be beneficial rather than detrimental. For example, enzyme stability is 
often better retained in immobilised formulations than on native free forms5, 8 and 
enzymatic activity can be enhanced in the presence of an interface.9,10 
The mechanistic aspects of protein interaction with surfaces can be investigated using self-
assembled monolayers (SAMs) of long-chain alkanethiols on gold [HS(CH2)nX].11 These 
highly ordered model surfaces can be prepared by exposing different functional groups (X) 
on the surface allowing a wide range of chemical compositions and wettabilities to be 
explored.12 The objective of the present study was to investigate some fundamental aspects 
of the interaction of glucocerebrosidase (GCR) with surfaces using SAMs of different 
functionalities (X= CH3, OH and COOH). 
The activity and/or stability of lysosomal GCR is defective in patients with Gaucher  
disease, the most prevalent metabolic storage disorder, which is characterised by a number 
of severe disabling symptoms including bone lesions.13 For enzyme replacement therapy 
(ERT), recombinant GCR is administered intravenously and is internalised by target cells 
by mannose receptor mediated endocytosis.13 Although ERT seems to be efficient in 
reverting most of the symptoms, the delayed and modest skeleton response remains the 
major issue in the overall effectiveness and management of affected patients.13,14 This is 
indicative that adjuvant therapies are necessary to restore bone function more rapidly 
and/or to a greater extent than with ERT alone.13 The development of a vehicle for site-
specific GCR delivery to bone resident Gaucher cells is currently under investigation in 
our group,15 as a therapy that may be used in association with ERT. 
In this study, radiolabelling was used to quantify the amount of GCR adsorbed onto SAMs 
as a function of solution pH. Fourier transform infrared reflection absorption spectroscopy 
(IRAS) and X-ray photoelectron spectroscopy (XPS) were used as alternative semi-
quantitative techniques. This information was complemented with data on the catalytic 
activity of adsorbed GCR, with the aim of providing insight on the biological status of the 
adsorbed enzyme. Fluorescence studies were performed to investigate if a pH variation 
induces conformational changes on the enzyme. 
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MATERIALS AND METHODS 
 
Preparation and characterisation of SAMs  
 
Preparation of gold substrates and monolayer formation 
 
Gold substrates were prepared as previously described.16 Briefly, chromium (5 nm) and 
gold (25 nm) films were deposited by ion beam sputtering onto silicon wafers 
(polished/etched; crystal orientation <100>; AUREL Gmbh). The Cr layer was used to 
improve adhesion of gold to silicon. Wafers were coated with 1.5 µm of photoresist 
(PFR7790EG, JSR Electronics) to protect the film surface, and diced into pieces (0.5×0.5 
and 1×1 cm2) using a DISCO DAD 321 automated saw. 
The following alkanethiols (Aldrich): 11-mercapto-1-undecanol [SH-(CH2)11OH; 97%], 1-
undecanethiol [SH-(CH2)10CH3; 92%] and 11-mercaptoundecanoic acid [SH-
(CH2)10COOH; 95%] were used as received. Alkanethiol solutions of 1 mM in ethanol 
(99.8%, Merck) were prepared under N2 in a glove box. Immediately prior to use, gold 
substrates were cleaned twice in acetone, rinsed with ethanol and immersed in a “piranha” 
solution (7 parts of H2SO4 and 3 parts of 30% v/v H2O2) for 10 min (Caution: this solution 
reacts violently with many organic materials and should be handled with care). Substrates 
were sequentially rinsed with ethanol/distilled-deionised water/ethanol for 2 min in an 
ultrasonic bath, and then dried with Ar. Subsequently, they were immersed in alkanethiol 
solutions and incubated at room temperature for 24 h in N2. SAMs were finally washed 3 
times in ethanol in an ultrasonic bath for 2 min, dried and maintained under Ar until used. 
 
Contact angle measurements 
 
Contact angle (θ) measurements were performed by the sessile drop method (Data Physics 
OCA 15, equipped with video CCD-camera and SCA 20 software), using an electronic unit 
with a gas tight dosing syringe (Hamilton). SAMs were placed in a closed, thermostated 
chamber (25º C) saturated with water to prevent evaporation. Measurements were carried 
out using distilled-deionised water (4 µL drops, n=3). After drop deposition, images were 
acquired every 2 s over 600 s. Droplet profiles were fitted using different mathematical 
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functions in order to calculate θ. The Young-Laplace method was used for θ≥90º; the 
ellipse method for 30º<θ<90º, and the tangent method for θ<30º. Water contact angles 
(θwater) were calculated by extrapolating the time dependent curve to zero. 
 
XPS measurements 
 
Measurements were carried out on a VG Scientific ESCALAB 200A (UK) spectrometer 
using magnesium Kα (1253.6 eV) as radiation source. The photoelectrons were analysed at 
a take-off angle normal to the interface. Survey spectra were collected over a range of 0–
1150 eV with analyser pass energy of 50 eV. High-resolution C1s, O1s, S2p, N1s and 
Au4f spectra were collected with analyser pass energy of 20 eV. Spectra were fitted with 
XPSPEAK (Version 4.1) software. 
 
Preparation and characterisation of GCR solutions 
 
Preparation of enzyme solutions 
 
Enzyme stock solutions (2 mg/mL) were prepared by reconstituting recombinant human 
glucocerebrosidase lyophilised powder (GCR; Genzyme Corporation) in distilled-
deionised water. Stability of CGR in the stock solution is maintained for more than one 
month at 4ºC. The final concentration of GCR solution was confirmed by the bicinchoninic 
acid assay using bovine serum albumin (BSA) as a standard. The stock solution was 
diluted to 0.1 mg/mL immediately prior to use, in 50 mM citrate buffer containing 0.154 M 
NaCl and 0.01 M NaI. The pH was adjusted after GCR addition to 4.5, 5.5, 7.0 and 8.0. pH 
values were always checked for stability after measurements. 
 
Activity of GCR after incubation at different pH 
 
GCR was pre-incubated at pH 4.5, 5.5, 7.0 and 8.0 for up to 60 min at room temperature. 
Aliquots were obtained periodically and GCR activity was assayed as the hydrolysis of the 
water-soluble substrate 4-methylumbelliferyl-β-D-glucopyranoside (4-MU-Glc; 
Glycosynth), as described elsewhere.17 The reaction mixture consisted of 0.06% v/v Triton 
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X-100, 5 mM 4-MU-Glc and 50-100 mM citrate-phosphate buffer (pH 5.5) with or without 
6 mg/mL of Na-taurocholate. After incubation for 30 min at 37ºC the reaction was stopped 
with 1 M glycine in 30% NaOH (pH 10.3). The product 4-methylumbelliferone (4-MU) 
was quantified by fluorescence spectroscopy with excitation at 366 nm and emission at 445 
nm. GCR activity is reported as nmol 4-MU/mL/h. 
 
Fluorescence spectroscopy 
 
Analyses were carried out in a Cary Eclipse Fluorescence Spectrophotometer (Varian, 
Inc.). Quenching studies were performed by recording fluorescence emission spectra of 
GCR at different pH, in the absence or presence of 0.1 M NaI. Excitation was set at 295 
nm and emission monitored in the range 310-400 nm with slit widths of 10 nm. Dye-
binding studies were performed by recording fluorescence emission spectra of 8-anilino-1-
naphtalene sulfonic acid (ANS, 20 µM) at different pH, in the absence or presence of 
GCR. Excitation was set at 370 nm and emission monitored in the range 400-600 nm with 
slit widths of 10 nm. Spectra were recorded 2 min after GCR addition. 
 
Adsorption of GCR to SAMs and enzymatic activity assay 
 
SAMs with varying functionalities (X= OH, COOH and CH3) were placed in 24-well 
tissue culture plates (Sarsted) with the surface facing up. Depending on the method of 
quantification subsequently used, incubation with GCR solutions (0.1 mg/mL) at different 
pH was carried out by placing a drop of solution on the top of each sample (radiolabelling 
studies), or by completely immersing the samples in 500 µL of GCR solution (IRAS and 
XPS studies). When drops were used, saline (0.154 M NaCl) was added to the periphery of 
the wells to avoid evaporation. Adsorption tests were carried out at room temperature for 
30 min. A concentration of 0.1 mg/mL and an adsorption time of 30 min were selected 
based on other studies, previously reported by the authors and in the literature,16 
concerning the adsorption behaviour of other proteins, namely albumin, which has 
approximately the same size of the enzyme used in the present investigation (ca. 60 kDa). 
These previous studies with albumin, using SAMs with the same functional groups that 
those used in the present investigation, have demonstrated that a concentration of 0.1 
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mg/mL induces the formation of a monolayer of albumin, and that higher concentrations 
may promote multilayer adsorption. Furthermore, kinetic studies demonstrated that an 
adsorption time of 30 min is sufficient to attain steady-state adsorption values, even when 
protein concentrations lower than 0.1 mg/mL are used.16 
After GCR adsorption, the solution was withdrawn and SAMs were rinsed three times with 
saline. The amount of adsorbed GCR was quantified using different techniques as 
described bellow. SAMs incubated under the same conditions in buffer solutions without 
GCR were used as controls. 
For enzymatic activity measurements, SAMs with adsorbed 125I-GCR were immediately 
incubated with the substrate and the catalytic activity assayed as described above but in the 
absence of detergents. At the end of the reaction, SAMs-associated radioactivity was 
counted and the product (4-MU) quantified. The GCR concentration per assay was kept 
constant. Free-GCR was used as a control. GCR activity is reported as nmol 4-MU/h/mg 
GCR (specific activity). 
 
Quantification of adsorbed GCR 
 
Radiolabelling measurements 
 
125I-labelled GCR was prepared according to the Iodogen method.18 125I-GCR was purified 
in a pre-packed PD-10 Sephadex G-25 M column (Amersham Pharmacia Biotech) 
previously blocked with 20% w/v BSA and equilibrated in phosphate-buffered saline (pH 
7.4). The final solution contained only trace amounts of free 125I (<2%), as estimated by 
trichloroacetic acid precipitation (TCA, 10% v/v). 125I-GCR was combined with non-
labelled GCR solutions (108 cpm/mg) and used immediately. 
The amounts of adsorbed GCR were estimated by counting SAMs-associated radioactivity 
in a γ-counter, after exposure to GCR solutions. Surface concentration was calculated by 
the equation: 
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=
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where, Counts: SAMs-associated radioactivity,  Asolution: specific radioactivity of GCR 
solution and SA: surface contact area of the drop (calculated with the contact angle 
measuring system software). 
Tests were carried out in the presence of 10 mM NaI to suppress the adsorption of residual 
free 125I.19 To test the effectiveness of this measure, adsorption of 125I (107 cpm/mL) to 
OH- and CH3-SAMs at pH 4.5 and 8.0 was analysed. The effect of radiolabelling on GCR 
adsorption behaviour was assessed by quantifying GCR adsorption on gold (n=4) using a 
series of solutions of constant GCR concentration (0.1 mg/mL) but of varying (10-50%) 
labelled-to-unlabelled GCR ratios.19 
 
XPS and IRAS measurements 
 
For XPS and IRAS measurements, samples with adsorbed GCR (CH3- and OH-SAMs, pH 
4.5 and 8.0) were dried with Ar before analyses. IRAS measurements were performed on a 
FTIR spectrophotometer (Perkin Elmer 2000), coupled with VeeMax II Accessory (PIKE) 
and a liquid N2-cooled MCT detector. Spectra were collected using the 80º grazing angle 
reflection mode. The incident light was p-polarised. Samples were analysed with 200 scans 
and 4 cm-1 resolution using a gold surface as the background. XPS measurements were 
performed as already described. 
 
 
RESULTS 
 
Characterisation of SAMs 
 
The chemical composition of SAMs was analysed by XPS. Survey spectra (data not 
shown) reveal only the presence of the expected monolayer elements (Au, C, S in all 
SAMs; and also O in OH- and COOH-SAMs), indicating the absence of contamination. 
Surface atomic compositions of the three types of SAMs calculated from the XPS high-
resolution spectra are in accordance with those described elsewhere, and for that reason 
were not included here.20 
The θwater found for the gold surfaces was 64 ± 2º. Similar values were obtained by other 
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authors.20,21 Although a clean gold surface has been described as hydrophilic, after some 
minutes of exposure to the laboratory atmosphere, its θwater significantly increases due to 
adsorption of non-polar contaminants.22 However, after 24 h of immersion in the thiol 
ethanolic solutions, the effect of the contaminant layers on the gold surface is negligible.21 
The θwater measurements indicate that CH3-SAMs are hydrophobic (107º ± 0.4), while the 
SAMs with OH- and COOH- functionalities are hydrophilic (19º ± 2.1 and 38º ± 0.9, 
respectively), in accordance with data obtained previously.20 
 
Characterisation of GCR solutions 
 
Activity of GCR after incubation at different pH 
 
Catalytic activity of GCR following incubation at different pH was assayed in the presence 
or absence of taurocholate, a well-known activator of the enzyme.17 When the detergent is 
absent GCR activity is low, while in its presence GCR is stimulated to a great extent (ca. 
30-fold). Both assays demonstrated that under the conditions used, the catalytic activity of 
GCR is maintained for at least 60 min or, if any alteration occurred during incubation, it 
may be assumed that it is reverted under the assay conditions. However, both assays show 
that the catalytic activity of GCR following incubation at pH 4.5 is lower compared to 
other pH.  
Figure 1. Catalytic activity (n=5) of GCR after pre-incubation at different pH for up to 60 min. 
Assays were performed at pH 5.5 in the absence of activators. 
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Fluorescence spectroscopy 
 
The intrinsic fluorescence of GCR derives mainly from its 12 tryptophan residues.23 No 
significant changes in the maximum emission wavelength (≈ 336 nm) were observed on 
GCR fluorescence emission spectra when the pH was varied from 8.0 to 4.0 (data not 
shown). Similar spectra were acquired in the presence of an aqueous quencher (0.1 M NaI) 
to probe the degree of exposure of non-polar tryptophan residues to the aqueous 
environment. Fig 2. shows the efficiency of quenching (1-F/F0) as a function of pH, where 
F0 and F are the fluorescence intensities at 336 nm before and after addition of the 
quencher, respectively. The higher quenching effect was detected at pH 4.0 (1-F/F0=0.76), 
and the efficiency of quenching decreased as the pH increased. No significant differences 
were observed between pH 7.0 and 8.0 (1-F/F0 ≈ 0.38). As a complementary method to 
detect subtle changes in GCR conformation as a function of pH, dye-binding experiments 
with the fluorescent probe ANS were performed. The fluorescence of ANS can be 
considerably enhanced upon interaction with exposed hydrophobic sites on proteins, and is 
frequently used as an indicator of relative surface hydrophobicity.24 Fig 3. shows the GCR-
dependent ANS fluorescence emission spectra at different pH, and reveals a trend towards 
increasing fluorescence intensity as a function of decreasing pH. A modest blue-shift in the 
emission maximum also occurs and increases when the pH is lowered. Both methods 
suggest that lowering the pH to more acidic values triggers an increased solvent exposure 
of non-polar sites in the enzyme. 
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Figure 2. Efficiency of quenching (1-
F/F0) by 0.1M NaI as a function of pH. 
F0 and F are the fluorescence 
intensities at 336 nm before and after 
addition of the quencher, respectively. 
Results are presented as mean ± 
standard deviations (n=3). 
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Quantification of adsorbed GCR 
 
Radiolabelling measurements 
 
The amounts of GCR adsorbed to gold and SAMs at different pH are presented in Fig. 4. 
In all the samples tested, GCR adsorption was pH dependent, with the highest adsorbed 
amounts being obtained at the more acidic pH (4.5). Moreover, adsorption was always 
higher on gold and hydrophobic SAMs (CH3-) than on hydrophilic SAMs (OH- and 
COOH-). 
For CH3-SAMs, the amount of adsorbed GCR increased from 4.2 ± 0.2 mg/m2 to 7.4 ± 0.2 
mg/m2 as the pH decreased from 8.0 to pH 4.5, respectively. GCR adsorption on gold 
followed a similar pattern. On OH-SAMs, the amount of adsorbed GCR attained the 
highest value (1.4 ± 0.4 mg/m2) at the more acidic pH (4.5). However, no significant 
differences were observed between surface concentrations of GCR adsorbed at the other 
pH, which were all in the range of 0.5−0.6 mg/m2. Finally, on COOH-SAMs, the adsorbed 
amounts were higher at acidic pH values, reaching 1.6 ± 0.3 mg/m2 at pH 4.5 and 1.1 ± 0.2 
mg/m2 at pH 5.5; while a lower surface concentration of ca. 0.5−0.6 mg/m2 was obtained 
for pH 7.0 and 8.0. 
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Figure 4. Amount of GCR adsorbed at different pH to SAMs of varying functionalities (X= OH, 
COOH and CH3). Adsorption was carried out for 30 min at room temperature and 125I-GCR was 
used as a tracer. Results are presented as mean ± standard deviations (n=5). 
 
Effect of radiolabelling and of free 125I on GCR adsorption  
 
Assessment of the effect of radiolabelling on the adsorption behaviour of 125I-GCR was 
carried out, since labelling may result in an alteration of the physicochemical and/or 
biological properties of the enzyme.19,25 The test relies on the assumption that if the 
labelled and unlabelled enzyme forms have the same adsorption behaviour, surface 
coverage will only be dependent on the total GCR concentration. Results showed that 
irrespective of the labelled-to-unlabelled ratios used, the adsorbed amount was always ca. 5 
mg/m2, suggesting that there is no preferential adsorption of one of the forms. 
Adsorption studies were carried out in the presence of NaI, which strongly reduces the 
adsorption of free 125I.19,26 In order to confirm the validity of this method when applied to 
our system, adsorption of 125I to OH- and CH3-SAMs at pH 4.5 and 8.0 in the presence of 
NaI was studied. Results showed that only ca. 0.2% of the total radioactivity present on 
each drop (7×104 cpm) becomes associated with the surfaces (≈ 120 cpm), irrespectively of 
the type of SAM or pH used. This demonstrates that during GCR adsorption the 
contribution of trace amounts of free 125I to total SAMs-associated radioactivity is very low 
and can be neglected. 
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IRAS measurements 
 
Proteins have characteristic vibrational absorption bands in the IR region. Amide I band 
(1690 ± 45 cm-1) represents primarily the C=O stretching vibrations, while amide II band 
(1540 ± 60 cm-1) represents the N-H in-plane deformation coupled with C-N stretching 
modes.27 
Fig. 5 shows IRAS spectra of the amide bands (I and II) of GCR adsorbed onto OH- and 
CH3-SAMs. The intensities of the bands were calculated with a baseline drawn from 1765 
cm-1 to 1440 cm-1. A higher amount of adsorbed GCR was detected in hydrophobic CH3-
SAMs than on hydrophilic OH-SAMs for both pH tested. On CH3-SAMs, a higher amount 
of adsorbed GCR was detected at pH 4.5. Differences were more evident in the amide II 
region. In the case of OH-SAMs, GCR adsorption did not appear to vary with pH. The 
position of amide II bands of GCR adsorbed on OH-SAMs is shifted to lower frequencies 
(1515 cm-1) compared to those of GCR adsorbed on CH3-SAMs (1550 cm-1). Since the 
shape and position of amide bands have been correlated with the presence of α-helical, β-
sheet and random-coil domains, changes of these parameters may reflect alterations in 
protein secondary structures. 
 
Figure 5. IRAS spectra in the amide I and amide II regions of GCR adsorbed on OH- and CH3-
SAMs. Adsorption was performed at pH 4.5 (black lines) and pH 8.0 (gray lines). Results are the 
average of two spectra. 
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XPS measurements 
 
The relative amount of GCR adsorbed on OH- and CH3-SAMs at pH 4.5 and 8.0 was 
followed by XPS. Differences in the atomic % of N1s and in the N1s/Au4f atomic ratio 
were calculated, since the N1s signal is specific for the protein and the Au4f signal is 
specific for the SAMs. Results are presented in Tab. I. The composition of SAMs without 
adsorbed enzyme (control) and the % of C1s, O1s and S2p in all samples were also 
included. Upon GCR adsorption, new elements are detected in the monolayers: N2 in both 
SAMs, and also O2 in CH3-SAMs. The atomic % of C increases, while the atomic % of Au 
and S decreases (CH3-SAMs) or remains practically unchanged (OH-SAMs). The atomic 
% of N1s as well as the N1s/Au4f atomic ratio are higher on hydrophobic CH3-SAMs than 
on hydrophilic OH-SAMs. Within each type of SAM, both parameters varied with pH, 
with higher amounts being detected at pH 4.5. This is well illustrated in the N1s high-
resolution XPS spectra (Fig. 6) by the relative intensity of the nitrogen peak (≈ 400 eV): 
CH3 (4.5) > CH3 (8.0) > OH (4.5) > OH (8.0). Fig. 7 shows that changes in the N1s/Au4f 
ratio as a result of varying the functional group of SAMs and solution pH are directly 
correlated (r2=0.987) with the mass per unit area of adsorbed GCR, as estimated by 
radiolabelling. 
 
 
Table 1. Atomic percentages (C1s, O1s, S2p, N1s and Au4f) obtained by XPS of OH- and CH3-
SAMs, before and after GCR adsorption at pH 4.5 and pH 8.0.  
Atomic    CH3      OH   
%  Control pH 4.5 pH 8.0  Control pH 4.5 pH 8.0 
Ctotal  35.4 46.5 40.6  30.9 32.2 36.0 
Ntotal  – 6.5 5.0  – 1.6 0.9 
O  – 6.5 6.8  8.9 5.1 2.6 
S  2.7 2.3 2.6  3.1 2.8 3.1 
Au  61.9 38.2 44.9  57.2 58.3 57.3 
Ntotal/Au  – 0.170 0.111  – 0.027 0.016 
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Figure 6. N1s high-resolution XPS spectra for CH3- and OH-SAMs, after GCR adsorption at pH 
4.5 and pH 8.0. 
 
Figure 7. Correlation of the surface concentration of GCR (mg/m2) estimated by radiolabelling 
with the N1s/Au4f atomic ratio obtained by XPS. 
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Fig. 8 represents the C1s high-resolution XPS spectra of CH3-SAMs before (Fig. 8a) and 
after (Fig. 8b) GCR adsorption (pH 4.5). These are presented as an example, to illustrate 
the appearance of new carbon peaks due to GCR adsorption. On control SAMs (Fig. 8a), 
the C1s spectra showed the characteristic peak of C-C/C-H bonds with a binding energy 
around 285.0 eV. On samples containing adsorbed GCR (Fig. 8b) broadening of C1s peak 
was observed. Peak-deconvolution was made considering the contribution of 4 peaks,28 
namely: C−C/C−H bonds (hydrocarbon) at 285.1 eV, C-N (amine) at 286.2 eV, O=C−N 
(amide) at 287.9 eV and O−C=O (carboxyl) at 288.9 eV. 
Figure 8. C1s high-resolution XPS spectra (resolved into component peaks) for CH3-SAMs, before 
(a) and after (b) GCR adsorption at pH 4.5. 
 
 
Catalytic activity of adsorbed GCR 
 
Fig. 9 shows the specific activity of GCR adsorbed on SAMs at different pH. specific 
activity. of free GCR following incubation at different pH is also depicted as a control (pH 
4.5: dashed line, other pH: solid line). The catalytic activity of adsorbed GCR was strongly 
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depended on the type of surface used. Higher activities were obtained on gold and on the 
more hydrophilic samples (OH- and COOH-SAMs) than on hydrophobic CH3-SAMs. For 
GCR adsorbed on CH3-SAMs, the specific activity was always lower than that of the 
control (ca. 30 %) and a pH-dependence was not evident. The specific activity of GCR 
adsorbed to the other surfaces was pH dependent, increasing as the adsorption pH 
increased. When GCR was adsorbed at pH 7.0-8.0 its specific activity was higher than that 
of the control. GCR adsorbed on OH-SAMs exhibited the highest specific activity (ca. 230 
% of control). 
 
 
Figure 9. Specific activity of GCR adsorbed at different pH to SAMs of varying functionalities 
(X= OH, COOH and CH3). The specific activity of free-GCR following incubation at pH 4.5 
(dashed line) and at the other pH (solid line) was used as a control. Results are presented as mean ± 
standard deviations (n=5). 
 
 
DISCUSSION 
 
The objective of the present work was to investigate some fundamental aspects of the 
behaviour of the lysosomal enzyme glucocerebrosidase (GCR) at a well-defined solid-
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liquid interface. GCR is a water-soluble glycoprotein with 497 amino acids, a molecular 
weight around 60 kDa and an isoelectric point (IP) around 7.29 It has four Asn-linked 
oligosaccharide structures, from which the terminal sialic acid, galactose and N-acetyl-
glucosamine sugars are removed during manufacturing.29 The modified oligosaccharides 
consist primarily (ca. 95%) of neutral species and contribute to approximately 6% of the 
total molecular weight.29 It has been ascertained that GCR has substantial hydrophobic 
properties.23,30 
Adsorption studies were performed using SAMs of different functionalities (X= CH3-, OH- 
and COOH-) and different solution pH (pH= 4.5, 5.5, 7.0, 8.0). The extent of GCR 
adsorption was analysed by radiolabelling. IRAS and XPS were used as alternative semi-
quantitative techniques. 
Consistent with the data reported by several authors for other proteins,3,31 maximal GCR 
adsorption was observed on gold and hydrophobic CH3-SAMs (θwater= 107º).  The extent of 
adsorption on this type of surface was strongly influenced by pH. However, in contrast to 
what is generally observed for several proteins, maximal adsorption was not observed at 
the enzyme IP (≈7). Instead, there was a gradually higher affinity for adsorption on gold 
and CH3-SAMs as the pH decreased. Since adsorption on these surfaces is likely to be 
initiated by hydrophobic interactions, it is reasonable to assume that GCR surface 
hydrophobicity dictates, at least partially, its adsorption behaviour.3 Therefore, based on 
studies with other systems,24,32,33 we hypothesised that lowering the pH from physiological 
to acidic values may trigger an increased solvent exposure of non-polar sites in the 
enzyme, thus promoting surface-binding. To investigate this, the effect of solution pH on 
GCR tryptophan fluorescence was evaluated. Maximum wavelength (λmax) shifts and 
changes in fluorescent intensity are related with alterations in the local environment of 
tryptophan residues, and are often used in protein structural analyses.34 The fluorescence 
emission spectra of GCR showed a λmax around 336 nm, but no significant changes were 
detected in its position over the pH range 4-8, which suggests that any pH-induced 
alterations in GCR must be subtle, without affecting its overall intrinsic fluorescence. In 
order to be able to detect eventual small changes on GCR conformation, complementary 
fluorescence studies were performed. GCR tryptophan fluorescence showed an increased 
sensitivity to external polar quenching by I- at lower pH, which is indicative of an 
increased exposure of non-polar tryptophan residues to the aqueous environment. 
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Similarly, ANS-binding experiments revealed an increased solvent accessibility of 
hydrophobic sites as a function of decreasing pH. Taken together these results correlate 
with the enhancement of surface-binding to more hydrophobic surfaces at lower pH. 
The specific activity of GCR upon adsorption to CH3-SAMs decreased significantly (≈ 
30% of control). This was not unexpected, since in general proteins change their 
conformation to a great extent upon adsorption to hydrophobic surfaces.3,4 Loss of activity 
upon adsorption is not, however, proof of conformational change in itself, since a 
considerable degree of loss might be expected, even with complete retention of the enzyme 
structure, due to an inadequate orientation of the active site at the surface. Clustering of 
enzyme molecules at the surface, may also lead to a decreased substrate-accessibility of the 
active site and hence a decreased specific activity. 
Adsorption of GCR to OH- and COOH- SAMs (θwater= 19º and 38º respectively) was 
significantly lower. Nevertheless, higher adsorption was also observed at the more acidic 
pH (4.5). The intrinsic structural stability of the enzyme may be the major driving force for 
adsorption under such conditions. At pH 4.5, which is considerably below its IP, GCR 
carries a substantial positive net charge and therefore relatively low native-state stability.3 
As a consequence, surface-binding may be favoured, irrespective of the type of surface, by 
providing increased conformational entropy to the enzyme. The lower activity of free GCR 
following incubation at pH 4.5, compared to that at other pH, seems to corroborate this 
observation. In addition, the specific activity of GCR when adsorbed at acidic pH is always 
lower, especially at pH 4.5, probably result7ing from a combination of multipoint surface-
interactions and lateral electrostatic repulsion between enzyme molecules. 
Interactions with OH-SAMs, are possibly mediated by hydrogen bonding, since under the 
pH range used the hydrogen of the OH- group (pKa=13) is retained.35 In what concerns 
adsorption to COOH-SAMs, as the pH decreases from 8 to 4.5 the COOH- groups become 
less ionised and the overall charge of the surface less negative, but GCR becomes more 
positively charged. Electrostatic interactions are thus probably favoured at pH 6.0 and 5.5, 
where the enzyme and the surface present opposite charges. Since the ionisation of COOH- 
at pH 4.5 is negligible,35 interaction between GCR and COOH- at that pH may be mediated 
by hydrogen bonding. Nevertheless, the adsorption amounts obtained for these two types 
of SAMs at all pH used are similar, probably because electrostatic interactions provide 
relatively low contributions to protein adsorption at ionic strength >100 mM due to the 
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screening of protein charge by counterions. 
The specific activity of GCR adsorbed on gold and on OH- and COOH-SAMs at pH 7-8, 
near the enzyme IP, was always higher than that of the free enzyme. Its has been 
previously suggested3 that pH affects the level to which native-state proteins undergo 
structural alterations upon adsorption to a solid surface, and that structural rearrangements 
are minimal when adsorption occurs at a pH equal to the IP. The enzyme activation may 
have several explanations. Possibly, the interface brings the enzyme in contact with the 
substrate at a higher concentration and/or in a more favourable orientation/conformation 
for efficient catalysis. Several studies showed that purified GCR exhibits a very low level 
of activity in vitro and that a micellar or liposomal interface is needed for reconstitution of 
its catalytic function.23,36 Presumably, anionic detergents like taurocholate, and also some 
acidic phospholipids, facilitate the interaction of the enzyme with the substrate by inducing 
a conformational change that conforms it into a more active state.23 The activation of many 
lipases by an interface, the so-called interfacial activation, has also been extensively 
reported.9,10 A similar mechanism could eventually explain the enhancement of GCR 
activity in the adsorbed state. 
 
 
CONCLUSIONS 
 
The adsorption of the enzyme glucocerebrosidase (GCR) to self-assembled monolayers 
(SAMs) of different functionalities (X= CH3-, OH- and COOH-) was evaluated as a 
function of solution pH. Maximal GCR adsorption was observed on gold and on 
hydrophobic CH3-SAMs. The extent of adsorption on this type of surfaces was strongly 
influenced by the solution pH. Lowering the pH from physiological to acidic values seems 
to trigger an increased solvent exposure of non-polar sites in the enzyme and modulate its 
adsorption behaviour. The specific activity of GCR adsorbed on gold and on OH- and 
COOH-SAMs was strongly dependent on the pH used. The activity was enhanced, 
compared to that of free enzyme, when adsorption was performed at a pH near the enzyme 
isoelectric point. 
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Chapter IX 
 
 
 
Preliminary studies on the adsorption of glucocerebrosidase to 
calcium phosphate microspheres 
 
 
 
 
ABSTRACT 
 
In this study the ability of hydroxyapatite (HAp) and calcium titanium phosphate (CTP) 
microspheres to reversibly adsorb the enzyme glucocerebrosidase (GCR) while preserving 
its biological activity, and to efficiently deliver it into GCR-deficient fibroblasts from GD 
patients was analysed. The amount of adsorbed GCR was determined by quantifying GCR 
depletion from the supernatants using the bicinchoninic acid assay. GCR release was 
monitored in cell culture medium by radiolabelling. Internalisation of GCR by GD 
fibroblasts was estimated by measuring the intracellular enzymatic activity before and after 
treatment with GCR-loaded microspheres. Under the conditions tested, CTP microspheres 
adsorbed ca. 3.6-fold more GCR than HAp microspheres. The activity of the adsorbed 
enzyme was higher than the control in the case of CTP microspheres and lower when HAp 
was used. GCR release from both types of microspheres was characterised by the elution 
of a large percentage of enzyme within 1 h of incubation, followed by a delayed release 
that extended for at least 30 days. Released GCR was internalised by GD fibroblasts 
increasing the intracellular enzymatic activity. In cells treated with the same amount of 
GCR-loaded CTP microspheres or free-GCR a higher intracellular activity was detected in 
the former case, suggesting that enzyme-loaded microspheres are more effective than the 
free enzyme. 
Keywords: Enzyme adsorption, microspheres, hydroxyapatite, calcium titanium phosphate 
 
Chapter IX  
166 
INTRODUCTION 
 
Successful reconstruction of bone defects remains a major concern in orthopaedic surgery. 
Micro or nanoparticles suspended in autologous blood or other appropriate vehicle have 
been used as injectable bone fillers.1, 2 Upon implantation, the microspheres-vehicle system 
is expected to easily conform to the irregular implant site, providing a permissible matrix 
for both tissue and vascular ingrowth, as required for effective healing. In addition, 
depending on the specificity of the illness, microparticles can be loaded with bioactive 
agents to accelerate the process of tissue regeneration. The preparation and characterisation 
of hydroxyapatite (HAp) and calcium titanium phosphate (CTP) microspheres with a 
uniform size have been previously described,3 and in vitro studies revealed that they can be 
used as supports for the culture of osteoblastic-like cells.1,2 
In this study, HAp and CTP microspheres were analysed as vehicles for the recombinant 
enzyme glucocerebrosidase (GCR). This enzyme is used in the treatment of Gaucher 
disease (GD, type I), which is characterised by a number of severe disabling symptoms, 
including bone pathologies.4 Enzyme-loaded microspheres could be used to fill GD bone 
defects and contribute to their treatment, by providing a physical support for new tissue 
formation and localised enzyme delivery. 
Most of the techniques used in the preparation of protein delivery systems rely on the 
association of proteins with soluble or solid carriers. There are several protein-carrier 
coupling strategies, such as: entrapment in matrix or reservoir systems, covalent binding to 
a surface and physical adsorption. These methods have been applied particularly within the 
field of enzyme immobilisation5 and, more recently, for controlled release of protein 
pharmaceuticals.6 
Non-specific physical adsorption of a protein from a solution on a solid surface is probably 
the simplest and longest known method of immobilisation. The ability to load the protein 
in a simple and cost-effective process, without using solvents or polymerization, is one of 
the greatest advantages of this method. Physical adsorption methods have been widely 
used in the development of microparticulate carriers for the localised delivery of vaccines 
to the site of action,7-10 and for the delivery of proteinaceous agents in tissue regeneration 
applications.11-14 
The objective of the present study was to investigate whether simple adsorption of GCR to 
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the surface of calcium phosphate microspheres could be used to immobilise the enzyme in 
a reversible way while preserving its biological activity, and allow it to be efficiently 
delivered it to GCR-deficient fibroblasts from GD type I patients. 
 
MATERIALS AND METHODS 
 
Preparation and characterisation of calcium phosphate microspheres 
 
Calcium titanium phosphate [CTP, CaTi4(PO4)6] and hydroxyapatite (HAp) microspheres 
were prepared as previously reported.3  The ceramic powders were mixed at a ratio of 0.2 
(HAp) or 0.4 (CTP) with 2% w/v sodium alginate solution. After homogenisation, the 
paste was extruded drop-wise into a 0.1 M CaCl2 crosslinking solution, where spherical-
shaped particles instantaneously formed and were allowed to harden for 30 min. The size 
of the microspheres was controlled by regulating the extrusion flow rate using a syringe 
pump and by applying a coaxial air stream (Encapsulation Unit Var J1; Nisco). At 
completion of the gelling period, microspheres were recovered and rinsed in water in order 
to remove the excess CaCl2. Finally, they were dried overnight in a vacuum-oven at 30ºC, 
and then sintered at 1100ºC for 1h, with a uniform heating rate of 5ºC/min from room 
temperature. The size of the microspheres was estimated using an inverted platen 
microscope (Olympus PME3-ADL) equipped with an ocular micrometer with an accuracy 
of 10 µm. Specific surface areas were measured by the Brunauer, Emmel and Teller (BET) 
method. Zeta potentials (ZP) of CTP and HAp microspheres were measured at pH 7.0 in 
10-4 M KCl with a EKA ElectroKinetic Analyser (Anton Paar). 
 
Preparation of GCR solutions 
 
Enzyme stock solutions (2 mg/mL) were prepared by reconstituting recombinant human 
glucocerebrosidase (GCR, Genzyme Corporation) lyophilised powder in distilled-
deionised water. The stability of CGR in the stock solution is maintained for more than one 
month at 4ºC. The final concentration of the GCR solution was confirmed using the 
bicinchoninic acid (BCA) assay.15 The stock solution was diluted to 0.1 mg/mL 
immediately prior to use, in phosphate-buffered saline (PBS, pH=7.4).  
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Adsorption of GCR to microspheres and enzymatic activity assay 
 
Microspheres were incubated with GCR solutions under rotation and end-over-end mixing 
for 30 min at room temperature. At the end, the supernatants were withdrawn and the 
microspheres were washed 3 times with PBS to remove unbound GCR. The concentration 
of GCR solutions before and after adsorption was determined by the BCA assay. The 
catalytic activities of the adsorbed and free enzyme were determined using a method 
previously described.16 Briefly, the enzyme was incubated with 5 mM 4-MU-Glc in 50-100 
mM citrate-phosphate buffer (pH 5.5), for 30 min in a humidified atmosphere at 37ºC. The 
reaction was stopped with 1 M glycine in 30% w/v NaOH (pH 10.3). The product 4-
methylumbelliferone (4-MU) was quantified by fluorescence spectroscopy with excitation 
at 366 nm and emission at 445 nm, using commercial 4-MU (Sigma) as a standard. The 
Michaelis-Menton constant (Km) was determined from a Lineweaver-Burk plot using 
varying concentrations of the substrate (1.56-25 mM). 
 
Release of GCR from calcium phosphate microspheres 
 
This study was performed using 125I-GCR, which was radiolabelled using the Iodogen 
method as previously described.17 125I-GCR loaded calcium phosphate microspheres were 
incubated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% v/v 
foetal bovine serum, 1.5% v/v Ultraser G, 2.5 µg/mL fungizone, 200 U-200 µg/mL 
peniciline-streptomicine and 50 µg/mL kanamicine (standard culture medium) at 37ºC in a 
humidified atmosphere of 5% v/v CO2 in air. At different time points, the supernatants 
were recovered, centrifuged (5 min at 5,000 rpm) to remove ceramic particles and counted 
for radioactivity in a γ-counter. Fresh medium was added. This assay was prolonged for 30 
days. 
 
Cell cultures 
 
Human fibroblasts from patients affected by type I GD (GCR-deficient cells) were 
obtained from skin explants under consent of the local Ethics Committee, and cultured as 
described elsewhere.18 Cells were routinely maintained at 37ºC in a humidified atmosphere 
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of 5% v/v CO2 in air in standard culture medium. The medium was renewed every 3 days. 
For subculture, cells were rinsed twice with warm PBS and harvested with 0.25% w/v 
trypsin-0.05% w/v ethylenediaminetetraacetic acid (EDTA). Cells were centrifuged (7 min, 
1,100 rpm), resuspended in fresh standard culture medium and used immediately.  
 
Uptake of GCR by GD fibroblasts 
 
Cells were seeded at 3×104 cells/cm2 in 24-well plates and incubated for 24 h with 
different amounts of free-GCR (from 1 to 30 µg) or GCR adsorbed to calcium phosphate 
microspheres. Untreated cells from type I GD patients were used as a reference. 
Microspheres without adsorbed GCR and GCR-loaded microspheres in the absence of cells 
were used as controls. At the end of the incubation period, the supernatants were discarded 
and cells were rinsed twice with PBS and brief sonicated in 0.1% v/v Triton X-100. The 
homogenates were centrifuged (5 min at 10,000 rpm and 4ºC) to remove ceramic particles 
and cell debris. The supernatants were used for GCR activity measurements as described 
above but in the presence of 6 mg/mL of sodium taurocholate.  
 
 
RESULTS AND DISCUSSON 
 
Adsorption of GCR to calcium phosphate microspheres 
 
Microspheres with a uniform size of 600±23 µm (CTP) and 535±25 µm (HAp) were 
obtained. Both types of microspheres presented an interconnected microporosity and their 
specific surface areas were 0.27 m2/g for the CTP microspheres and 0.68 m2/g for the HAp 
microspheres, as determined by the BET method. Further details on the physicochemical 
and morphological characterisation of the microspheres are provided elsewhere.3 
Adsorption of GCR was performed at pH 7.4, in the vicinity of the enzyme isoelectric 
point IP, which occurs around 7-8, where it exhibits higher structure stability and therefore 
a smaller tendency to denaturate upon adsorption.19 Although GCR adsorbed to both types 
of microspheres, the properties of the materials largely influenced the amount of adsorbed 
enzyme. Under the conditions used, CTP microspheres adsorbed 36 ± 5.0 ng GCR/cm2, 
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while HAp microspheres adsorbed 10 ± 2.0 ng GCR/cm2.  These figures refer the real 
surface are of the microspheres. The differences in the adsorbed amounts may be related to 
differences in protein-surface electrostatic interactions. Zeta potential (ZP) measurements 
showed that at physiological pH both types of microspheres are negatively charged, the ZP 
of CTP microspheres (-54.33 ± 6.35 mV) being more negative than the one of HAp 
microspheres (-15.96 ± 2.12 mV). Although at physiological pH the enzyme exhibits a 
neutral net charge, it has positively and negatively charged residues that may mediate 
adsorption. In this study only an enzyme concentration and an adsorption time were used 
and the choice of these parameters was based on a previous work.17 
The catalytic activity of adsorbed GCR was strongly depended on the type of ceramic 
used. Results are expressed as a percentage of the activity obtained with the same 
concentration of free-GCR. For GCR adsorbed on CTP microspheres the activity was 
higher than that of the control (367.1 ± 87.3%), while in the case of HAp microspheres it 
was lower (9.5 ± 3.0%). Similar results were previously reported concerning the adsorption 
of GCR to CTP and HAp powders.20 Activation of GCR by CTP microspheres was further 
confirmed by calculation of the Michaelis-Menton constant (Km). A Km= 9.0 mM was 
obtained for the adsorbed enzyme while a Km= 30.5 mM was obtained for the free enzyme. 
This parameter is roughly an inverse measure of the affinity or strength of binding between 
the enzyme and its substrate, and so the lower the Km, the greater the affinity. 
Even if the integrity of the enzyme is preserved, a certain degree of inactivation is usually 
expected in immobilised enzymes. It may result, for example, from a decreased substrate-
accessibility due to diffusional limitations or from an inadequate orientation of the enzyme 
active site at the surface. 
The enhancement of enzymatic activity, such as that reported above, is a less common 
effect, although the activation of many lipases by an interface, the so-called interfacial 
activation, has been reported.21,22 It is well documented that purified GCR exhibits a very 
low level of activity in vitro and that a micellar or liposomal interface, is needed for 
reconstitution of its catalytic function.23 Presumably, this interfaces facilitates the 
interaction of GCR with the substrate by inducing a conformational change in the enzyme 
that converts it into a more active state.23 A similar mechanism could eventually explain 
the enhancement of GCR activity in the adsorbed state, as already suggested in a previous 
work.17 Activation of GCR by liposomal vesicles is only observed when phospholipid with 
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negatively charged polar groups are used.23 Under the acidic conditions of the activity 
assay (pH 5.5), the surface of the CTP microspheres (IP around 3)24 is negatively charged 
while the HAp microspheres (IP around 6)24 is slightly positive, which may partially 
explain the results obtained.  
 
Release of GCR from calcium phosphate microspheres 
 
GCR release from calcium phosphate microspheres was monitored in cell culture medium 
supplemented with serum, to simulate a physiological environment and also to reproduce 
the conditions used in the subsequent cell culture studies. Upon implantation, microspheres 
will be in contact with plasma containing proteins and different ions, which are likely to 
influence GCR displacement from the surface of the vehicle. 
Desorption of proteins from solid surfaces may be driven by different factors.25-28 For 
example, it may be promoted by replacing the bulk solution used during adsorption by 
another of different ionic composition, pH and/or increased ionic strength.28 Adsorbed 
proteins may also be exchanged to varying degrees by other proteins present in solution if 
they have a stronger affinity for the surface.25-28 Results are presented in Fig. 1. Upon 
incubation, a large percentage of the enzyme was rapidly eluted from the microspheres 
within 1 h. After this initial stage, there was a delayed release of GCR, which extended for 
at least 30 days. At this point, the amount of released GCR in relation to that initially 
present in the microspheres was ca. 50% for both types of microspheres. In order to 
attenuate the initial burst effects and obtain a more sustained release, some authors have 
coated ceramic microspheres with polymers, such as polylactic acid or polyethylene vinyl 
alcohol.11,12  
The occurrence of two distinct kinetic stages during GCR desorption from the 
microspheres may have several explanations. A fraction of the enzyme may be present 
inside the pores of the microspheres (absorbed) and not adsorbed to the surface, being 
rapidly eluted. 
Moreover, the adsorbed enzyme molecules may present different conformational states.28 
Upon incubation in a solution containing a desorbing agent the enzyme molecules that are 
adsorbed by weaker forces may be easily displaced from the surface and transferred to the 
bulk solution by diffusion. Desorption of loosely attached proteins leaves a fraction of the 
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interface available for the lateral expansion of the remaining adsorbed proteins.28 As a 
result, these protein molecules may alter their conformation and establish more contact 
points with the surface. These strongly bound molecules are expected to desorb at a slow 
rate or even become irreversibly adsorbed.28 
 
Figure 1. Percentage of GCR released from CTP and HAp microspheres into cell culture medium 
supplemented with serum during 30 days of incubation. 
 
 
Uptake of GCR by GD fibroblasts 
 
For their application as a delivery system, the microspheres must be able to bind GCR and 
release it in a biologically active conformation.In order to evaluate the integrity of the 
released enzyme, GD fibroblasts were incubated with GCR-loaded microspheres and after 
24 h the increase on intracellular enzyme activity (internalised enzyme) was measured. 
Since the different materials result in different quantities of adsorbed GCR per mg of 
microspheres, cells treated with different quantities of free-GCR were used as control. As 
shown in Fig. 2, by increasing the amount of free-GCR in the medium from 1 µg to 30 µg, 
the level of GCR intracellular activity in cells increases in a dose-dependent manner, 
without reaching saturation.The values of intracellular GCR activity (IA) were related with 
the amount of free-GCR by mathematical fitting (Fig. 3). 
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Figure 2. Uptake of free-GCR by GD fibroblasts as a function of enzyme amount in the medium. 
Cells were incubated at 37ºC for 24 h with 1-30 µg of free-GCR. Results are presented as mean ± 
standard deviation (n=3). 
 
 
Figure 3. Relationship between the intracellular GCR activity (IA) and the amount of free-GCR in 
the medium: Experimental data (♦) and mathematical fitting (⎯). 
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The equation: IA/GCR= 21 × GCR-0.56 was then used to generate the values of intracellular 
activity that would be obtained if cells had been treated with amounts of free-GCR 
matching the amounts of adsorbed GCR (total loaded enzyme) for the two materials. In 
this way the effects of treating cells with adsorbed-GCR or exactly the same amount of 
free-GCR (control) can be compared. Results are presented as a percentage of the control 
(Fig. 4). When GCR-loaded CTP microspheres were used, the increase in intracellular 
GCR activity was 170 ± 3 % of the control. In the case of HAp microspheres the increase 
of intracellular activity represented only 20 ± 13 % of the control. 
These values were, in principle, underestimated, since a fraction of the total loaded enzyme 
was probably lost during washing, while another fraction (ca. 50%, as suggested by the 
previous release studies) remained adsorbed to the microspheres and thus unavailable for 
uptake. 
Figure 4. Intracellular GCR activity in cells treated with GCR-loaded CTP or HAp microspheres, 
depicted as a percentage of the control (cells treated with the same total amount of free-GCR). 
Results are presented as mean ± standard deviation (n=2). 
 
Taken together these findings suggest not only that GCR maintains its integrity upon 
adsorption, but also that enzyme-loaded microspheres are more effective than the free 
enzyme, at least in the case of CTP microspheres. 
The reasons for this still remain unclear. However, we have verified that upon incubation 
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at the conditions used (37ºC in complete cell culture medium) free-GCR becomes rapidly 
inactivated, exhibiting a very significant decrease in biological activity over time, with a 
half-life of ca.  60 min (data not shown). The low stability of purified GCR in solution, 
especially at pH ≥7.4, and even in the presence of stabilisers was also reported by Xu et 
al.29 Moreover, other authors reported that the enzyme is susceptible to oxidation and self-
aggregation.30 So, it is reasonable to assume that the vehicle provides a more favourable 
microenvironment to the enzyme, protecting it from the deleterious external conditions, for 
example by preventing structural rearrangements and denaturation.  It appears that 
association with the carrier potentiates the biological effect of the enzyme under 
physiological conditions. 
 
 
CONCLUSIONS 
 
Physical adsorption provides a simple way to couple the enzyme GCR to HAp and CTP 
microspheres. The properties of the materials largely influenced the amount and activity of 
the adsorbed enzyme. CTP microspheres adsorbed higher GCR amounts for unit surface 
area than HAp microspheres. The activity of the adsorbed enzyme was enhanced in the 
case of CTP microspheres and was partially lost when HAp was used. When incubated in 
cell culture medium, the enzyme is released for at least 30 days from both types of 
microspheres. Cell culture studies using GD fibroblasts showed that GCR-loaded CTP 
microspheres are more effective than the free enzyme, rendering these microspheres 
potentially useful for in vivo localised enzyme delivery. 
The adsorption-approach, which is attractive mainly due to its simplicity and 
reproducibility, has proven, in this particular study, to be effective in improving the 
activity of the enzyme. 
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Concluding remarks and perspectives 
 
 
1. Concluding remarks 
 
The main objective of this thesis was to develop microparticles, with a spherical shape and 
a narrow size distribution, to be used as injectable fillers for the regeneration of bone 
defects and localised delivery of enzymes.  As a specific application, the use of the system 
as an adjuvant therapeutic strategy to treat bone lesions associated with Gaucher disease 
(GD) was investigated, and microspheres were analysed as vehicles for the recombinant 
enzyme glucocerebrosidase (GCR), currently employed in its treatment. 
Bone lesions are among the most debilitating manifestations of GD, and have an enormous 
impact on patient’s quality of life by restricting mobility and interfering with the day by 
day activities.1, 2 Skeleton response to enzyme replacement therapy (ERT) is slow and 
incomplete, particularly in the case of adults with lesions in an advanced state of 
progression.3  This is indicative that new adjuvant therapies must be developed to restore 
bone function more rapidly and/or to a greater extent than with the currently available 
ones. 
In association with ERT, the system proposed in this work could potentially contribute to 
repair GD bone-defects, namely those more susceptible to fractures, in two different ways: 
 
• By acting as a bone-filler to provide a physical support for new tissue formation, guide 
the process of tissue development, and even elicit specific cell functions; 
• By providing localised delivery of glucocerebrosidase to bone, reducing its overall 
systemic exposure. The use of a vehicle may, in addition, enhance the therapeutic 
potential of the enzyme by functioning as a protective matrix, since it is known that 
purified GCR is highly unstable in solution under physiological conditions, and is 
susceptible to oxidation and aggregation.4, 5 
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The use of an injectable material, which gives the possibility of filling bone-defects 
through a minimally invasive surgery, is particularly relevant when applying it to the 
treatment of GD bone lesions. GD patients suffer from haematological abnormalities, 
namely from disorders of the coagulation system that often result in a tendency for 
excessive bleeding,6 which could pose serious problems if the material had to be implanted 
by a traditional surgical procedure. 
 
To achieve these goals, the developed microspheres had to fulfil the following 
requirements: be small enough to be injected; have the ability to reversibly immobilise the 
enzyme GCR while preserving its biological activity; and be able to support osteoblastic-
like cells adhesion, proliferation and differentiation. 
 
During this research work, different types of microspheres were sequentially prepared: 
polymeric, polymer-ceramic and ceramic based. In all the cases, the ability of alginate to 
instantaneously form a hydrogel matrix in the presence of divalent ions was exploited, and 
microspheres were obtained by droplet extrusion of an alginate-containing paste under a 
coaxial air flow, followed by cross-linking of the polymer with Ca2+. Besides its simplicity, 
some advantages of the selected technique include the possibility of carrying out the 
process at room temperature and in the absence of organic solvents, which makes it 
suitable for enzyme entrapment purposes, and of allowing microspheres to be recovered 
without the need for fastidious washing processes. To obtain ceramic microspheres, this 
process was followed by a sintering stage, to burn-off the polymer and bond together the 
ceramic granules, while maintaining the spherical shape of the particles. The described 
methodologies enabled the preparation of spherical particles with a uniform size, from c.a 
350 µm to up 2000 µm, which may present some advantages compared to other types of 
microparticles described in the literature. 
 
For glucocerebrosidase immobilisation, two different coupling techniques were selected, 
depending on the type of microspheres. GCR entrapment was used in the case of alginate 
and calcium phosphate-alginate microspheres, and GCR adsorption was used in the case of 
calcium phosphate powders and microspheres. By selecting the appropriate conditions, the 
different matrices and immobilisation strategies used allowed GCR to be loaded with none 
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or minor losses of integrity, and gave the possibility of obtaining different release kinetics. 
Whether or not a specific release profile is the more adequate for the therapeutic efficiency 
of GCR in the in vivo targeting of bone resident Gaucher cells needs to be evaluated. 
However, the possibility of modulating the release kinetics may allow the optimization of 
the system and expand the range of applications. 
An important finding was that, upon adsorption to a solid surface, not only GCR integrity 
could be preserved, but in certain cases its catalytic efficiency could even be improved. 
The mechanisms that underlie this enzyme activation are not clearly understood yet. 
However, it is well established that purified GCR exhibits a very low level of activity in 
vitro and that a micellar or liposomal interface is needed for reconstitution of its catalytic 
function.7 Presumably, anionic detergents like taurocholate, and also some negatively 
charged phospholipids, facilitate the interaction of the enzyme with the substrate by 
inducing a conformational change that converts it into a more active state.7 The activation 
of many lipases by an interface, the so-called interfacial activation, has also been 
extensively reported.8 A similar mechanism could eventually explain the enhancement of 
GCR activity in the adsorbed state. 
From the manufacturing point of view, the adsorption immobilisation approach offers a 
number of important advantages, it is simple, rapid and highly reproducible, which makes 
it very attractive for biomedical applications. 
 
The in vitro biological performance of the system was assessed using GCR-deficient 
fibroblasts obtained from a GD patient. Although not being the relevant target cells, 
fibroblasts were used because they are routinely cultured for diagnostic purposes and thus 
are readily available. Obtaining sufficient amounts of bone Gaucher cells, which would be 
ideal or, in alternative, of Gaucher macrophages from other tissues or derived from 
peripheral blood monocytes would be extremely difficult, if not impossible. However, 
since fibroblasts also internalise recombinant GCR, through yet unknown mechanisms, 
they were considered to be an adequate model for the studies conducted to evaluate the 
integrity of GCR after being released from the different matrices. The objective was not to 
establish the correct GCR dosage, which is largely an in vivo problem and was out of the 
scope of this study. 
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The behaviour of bone cells cultured on the different types of microspheres was also 
investigated. Because the ability of cells to attach, adhere and spread will influence their 
capacity to proliferate and differentiate in contact with the material, this initial phase is of 
critical importance.9 Preliminary adhesion studies were performed using the MG63 human 
cell line, which expresses a number of features characteristic of relatively immature 
osteoblasts, and has been considered as an adequate cell culture model for this type of 
studies.10 However, results showed that cell response to alginate-containing microspheres 
was not satisfactory. Cells were unable to interact with alginate microspheres, probably 
due the high hydrophilic nature of the polymer,11 and were only able to spread and adopt a 
flattened morphology on calcium phosphate-alginate microspheres with a high percentage 
of ceramic. 
In what concerns cells response to calcium phosphate microspheres, some preliminary 
studies with HAp microspheres were also carried out using MG63 osteoblastic cells. These 
studies were important to establish the ideal methodology for culturing cells on the surface 
of microspheres, namely in what concerned manipulating the microspheres, and obtaining 
a uniform and sufficient density of attached cells.  
A more complete investigation of cell behaviour was only carried out with CTP 
microspheres, using primary cultures of bone marrow cells, since HAp is a very commonly 
used ceramic that is already well studied. Bone marrow has long been recognized as a 
source of progenitor stromal cells that can be induced to differentiate along the osteoblastic 
lineage under appropriate conditions. When cultured on CTP microspheres, cells were able 
to attach, adopt a typical osteoblast-like morphology and gradually proliferate. The surface 
of the microspheres became almost completely covered by dense layers of bone cells and a 
fibrillar extracellular matrix. Cells were able to bridge adjacent microspheres forming cell-
microspheres clusters, and expressed bone phenotypic markers, which confirmed that 
differentiation along the osteoblastic lineage occurred. 
A synergistic effect between the chemical composition of the microspheres and their 
structural features, namely the surface roughness, may possibly underlie these promising 
results. On one hand, several reports on the positive effects of different types of calcium 
phosphates, and in particular of CTP, on osteogenic differentiation may be found in the 
literature.12, 13 On the other hand, it is well known that surface roughness modulates the 
expression of phenotypic markers, and enhanced differentiation of osteoblast-like cells on 
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rough surfaces in comparison with smother ones has been already reported by several 
authors.14 
In view of these findings, from the different types of microspheres developed during this 
investigation, calcium phosphate microspheres appeared to be the most promising for the 
envisaged application as they fulfilled all the requirements already state. The best results in 
terms of GCR immobilisation were obtained when calcium titanium phosphate was used as 
the ceramic phase. 
 
 
2. Perspectives 
 
The research conducted during this thesis has put in evidence some of the potentialities of 
the developed microspheres, which may find applicability as bone-defects fillers and 
enzyme delivery vehicles to be used in several orthopaedic surgical procedures. 
Nevertheless, several topics still need to be addressed and should be investigated in the 
future, namely: 
 
 
• Injectability of the microspheres: in order to be implanted through a minimally 
invasive surgery, the microspheres must be suspended in a vehicle with adequate 
rheological properties, which has to be selected and tested. The microspheres-vehicle 
system must be easily manipulated during surgery and adaptable to the irregular 
wound site, where it must remain for an adequate period of time. Several polymeric 
gels, autologous blood, and fibrin glues are some examples of vehicles that have 
already been used for the implantation of particulate materials. 
 
• In vivo osteogenic potential of the microspheres: The in vitro studies performed 
during this investigation suggested that calcium phosphate microspheres are 
appropriate for culturing osteoblastic-like cells. However, the in vivo performance of 
the microspheres upon implantation on critical size bone-defects created in a suitable 
animal model must be investigated. 
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• Evaluation of enzyme release kinetics and tissue distribution in vivo: In vitro 
release studies are very useful to determine the reproducibility of the release kinetics, 
to analyse the integrity of the protein after interacting with the material, and to study 
the effect of formulation parameters on the system performance in a systematic way. 
Nevertheless, they often do not mimic the in vivo situation. For this reason, in vivo 
studies should be performed in order to establish the correct doses and release kinetics 
for the therapeutic efficiency of GCR in targeting bone resident Gaucher cells. 
However, no naturally occurring animals are presently available, since the lineage of 
the only one described was not maintained.15 A mouse model of Gaucher disease was 
obtained in 1992 by targeted disruption of glucocerebrosidase gene.16 However, due to 
the very severe phenotype, death occurs within the first 24 h of life, hence this animal 
is not a useful model to study new therapeutical approaches. Conduritol B-epoxide 
(CBE), an irreversible glucocerebrosidase inhibitor as been used to mimic some GD in 
mice.17 More recently, a chimeric mouse model of Gaucher disease that reflects the 
increased glycolipids storage in the reticuloendothelial system has been described.18 In 
the future, if one of these models proves to be useful to study bone alterations 
associated with GD in vivo studies may be carried out. 
 
• Physicochemical characterisation of the microspheres: A more complete 
physicochemical characterisation of the microspheres should be carried out in the 
future, namely in what concerns the following parameters: 
 
Porosity: The CTP and HAp microspheres developed during this work present a 
uniform and interconnected porous network with different pores sizes, depending 
on the formulation. This feature, however, was not completely explored in the 
present work and a more complete characterisation of the porosity should be the 
object of future studies. Moreover, the possibility of obtaining different porosities, 
namely by varying the granulometry of the starting ceramic powders and the 
sintering conditions should also be investigated. 
 
Degradation behaviour: the in vivo degradation behaviour of the microspheres is 
also an important parameter that should be investigated. It has been repported that 
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the degradation of alginates is slow and uncontrollable.19 However, modulation can 
be achieved by using, for example, partially oxidized alginates with bimodal 
molecular weight distributions.19  In this case, the rate of degradation was found to 
be controlled by both the oxidation and the ratio of high to low molecular 
weights.19 
In what concerns the ceramics used, while the degradation behaviour of 
hydroxyapatite has been already studied,20 little is known about the degradation 
behaviour of calcium titanium phosphate. This calcium phosphate is expected to 
degrade at a slow rate,21 which seems to be advantageous for the present 
application. Bone lesions associated with GD are frequently end-stage lesions with 
a very low regeneration potential, and so the material will probably have to remain 
within the cavity for long periods of time. It should be noted, however, that the 
versatility of the technique used to prepare the microspheres would enable other 
calcium phosphate materials to be used in alternative. This way, the degradation 
behaviour could in principle be tailored to a specific situation, thus expanding the 
range of applications of the system. 
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